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Apoptin, the VP3 protein derived from chicken anaemia virus (CAV), induces tumour 
cell-specific apoptosis and therefore represents a potential anti-cancer therapeutic 
agent of the future. In human tumour cells, but not in normal cells, Apoptin is 
phosphorylated and subsequently translocates to the nucleus, which are essential 
important steps for its cytotoxic activity. Recently, the β isozyme of protein kinase C 
(PKCβ) was identified as a kinase phosphorylating Apoptin in multiple myeloma cells. 
However, the exact mechanism and nature of interaction between PKCβ and Apoptin 
as well as its importance for Apoptin-induced cell death remain to be characterised. 
This project aimed to further investigate the physical and functional interaction 
between PKC isoforms, in particular PKCβ, and Apoptin.  
Recently, the first human Gyrovirus (HGyV) was isolated which shows significant 
structural and organisational resemblance to CAV and encodes a homologue of 
CAV-Apoptin. Using a synthetic HGyV-Apoptin construct the subcellular distribution and 
apoptotic function of this novel Apoptin protein in several human cancer cell lines was 
analysed and compared to CAV-Apoptin. The results demonstrated a comparable 
tumour-specific nuclear translocation and cytotoxic effect between the two proteins.  
A model of colon carcinoma and normal mucosa cell lines was used to investigate the 
functional link between PKC and Apoptin in other cancer types. Immunoprecipitation 
and proximity ligation assay studies confirmed the binding of both CAV- and 
HGyV-Apoptin to PKCβI in HCT116 colorectal cancer cells and identified the N-terminal 
region of Apoptin to be important for the interaction with PKC. In contrast to HCT116 
cells two normal colon mucosa cell lines tested expressed low levels of PKCβI. This 
differential expression pattern of PKCβI correlated with reduced Apoptin activation in 
normal cells, as evident by its localisation to the cytoplasm, decreased phosphorylation 
and lack of cytotoxic activity. Further studies revealed that PKCβI knockdown in 
HCT116 cells resulted in reduced Apoptin phosphorylation but did not impair Apoptin 
cytotoxicity. Additionally, overexpression of PKCβI was not sufficient to activate 
Apoptin in normal cell lines, indicating that other kinases or processes may contribute 
to the tumour-specific function of Apoptin. 
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Using the FRET-based PKC activity reporter CKAR and fluorescence lifetime imaging 
microscopy (FLIM) the effect of Apoptin or other stimuli on PKC activity was analysed. 
Similar to treatment with the phorbol ester TPA, Apoptin expression in HCT116 cancer 
cells resulted in a significant increase in PKC activity, correlating with the expression 
and increased phosphorylation levels of Apoptin. In contrast, normal colon mucosa cell 
lines with low PKCβI expression showed a delayed and reduced induction of PKC 
activation in response to Apoptin. Overexpression and knockdown studies in 
combination with FLIM provided some evidence that Apoptin predominantly activates 
the PKCβI isoform in HCT116 cells.  
Another tumour-selective cytotoxic agent, TRAIL, was tested on a panel of head and 
neck cancer cell lines associated with human papillomavirus (HPV) infection. Addition 
of the proteasome inhibitor Bortezomib sensitised TRAIL-resistant HPV positive head 
and neck cancer cells to TRAIL. This seemed to involve activation of caspases, the 
anti-apoptotic protein XIAP as well as stabilisation of functional p53, but the precise 
mechanism has so far not yet been established 
In conclusion, the results of this study propose an important link between Apoptin and 
PKCβI in cancer cells, involving their interaction and co-localisation, Apoptin-induced 
activation of PKC and PKCβI-mediated phosphorylation of Apoptin to promote its 
nuclear translocation and cytotoxic function. In addition, the novel HGyV-Apoptin was 
shown to function in a similar manner to CAV-Apoptin, providing a further tumour-
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ACDase acid ceramidase 
Ad-Apoptin adenoviral Apoptin 
Ad-GFP adenoviral GFP 
ALL acute lymphoblastic leukaemia 
Apaf-1 apoptotic protease-activating factor 
APC allophycocyanin 
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Cancer is one of the leading causes of death worldwide and its incidence is predicted 
to rise due to a higher risk of developing cancer with age combined with an increase in 
overall life expectancy. It describes a large family of diseases that comprises more than 
100 different types of cancer, reflecting the site and tissue of origin, which can be 
further classified into various subtypes. 
Cancer can be defined as the uncontrolled clonal expansion of somatic cells leading to 
the formation of a tumour that invades, destroys and disrupts the function of normal 
tissues. Cancer cells accumulate multiple mutations in oncogenes or tumour suppressor 
genes which is often promoted by genomic instability within these cells that facilitates 
mutagenesis (Sarasin 2003). These alterations promote the survival and proliferation 
of cancer cells over normal cells and confer insensitivity to homeostatic regulation by 
the surrounding tissue, resulting in uncontrolled growth of altered cells and the 
formation of a malignant tumour. 
Tumourigenesis seems to be a well-defined multistep process, requiring several genetic 
alterations that drive the progression from normal cells through premalignant states to 
invasive tumours. Based on the characteristics of cancer cells Hanahan and Weinberg 
proposed the so-called “Hallmarks of Cancer”, a number of features that are shared by 
most malignant cells and contribute to cancer development. Initially, these included 
sustained proliferative signalling, insensitivity to growth suppressors, evasion of cell 
death, replicative immortality, induction of angiogenesis and invasive or metastatic 
potential (Hanahan and Weinberg 2000). Since then reprogramming cellular 
metabolism and evading immune destruction have emerged as additional acquired 
capabilities of cancer cells (Hanahan and Weinberg 2011). All these changes disrupt 
the normal function of tissue homeostasis, altering the balance between cell 
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proliferation and cell death to promote tumour development. This process is made 
more complex by interactions of malignant cells with other cells in the tumour 
microenvironment including cancer-associated fibroblasts, infiltrating immune cells and 
endothelial cells (Hanahan and Coussens 2012). 
1.2 Apoptosis 
Apoptosis, or programmed cell death, is a physiological process that is essential for the 
development and life of multicellular organisms. Amongst others, apoptosis is required 
for the maintenance of tissue homeostasis in adult organisms, the proper function of 
the immune system as well as a defence mechanism against external damaging 
agents. 
The term “apoptosis” was first introduced by Kerr et al. in 1972 who defined 
morphological features of programmed cell death as opposed to necrosis (Kerr et al. 
1972). When undergoing apoptosis cells display a characteristic morphology that is 
clearly distinct from that of healthy or necrotic cells. It is characterised by cell 
shrinkage and chromatin condensation (pyknosis) during early stages of apoptosis and 
membrane blebbing and nuclear fragmentation (karyorrhexis) at later stages. 
Eventually, the cell disintegrates into apoptotic bodies which are ultimately engulfed 
and digested by phagocytic cells due to exposure of phosphatidylserine on the cell 
surface (Hacker 2000). 
1.2.1 Execution and regulation of apoptosis 
During apoptosis cells carry out a series of tightly regulated intracellular events. All 
apoptotic stimuli result in the activation of caspases, specific cysteine proteases that 
reside as inactive cytosolic zymogens, or pro-caspases, and require activation by 
proteolytic processing (Earnshaw et al. 1999; Nicholson 1999; Riedl and Shi 2004). The 
human caspase family comprises 11 members, at least 7 of which are involved in 
apoptosis. The initiator phase of apoptosis is marked by the recognition of an apoptotic 
signal and activation of initiator caspases (caspase-2, -8, -9 and -10). These in turn 
activate effector caspases (caspase-3, -6 and -7) that specifically cleave cellular 
substrates during the effector phase leading to disintegration of the cell (Luthi and 
Martin 2007). Key events triggered by caspase activation, marking the final steps of 
apoptosis, include shutdown of translation, disruption of the cytoskeleton, DNA 
fragmentation and cleavage of nuclear lamins. 
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There are two main apoptotic signalling pathways that are triggered by different 
apoptotic signals and employ different initiator caspases and regulatory components 
(Figure 1-1). Both pathways ultimately merge into activation of the same effector 
caspases and induction of apoptosis. 
1.2.2 Intrinsic pathway of apoptosis 
The intrinsic, or mitochondrial, pathway is triggered by various stress stimuli such as 
DNA damage, growth factor deprivation or endoplasmic reticulum (ER) stress. Its 
activation by these signals results in the permeabilisation of the mitochondrial outer 
membrane (MOMP) leading to the release of several pro-apoptotic factors from the 
mitochondrial intermembrane space into the cytoplasm (van Gurp et al. 2003). One of 
these factors is cytochrome c, which associates with apoptotic protease-activating 
factor (Apaf-1) and initiator caspase-9 to form the heptameric apoptosome in an 
ATP-dependent fashion. In this complex caspase-9 is activated and can cleave 
caspase-3 and other effector caspases (Hu et al. 1999). 
1.2.3 Extrinsic pathway of apoptosis 
The extrinsic pathway is initiated following engagement of death receptors of the 
tumour necrosis factor (TNF) receptor family such as TNF-R1, TRAIL-R or CD95/Fas by 
their corresponding ligands (Locksley et al. 2001). Upon ligand binding death receptors 
undergo oligomerisation and a conformational change exposing the receptor’s death 
domain (DD) on the cytoplasmic side of the plasma membrane. Subsequently, adaptor 
proteins such as Fas-associated protein with death domain (FADD) or TNF 
receptor-associated protein with death domain (TRADD), containing a DD and a death 
effector domain (DED) are recruited to the receptor (Chinnaiyan et al. 1995; Grimm et 
al. 1996). Pro-caspase-8 associates with the DED of FADD or TRADD to form the 
death-inducing signalling complex (DISC), triggering its proteolytic activation (Kischkel 
et al. 1995; Peter and Krammer 2003). Activated caspase-8 can either directly cleave 
effector caspases (type I pathway) or cleave the BH3-only protein Bid to initiate the 
intrinsic apoptotic pathway (type II pathway) (Li et al. 1998). 
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Figure	  1-­‐1:	  Extrinsic	  and	  Intrinsic	  Pathways	  of	  Apoptosis	  The	  intrinsic	  pathway	  of	  apoptosis	  is	  activated	  by	  stress	  signals	  such	  as	  DNA	  damage	  or	  growth	  factor	  withdrawal	  and	  regulated	  by	  pro-­‐	  and	  anti-­‐apoptotic	  members	  of	  the	  Bcl-­‐2	  protein	  family.	  It	  results	  in	  permeabilisation	  of	  the	  outer	  mitochondrial	  membrane	  (MOMP)	  and	  the	  release	  of	  cytochrome	  c	  (cyt	  c)	  into	  the	   cytoplasm	  which	   triggers	   formation	  of	   the	  apoptosome	  and	  activation	  of	  initiator	  caspase-­‐9.	  Engagement	  of	  death	  receptors	  results	  in	  the	  recruitment	  of	   adaptor	   proteins	   and	   formation	   of	   the	   DISC	   in	   which	   pro-­‐caspase-­‐8	   is	  activated.	   Caspase-­‐8	   directly	   activates	   caspase-­‐3	   or	   mediates	   generation	   of	  tBid	   to	   trigger	   the	   intrinsic	  pathway	   in	  an	  amplification	   loop.	  Both	  pathways	  ultimately	   converge	   in	   the	   activation	   of	   effector	   caspases-­‐3	   or	   -­‐7	   leading	   to	  apoptosis.	   IAPs	   prevent	   the	   activation	   of	   caspases-­‐9,	   -­‐3	   and	   -­‐7	   but	   can	   be	  inhibited	   by	   Smac	   released	   from	   the	   mitochondria	   while	   c-­‐FLIP	   blocks	  caspase-­‐8	  activation.	  In	  the	  absence	  of	  caspase-­‐8	  activity	  receptor-­‐interacting	  protein	   1	   and	   3	   (RIP1/RIP3)	   kinases	   can	   form	   the	   necrosome	   complex	   to	  initiate	  necroptotic	  cell	  death	  (adapted	  from	  Strasser	  (2005).	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1.2.4 Necroptosis 
The term necroptosis refers to programmed necrotic cell death that is mediated by 
receptor-interacting protein (RIP) kinases RIP1 and RIP3 following activation of cell 
surface receptors such as TNF-R1 or Fas by TNFα or other ligands (Holler et al. 2000; 
He et al. 2009). RIP1 is recruited to the activated cytosolic TNF-R1 complex (Micheau 
and Tschopp 2003), or DISC, which contains the adapter proteins TRADD and FADD as 
well as pro-caspase-8 and normally triggers activation of caspase-8 to initiate the 
extrinsic pathway of apoptosis (Figure 1-1). Activated caspase-8 also cleaves and 
thereby inactivates RIP kinases, preventing the induction of necroptosis (Lin et al. 
1999; Feng et al. 2007).  
Inhibition of apoptotic signalling, for example due to pharmacological caspase 
inhibition or genetic depletion of caspase-8, results in stabilisation of RIP1 and RIP3. 
Phosphorylation of RIP1 and RIP3 results in their activation and triggers assembly of 
the necrosome complex to initiate necroptotic cell death (Cho et al. 2009; Declercq et 
al. 2009). Execution of necroptosis involves several molecular mechanisms including 
generation of reactive oxygen species (ROS), lysosome membrane permeabilisation 
and autophagy (Lin et al. 2004b; Zhang et al. 2009a; Vandenabeele et al. 2010; Ullio 
et al. 2012). 
1.2.5 Regulators of apoptosis 
1.2.5.1 Bcl-2 protein family 
The main regulatory proteins of the intrinsic pathway controlling MOMP belong to the 
B cell lymphoma 2 (Bcl-2) protein family which comprises both pro- and anti-apoptotic 
members (Cory and Adams 2002). They share homology in at least one out of four 
conserved Bcl-2 homology (BH) domains and interact with each other to control 
induction of apoptosis. Briefly, stress signals are sensed by BH3-only proteins such as 
p53-upregulated modulator of apoptosis (PUMA) or Noxa, which accumulate to 
overcome the anti-apoptotic effect of pro-survival Bcl-2-like proteins including Bcl-2 or 
Bcl-xL. Consequently, the pro-apoptotic proteins Bax and Bak are activated to 
oligomerise in the outer mitochondrial membrane leading to the formation of pores, 
MOMP and the release of apoptogenic factors into the cytoplasm. 
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1.2.5.2 Inhibitor of apoptosis (IAP) proteins 
Inhibitor of apoptosis (IAP) proteins function as negative regulators of initiator and 
effector caspases during apoptotic signalling. Recent evidence also indicates a role of 
IAPs in other cellular processes, such as activation of nuclear factor kappa B (NF-κB), 
innate immune signalling, cell migration and survival (Gyrd-Hansen and Meier 2010). 
So far eight mammalian IAPs have been identified, including XIAP (X-linked inhibitor of 
apoptosis), cIAP-1 and cIAP-2. They contain three baculovirus IAP repeat domains as 
well as a C-terminal RING (really interesting new gene) finger domain (Sun et al. 1999) 
- a zinc finger type structural domain contained in many proteins that function as 
ubiquitin ligases and transfer ubiquitin from ubiquitin-conjugating enzymes to substrate 
proteins. XIAP can directly block the activation of several caspases by different 
mechanisms (Huang et al. 2001). Caspase-3 and caspase-7 are inhibited due to 
binding of XIAP to their catalytic pockets preventing substrate entry (Riedl et al. 2001) 
while binding of XIAP to caspase-9 prevents its dimerisation and subsequent activation 
(Shiozaki et al. 2003). Moreover, through their RING domain all IAPs can target 
caspase-3 for ubiquitination and proteasomal degradation (Huang et al. 2000; Suzuki 
et al. 2001; Choi et al. 2009). During apoptosis Smac/DIABLO is released from the 
mitochondrial intermembrane space into the cytoplasm where it binds to IAPs, thereby 
relieving the IAP-mediated inhibition of initiator and effector caspases (Chai et al. 
2000).  
1.2.5.3 Cellular FLICE-inhibitory protein (c-FLIP) 
Cellular FLICE-inhibitory protein (c-FLIP) is an inactive caspase-8 homologue that 
interferes with death receptor signalling by competitive binding at the DISC. The short 
splice variant c-FLIPS contains only the two DEDs and inhibits caspase-8 activation at 
the DISC, while the long form c-FLIPL shares significant homology with caspase-8 but 
is catalytically inactive (Tschopp et al. 1998; Krueger et al. 2001). Depending on its 
expression levels c-FLIPL can exert either a pro- or anti-apoptotic effect on caspase-8 
activation (Chang et al. 2002). 
1.2.6 Apoptosis and cancer 
During tumourigenesis cancer cells are put under constant stress, including oncogenic 
stress, genomic instability and hypoxia, which would trigger the intrinsic pathway of 
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apoptosis under normal circumstances. Suppression of apoptosis is therefore essential 
for the persistence of cancer cells and tumour growth and has been proposed as one 
of the hallmarks of cancer development (Hanahan and Weinberg 2000). Cancer cells 
have evolved various mechanisms to evade apoptosis which include the up- or 
downregulation of pro- or anti-apoptotic proteins, respectively, as well as modification 
of the stability and function of regulatory proteins through post-translational 
modifications (Fernald and Kurokawa 2013). Bcl-2 was originally identified as an 
oncogene in B cell follicular lymphoma (Vaux et al. 1988) and the overexpression of 
other anti-apoptotic Bcl-2 family members has been reported in various types of cancer 
(Beroukhim et al. 2010). On the other hand the p53 tumour suppressor protein, which 
triggers the transcription of many pro-apoptotic genes following cellular stresses, is 
frequently mutated in cancers (Levine et al. 1991; Muller and Vousden 2013). 
1.3 Tumour-specific therapeutic agents 
The principal aim of cancer therapy is the complete removal of malignant cells without 
damaging the rest of the body. While surgical excision alone can be used to remove a 
primary tumour, combination with a systemic adjunct treatment is often required. 
Current conventional treatment strategies such as chemotherapy or radiotherapy are 
unspecific and inevitably produce unwanted side effects. Moreover, dysregulation of 
apoptosis is considered one of the hallmarks of cancer and might impair the response 
of tumour cells to cytotoxic agents. It is therefore essential to develop more specific 
and more effective therapies to improve the care of cancer patients. 
One approach to enhance the specificity and efficacy of anti-cancer treatment is 
selective targeting of proteins or pathways that are required to maintain the 
proliferation and survival of tumours cells. For example small molecule inhibitors of the 
BCR-Abl kinase or neutralising monoclonal antibodies for receptor tyrosine kinases are 
already in clinical use for specific cancer types and are described in more detail below 
(Harris 2004; Giamas et al. 2010). While these targeted therapies initially induce 
tumour regression, they are often accompanied by emerging drug resistance and 
tumour persistence. Moreover, as for conventional cytotoxic agents, their inhibitory 
effect is not restricted to cancer cells but can also block essential pathways such as 
epidermal growth factor receptor (EGFR) signalling in normal cells, causing severe side 
effects. 
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Other novel anti-cancer agents are designed to induce apoptosis on their own or to 
enhance the apoptotic effect of other agents by targeting regulators of apoptosis. 
These include small molecule inhibitors of Bcl-2 like obatoclax which is in phase I/II 
clinical trials for several haematological malignancies (Konopleva et al. 2008; Schimmer 
et al. 2008; Scarfo and Ghia 2013). BH3-only mimetics, such as ABT-737 or its orally 
available derivative ABT-263, mimic the inhibitory function of BH3-only proteins on the 
pro-survival proteins Bcl-2, Bcl-xL and Bcl-w, thereby facilitating apoptosis (Oltersdorf 
et al. 2005; van Delft et al. 2006). While ABT-737 has shown promising anti-tumour 
activity in initial pre-clinical studies, ABT-263 is currently in clinical trials alone or in 
combination with other chemotherapeutic agents for solid tumours as well as chronic 
lymphocytic leukaemia (CLL) (Tse et al. 2008; Gandhi et al. 2011; Scarfo and Ghia 
2013). Another approach to facilitate apoptosis is antagonising the function of IAPs 
using antisense oligonucleotides or small molecule inhibitors that are currently in 
clinical trials (Gyrd-Hansen and Meier 2010). Alternatively, Smac mimetics inhibit IAPs 
similarly to the endogenous Smac/DIABLO protein and have shown potential in 
combination with other apoptosis-inducing agents such as TRAIL (Chen and Huerta 
2009; Lu et al. 2011). Lastly, apoptosis in cancer cells can be promoted by 
re-introduction of wild type p53 into p53-mutant tumours using recombinant 
adenoviral vectors (Tazawa et al. 2013) or using small molecule inhibitors that block 
MDM2-mediated p53 degradation (Shangary and Wang 2009). Similar to other 
cytotoxic agents these compounds are relatively unspecific and might therefore have 
undesired effects on normal cells as well as on tumour cells.  
In recent years, cancer immunotherapy has emerged as a strategy to take advantage 
of the immune system to kill cancer cells (Gajewski 2012). In general there are several 
potential aims for therapeutic intervention, namely to enhance antigen presentation by 
dendritic cells, to promote the activity of T cells and to suppress immunological 
checkpoints. While only few therapeutic approaches have been clinically approved so 
far, cancer immunotherapy represents a promising anti-cancer treatment of the future. 
Despite advances in drug design there remains a need for more targeted therapies that 
will only affect tumour cells. Recent studies have revealed a growing group of cellular 
or viral proteins that have the ability to induce tumour-specific cell death. These 
include TRAIL (TNF-related apoptosis-inducing ligand), HAMLET (Human α-lactalbumin 
made lethal to tumour cells), mda-7 / IL-24, adenoviral E4orf4, parvovirus-H1 NS1 or 
Apoptin as reviewed in Grimm and Noteborn (2010). Some of these are already in 
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clinical development with a potential as novel tumour-selective agents while others are 
still in early stages of pre-clinical research. In the following section the function of the 
two tumour-selective anti-cancer agents TRAIL and Apoptin, which were used in this 
study, will be described in more detail. 
1.3.1 TRAIL (TNF-related apoptosis-inducing ligand) 
TRAIL is a cytokine of the TNF family that induces apoptosis in a range of human 
cancer cell lines without affecting the viability of normal cells (Walczak et al. 1999; 
Falschlehner et al. 2009). Several agents that target TRAIL receptors, including 
recombinant TRAIL and monoclonal antibodies, have shown in vivo anti-tumour activity 
and have been tested in Phase I/II clinical trials for advanced tumours with promising 
results (Herbst et al. 2010; Younes et al. 2010; Stuckey and Shah 2013).  
Despite its tumour-selective potential many cancers remain resistant to TRAIL, limiting 
the clinical application as a monotherapy. This has led to the testing of TRAIL in 
combination with other therapeutic agents, aiming to sensitise cancer cells to 
TRAIL-mediated apoptosis or to augment the cytotoxic effect of TRAIL (Newsom-Davis 
et al. 2009; Hellwig and Rehm 2012). These include chemotherapeutic agents, 
proteasome inhibitors, histone deacetylase inhibitors or SMAC mimetics which have all 
shown promising effects in vitro and partially in vivo as a basis for future pre-clinical 
investigations (Ganten et al. 2004; Guo et al. 2004; Koschny et al. 2007; Voortman et 
al. 2007; Lu et al. 2011). 
The induction of apoptosis is initiated by binding of TRAIL to its respective death 
receptors that are expressed on the cell surface in most human tissues (Sheridan et al. 
1997). Five human TRAIL receptors have been identified: TRAIL-R1 (DR4), TRAIL-R2 
(DR5), TRAIL-R3 (DcR1), TRAIL-R4 (DcR2) and osteoprotegerin (Truneh et al. 2000). 
DR4 and DR5 are transmembrane receptors that contain cytoplasmic DDs to mediate 
the pro-apoptotic effect of TRAIL binding. In contrast, DcR1 and DcR2 lack the 
cytoplasmic domains and act as antagonistic or decoy receptors in TRAIL signalling 
(Merino et al. 2006). Activation by binding of TRAIL results in a conformational change 
of the receptor’s cytoplasmic domain, leading to the recruitment of the adaptor protein 
FADD and formation of the DISC in which pro-caspase-8 is activated to initiate 
apoptosis (Figure 1-1). 
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TRAIL has also been shown to trigger other cellular signalling pathways including 
NF-κB, mitogen-activated protein kinases (MAPK), c-Jun N-terminal kinase (JNK) and 
Akt (Falschlehner et al. 2007; Gonzalvez and Ashkenazi 2010), which might counteract 
its cytotoxic effect and represent a concern for the use of TRAIL in resistant cancers. 
1.3.2 Apoptin1 
Apoptin was originally identified as the death-inducing protein from chicken anaemia 
virus (CAV), a single-stranded DNA virus of the Gyrovirus genus (Noteborn et al. 
1991). Infection with the virus results in a severe disease in young chicken, 
characterised by lymphoid atrophy, anaemia, thrombocytopenia and intramuscular 
haemorrhages with mostly fatal consequences (Noteborn and Koch 1995; Adair 2000). 
The major targets of the virus include myeloid progenitor cells in the bone marrow and 
T lymphocyte precursor cells in the thymus, which undergo apoptosis after infection. 
This causes depletion of mature erythroid, myeloid and lymphoid cells, resulting in the 
characteristic disease symptoms of CAV infection (Jeurissen et al. 1992).  
The CAV genome contains three partially overlapping open reading frames encoding 
three viral proteins from a single polycistronic mRNA: VP1 (capsid protein), VP2 
(protein phosphatase, scaffold protein) and the death-inducing protein VP3 (Noteborn 
and Koch 1995). Expression of VP3 alone was sufficient to trigger cell death in chicken 
lymphoblastoid T cells and myeloid cells but not in fibroblasts and it was therefore 
renamed Apoptin (Noteborn et al. 1994).  
Recent studies have identified several viruses resembling the structure and overall 
organisation of CAV in human specimens, which have now been included in the 
Gyrovirus genus (Rijsewijk et al. 2011; Sauvage et al. 2011; Maggi et al. 2012; Phan et 
al. 2012; Phan et al. 2013). Like CAV the first human Gyrovirus (HGyV) contains a VP3 
protein that exhibits similar functional properties as CAV-Apoptin as described in 
Chapter 3 (Bullenkamp et al. 2012). However, the relevance of these human 
Gyroviruses in human disease as well as the therapeutic potential of HGyV-Apoptin still 
remain to be determined. 
                                            
1 parts of this literature review were published as a book chapter in “Anticancer Genes” 
published by Springer (Bullenkamp & Tavassoli 2012, Adv Exp Med Biol. 2014;818:11-37, see 
Appendix I). 
  Chapter 1: General Introduction 
 29 
Since its discovery in the early 1990s Apoptin has become of interest in cancer 
research due to its ability to selectively kill a variety of human tumour cells while 
leaving normal cells unharmed (Zhuang et al. 1995a; Danen-Van Oorschot et al. 1997; 
Pietersen et al. 1999; Guelen et al. 2004). Overall more than 70 cell lines derived from 
different tumour types, including melanoma, lymphoma, colon carcinoma and lung 
cancer, have displayed sensitivity to Apoptin-induced cell death. Moreover, 
SV40-transformed cells or UV-irradiated cells from patients with hereditary cancer-
prone disorders were found to be susceptible to Apoptin expression (Danen-Van 
Oorschot et al. 1997; Zhang et al. 1999). Apoptin therefore seems to sense an early 
event of oncogenic transformation and induces cancer-specific apoptosis regardless of 
tumour type, representing a potential future anti-cancer therapeutic agent. 
1.3.2.1 Organisation of Apoptin 
Apoptin is a small protein, 14 kDa in size, rich in proline, serine, threonine and basic 
amino acids and does not share sequence homology with any known cellular proteins 
described so far (Figure 1-2). Crystallography or NMR studies have so far failed to 
determine the three-dimensional structure of Apoptin. Using computational protein 
modelling a recent study has however predicted a three-dimensional model of Apoptin 
based on alignment of its sequence with known structures (Panigrahi et al. 2012).  
 
Figure	  1-­‐2:	  Organisation	  and	  Sequence	  of	  Apoptin	  The	   positions	   of	   key	   functional	   domains	   of	   the	   protein	   such	   as	   the	   nuclear	  localisation	   sequences	   (NLS),	   putative	   nuclear	   export	   signals	   (NES),	   the	  leucine-­‐rich	  stretch	  (LRS)	  or	   the	  Thr-­‐108	  phosphorylation	  site	  are	   indicated.	  The	   lower	   panel	   shows	   the	   sequence	   of	   Apoptin;	   the	   corresponding	   amino	  acids	  of	  indicated	  domains	  are	  highlighted.	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The amino acid sequence of Apoptin contains several regions or motifs that are 
important for its regulation and activity and have been identified in a number of 
mapping studies (Figure 1-2). The N-terminal region (amino acids 1 to 31) upstream of 
a short leucine rich stretch (LRS) was recently shown to be required for the selective 
targeting of cancer cells by Apoptin (Shen Ni et al. 2013), while the LRS (amino acids 
33 to 46) mediates Apoptin binding to promyelocytic leukaemia (PML) protein and its 
localisation to PML bodies (Poon et al. 2005; Janssen et al. 2007).  
Apoptin comprises a nuclear export signal (NES), which has been mapped to either the 
N-terminus (amino acids 37 to 46) or the C-terminus (amino acids 97 to 105) of the 
protein in separate studies (Poon et al. 2005; Heilman et al. 2006). Moreover, it 
contains a C-terminal bipartite nuclear localisation sequence (NLS) spanning amino 
acids 82 to 88 (NLS1) and 111 to 121 (NLS2). These domains are required to facilitate 
the shuttling of Apoptin in and out of the nucleus (Danen-Van Oorschot et al. 2003; 
Poon et al. 2005; Heilman et al. 2006). 
Furthermore, Apoptin contains a number of serine and threonine residues serving as 
potential phosphorylation sites. These include threonine-108 (Thr-108) as well as the 
adjacent Thr-106 and Thr-107 residues (Rohn et al. 2002) that allow for tumour-
specific modification by cellular kinases to regulate Apoptin activity, which will be 
highlighted in Section 1.3.2.3.   
A number of studies have investigated the multimerisation state of Apoptin in cancer 
and normal cells. Recombinant Apoptin fused to maltose binding protein (MBP-Apoptin) 
aggregates into globular complexes approximately 40 nm in diameter that comprise 30 
to 40 non-covalently attached Apoptin monomers in vitro (Leliveld et al. 2003b). The 
N-terminal region of the protein (amino acids 1 to 69) was found to be sufficient for 
multimerisation. Apoptin multimers were detected as distinct particles in Saos-2 
osteosarcoma cells and retained the ability to translocate to the nucleus and induce 
apoptosis in tumour cells (Leliveld et al. 2003b; Zhang et al. 2003). In contrast, 
Apoptin initially forms large aggregates in the cytoplasm of normal cells which are, 
however, unstable and are eventually eliminated in normal cells (Leliveld et al. 2003b; 
Zhang et al. 2003). While Apoptin multimers have shown biological activity in tumour 
cells it remains to be resolved whether Apoptin also exists as a monomer in vivo and 
can induce apoptosis in that form. 
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1.3.2.2 Tumour-specific localisation of Apoptin 
The precise mode of Apoptin’s tumour cell-specific cytotoxicity so far remains largely 
unknown. One of the major differences between normal and cancer cells is the 
differential subcellular distribution of Apoptin that correlates with its ability to induce 
apoptosis. Apoptin is predominantly expressed in the nucleus of tumour cells whereas 
in normal cells it mainly localises to the cytoplasm. 
The nuclear shuttling of Apoptin is controlled by a C-terminal bipartite NLS (Danen-Van 
Oorschot et al. 2003) as well as an NES mapped to either the C-terminal or N-terminal 
region of the protein as shown in Figure 1-2 (Danen-Van Oorschot et al. 2003; Poon et 
al. 2005; Heilman et al. 2006). Whereas nuclear import of Apoptin seems to occur both 
in tumour and normal cells its export to the cytoplasm was blocked in tumour cells, 
resulting in nuclear accumulation (Poon et al. 2005; Heilman et al. 2006). In addition 
to nuclear localisation or export motifs, the localisation of Apoptin can also be affected 
through interaction with cellular proteins retaining it in the nucleus or the cytoplasm as 
described below (Table 1-1). 
Translocation to the nucleus is at least partially required for the ability of Apoptin to 
trigger cell death. Apoptin mutants lacking the NLS or targeted to other subcellular 
regions such as the ER or the mitochondria induced apoptosis less efficiently than wild 
type Apoptin (Zhuang et al. 1995b; Danen-Van Oorschot et al. 2003; Guelen et al. 
2004). Forced localisation of Apoptin to the nucleus of normal cells was, however, not 
sufficient to induce cell death, suggesting that other factors contribute to the activation 
of its cytotoxic function. Despite a differential expression pattern both the C-terminal 
(amino acids 1 to 69) and N-terminal (amino acids 80 to 121) domains of Apoptin were 
found to be able to kill tumour cells when expressed on their own, albeit less potently 
than full-length Apoptin (Danen-Van Oorschot et al. 2003). Taken together, while there 
is a correlation between tumour-specific nuclear accumulation and induction of cell 
death it seems to be only partially important for Apoptin’s cytotoxicity. 
Localisation of Apoptin to the cytoplasm has been associated with epitope shielding 
and eventual degradation of the protein, providing a link between cytoplasmic 
expression of Apoptin and lack of cytotoxicity in normal cells (Zhang et al. 2003). A 
recent study showed that treatment with proteasomal inhibitors such as Bortezomib 
increases expression levels of Apoptin in normal cells but not in tumour cells, 
suggesting proteasome-dependent degradation of Apoptin in non-transformed cells 
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(Lanz et al. 2012b). However, the relevance and functional implication of this 
differential sensitivity of Apoptin to degradation depending on its localisation and the 
cell type still require further evidence. 
Although nuclear translocation promotes Apoptin-induced killing of tumour cells the 
precise link to apoptotic pathways remains unclear. Biologically active aggregates of 30 
to 40 Apoptin monomers as described above have been shown to bind both single- and 
double stranded DNA in vitro with a preference for strand ends (Leliveld et al. 2003a). 
Similarly, following its expression in tumour cells Apoptin localises to DNA-dense 
heterochromatin and nucleoli (Leliveld et al. 2003a). Despite this DNA-binding ability 
Apoptin does not act as a direct transcriptional activator or repressor but might affect 
transcription indirectly (Danen-Van Oorschot et al. 2003). Furthermore, nuclear 
translocation might be required for interaction of Apoptin with cellular binding partners 
that are discussed below.  
Recently, the induction of DNA damage response (DDR) signalling was shown to 
trigger nuclear translocation of Apoptin and induction of apoptosis even in 
non-transformed cells (Kucharski et al. 2011). Conversely, inhibition of DDR signalling 
resulted in cytoplasmic localisation of Apoptin in tumour cells. Many cancer cells are 
characterised by constitutive activation of DNA damage signalling and this study 
therefore suggests a possible link between the DDR, nuclear localisation of Apoptin and 
induction of cell death in tumour cells.  
1.3.2.3 Tumour-specific phosphorylation of Apoptin 
Further studies on Apoptin revealed another interesting property of the protein that 
provides a link to tumour-specific signalling pathways. In tumour cells but not in 
normal cells Apoptin is phosphorylated on Thr-108 by a yet unknown cellular kinase 
(Rohn et al. 2002). Activity of this Apoptin kinase was also detected in extracts from 
human tissue samples using an in vitro kinase assay. Similarly, transient expression of 
the SV40 large T antigen was shown to trigger Apoptin phosphorylation in normal cell 
lines suggesting that the Apoptin kinase can be activated in response to a transforming 
signal (Zhang et al. 2004b). The phospho-amino acid mapping performed during the 
study by Rohn et al. only identified a single radiolabelled fragment, indicating that 
despite the presence of other potential phosphorylation sites Apoptin is only 
phosphorylated in the region of Thr-108 (Rohn et al. 2002). 
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A gain-of-function point mutation of Thr-108 to a phospho-mimicking glutamic acid 
(T108E) led to enhanced translocation of Apoptin and induction of cell death in normal 
fibroblasts in separate studies (Rohn et al. 2002; Poon et al. 2005; Kuusisto et al. 
2008). Based on these findings, Apoptin phosphorylation on Thr-108 was suggested to 
drive nuclear accumulation of Apoptin through inactivation of the adjacent NES (amino 
acids 97 to 105). This mechanism of Apoptin activation in tumour cells through 
phosphorylation and subsequent nuclear translocation is summarised in Figure 1-3. 
However, mutants lacking the Thr-108 phosphorylation site still retained a partial 
ability to accumulate in the nucleus and induce apoptosis (Lee et al. 2007). This might 
be due to a pro-apoptotic activity of the N-terminal region of Apoptin as described 
above which is independent of Thr-108 phosphorylation. Moreover, Apoptin can 
alternatively be phosphorylated on the adjacent threonine residues if Thr-108 is 
inactivated with a similar outcome (Rohn et al. 2005). Mutation of both Thr-108 and 
Thr-107 was required to completely abolish phosphorylation of Apoptin and its 
cytotoxic effect. Overall, the precise contribution of phosphorylation to nuclear 
translocation and induction of apoptosis remains to be identified and confirmed. 
 
Figure	  1-­‐3:	  Model	  of	  Apoptin	  Activation	  in	  Tumour	  Cells	  In	   tumour	   cells	   Apoptin	   is	   phosphorylated	   by	   a	   cellular	   kinase	   and	  translocates	   to	   the	   nucleus	   where	   it	   accumulates.	   Subsequently	   Apoptin	  activates	   the	   apoptotic	  machinery	   either	   through	   the	  mitochondria	   or	   other	  pro-­‐apoptotic	   signalling	   pathways	   resulting	   in	   cell	   death.	   In	   contrast,	   in	  normal	   cells	   Apoptin	   shuttles	   back	   to	   the	   cytoplasm,	   becomes	   epitope	  shielded	  and	  is	  eventually	  degraded.	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The tumour cell-specific phosphorylation of Apoptin might be due to the presence of a 
cancer-associated signalling pathway marked by increased activation of a cellular 
kinase. Several studies have therefore attempted to identify potential kinases that 
mediate the phosphorylation of Apoptin specifically in tumour cells. Identification of 
such kinases is important not only for unravelling the function of Apoptin but might 
also indicate novel targets for the development of tumour-selective anti-cancer drugs. 
In 2010 Jiang et al. proposed the β isozyme of protein kinase C (PKCβ) as an Apoptin 
kinase in a model of human multiple myeloma cell lines (Jiang et al. 2010). 
Dexamethasone-resistant MM1.R cells displayed a higher susceptibility to Apoptin-
induced cell death than the parentally matched MM1.S cells, correlating with enhanced 
phosphorylation of Apoptin in MM1.R cells. Microarray expression analysis revealed a 
differential expression pattern of several kinases, including PKCβ which showed a 
9-fold higher expression level in MM1.R cells compared to MM1.S cells. Recombinant 
PKCβ was able to phosphorylate MBP-Apoptin in an in vitro kinase assay while 
pharmacological inhibition or shRNA-mediated knockdown of PKCβ significantly 
reduced Apoptin phosphorylation in MM1.R cells, suggesting PKCβ as a potential 
Apoptin kinase. Moreover, this study indicated an interaction between Apoptin and 
PKCβ based on co-immunoprecipitation studies and showed Apoptin-induced 
translocation of PKCβ to the nucleus. Overall, PKCβ was proposed as an important 
regulator of Apoptin phosphorylation and function in multiple myeloma cells.  
In a separate study Apoptin was found to bind to the p85 subunit of phospho-
inositide 3-kinase (PI3K) in co-immunoprecipitation or GST pull-down assays (Maddika 
et al. 2007; Maddika et al. 2008). Expression of Apoptin in prostate or breast cancer 
cells triggered sustained activity and nuclear translocation of Akt downstream of PI3K 
activation which promoted Apoptin-induced cell death. However, neither PI3K nor Akt 
were able to directly phosphorylate Apoptin. Instead, Apoptin expression triggered 
activation of cyclin-dependent kinase 2 (Cdk2) through Akt which in turn mediated the 
phosphorylation of Apoptin on Thr-108 (Maddika et al. 2009).  
Recently, inactivation of the protein phosphatase PP2A through expression of the SV40 
small T antigen or RNA interference was shown to activate Apoptin in normal 
fibroblasts (Zimmerman et al. 2012). This study proposes the differential activity of 
phosphatases rather than kinases in regulating Apoptin’s tumour-selective 
phosphorylation and function, which needs to be confirmed in further studies 
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In summary, while Apoptin phosphorylation on Thr-108 represents an important step 
for its death-inducing function, an exclusive kinase that generally regulates Apoptin 
function in tumour cells does not seem to exist. PKCβ and Cdk2 have emerged as 
candidate Apoptin kinases in different cellular models, suggesting that Apoptin is able 
to switch established pro-survival kinase pathways such as PI3K/Akt or PKC signalling 
into a pro-apoptotic signal as a common denominator.  
1.3.2.4 Cellular Apoptin binding partners 
In order to exert its tumour-specific cytotoxicity Apoptin needs to be activated and 
trigger cellular signalling pathways. Apart from PI3K, Akt and PKC that are discussed 
above, several other cellular proteins have been described as Apoptin binding partners 
to influence its cytotoxic function and/or subcellular localisation (Table 1-1).  
In tumour cells Apoptin displays a distinct expression pattern forming nuclear 
aggregates. These resemble PML bodies or nuclear matrix domains organised by PML 
which have been implicated in many cellular processes including cell cycle regulation, 
apoptosis and anti-viral responses. Two separate studies have demonstrated that 
Apoptin co-localises with PML bodies dependent on sumoylation of yet unidentified 
lysine residues within the protein. This interaction was abrogated upon mutation of 
specific leucine or isoleucine residues within the N-terminal LRS of Apoptin (Poon et al. 
2005; Janssen et al. 2007). However, neither sumoylation nor localisation to PML 
bodies were required for the pro-apoptotic activity of Apoptin but might be relevant for 
CAV replication. In human cancer cells but not in normal cells Apoptin was shown to 
associate with the APC1 subunit of the APC/C, resulting in disruption of the APC/C and 
cell cycle arrest in G2/M phase and apoptosis (Teodoro et al. 2004) as well as 
sequestration of APC/C components in PML bodies (Heilman et al. 2006).  
Other cellular proteins seem to regulate the subcellular distribution of Apoptin in a cell 
type-specific manner. One study reported co-localisation of Apoptin with FADD and 
Bcl-10 in cytoplasmic death effector filaments but the significance of this association 
for Apoptin function is still unclear (Guelen et al. 2004). Overexpression of peptidyl-
prolyl isomerase-like 3 (Ppil3) resulted in increased retention of Apoptin in the 
cytoplasm of tumour cells through direct binding (Huo et al. 2008). In normal cells 
Apoptin and Hippi, an interaction partner of Huntingtin-interacting protein 1 (Hip-1), 
were found to co-localise in the cytoplasm whereas in cancer cells Apoptin translocated 
to the nucleus while Hippi remained in the cytoplasm (Cheng et al. 2003). 
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Protein Biological Function Ref. 
Protein Kinase C β  
(PKCβ) 
Binding of Apoptin to PKCβ results in PKCβ-
dependent phosphorylation and activation of 
Apoptin and nuclear translocation of PKCβ. 
(Jiang et al. 2010) 
Fas-associated 
protein with DD 
(FADD) 
Overexpression causes co-localisation of FADD 
and Apoptin in cytoplasmic death effector 
filaments, potentially interfering with death 
receptor signalling. 
(Guelen et al. 2004) 
Bcl-10 
Apoptin and the NF-κB regulator Bcl-10 co-localise 
in cytoplasmic filaments with a yet unknown 
consequence. 
(Guelen et al. 2004) 
Protein Kinase G 
(PKG-I) 
High levels of PKG-I in normal cells correlate with 
lower Apoptin activation; however the precise role 





Apoptin binding to the p85 subunit of PI3K, results 
in sustained activation and nuclear translocation 
of Akt, triggering activation of Cdk2 which in turn 
phosphorylates Apoptin. 
(Maddika et al. 2007; 
Maddika et al. 2008) 
 
Heat shock 
cognate protein 70 
(Hsc70) 
Binding of Apoptin triggers nuclear translocation 
of Hsc70 which might be required for Apoptin-
induced Akt activation and downregulation of p65. 
(Chen et al. 2011a; 




Apoptin is sumoylated and targeted to nuclear 
PML bodies. However, the interaction with PML is 
not required for the cytotoxic function of Apoptin. 




Apoptin binds to APC1, disrupting the APC/C and 
resulting in G2/M arrest and apoptosis. 
(Teodoro et al. 2004) 
Hip-1 protein 
interactor (Hippi) 
In normal cells but not in tumour cells Apoptin 
and Hippi interact in the cytoplasm. 
(Cheng et al. 2003) 
DED-associated 
factor (DEDAF) 
Co-expression of Apoptin and DEDAF results in 
enhanced apoptosis compared to expression of 
either protein alone. 
(Danen-van Oorschot 




Overexpression of Ppil3 can promote cytoplasmic 
localisation of Apoptin. 
(Huo et al. 2008) 
N-myc interacting 
protein (Nmi) 
Nmi was identified as an Apoptin-binding partner 
but no functional studies are available yet. 
(Sun et al. 2002) 
Breast cancer 
associated gene 3 
(Bca3) 
Bca3 enhances Apoptin phosphorylation and 
cytotoxic function by a still unknown mechanism. 
(Zimmerman et al. 
2012) 
 
  	  
Table	  1-­‐1:	  Apoptin-­‐interacting	  Proteins	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1.3.2.5 Mechanisms of Apoptin-induced cell death 
1.3.2.5.1 Activation of apoptotic pathways 
Several key events and molecular players in Apoptin-induced cell death have been 
identified and discussed; however the precise mechanism of cell death induction is still 
not clearly understood. Expression of Apoptin seems to trigger activation of effector 
caspase-3 to execute the apoptotic program. Inhibition of caspases using the pan-
caspase inhibitor z-Vad-fmk or viral caspase inhibitors reduced the sensitivity of cancer 
cells to Apoptin, indicating that caspase activation is required for Apoptin-induced cell 
death (Danen-van Oorschot et al. 2000; Burek et al. 2006). Activation of caspases, 
however, was mainly observed at late stages of cell death after expression of Apoptin 
and it might only represent a consequence of cell death rather than a cause (Danen-
van Oorschot et al. 2000). Hence there remains a need to further investigate the 
involvement and requirement of caspases in Apoptin-induced cell death as briefly 
addressed in Chapter 6 of this study. 
Jurkat cells lacking key regulators of the death receptor pathway, including caspase-8 
and FADD, remained sensitive to treatment with Apoptin, indicating that Apoptin 
mediates cell death independently of death receptor signalling (Maddika et al. 2005). 
Instead, Apoptin triggered a loss of the mitochondrial membrane potential and release 
of cytochrome c, both representing key events of the intrinsic pathway of apoptosis 
(Maddika et al. 2005). Moreover, knockdown of the adaptor protein Apaf-1, which is 
required for caspase-9 activation following MOMP, blocked Apoptin-induced cell death 
in transformed fibroblasts (Burek et al. 2006). Taken together these data suggest that 
Apoptin-triggered apoptosis is executed via the mitochondrial pathway which is 
regulated by pro- or anti-apoptotic members of the Bcl-2 protein family. 
The role of the anti-apoptotic protein Bcl-2 in Apoptin-induced apoptosis still remains 
controversial. Several studies suggest that Apoptin triggers cell death independently of 
the Bcl-2 status of cancer cells and that Bcl-2 overexpression in Saos-2 osteosarcoma 
cells rather sensitises cells to Apoptin than prevent apoptosis induction (Danen-Van 
Oorschot et al. 1999a; Danen-Van Oorschot et al. 1999b). Similarly, overexpression of 
Bcl-xL did not impair Apoptin-induced apoptosis in head and neck cancer cells (Schoop 
et al. 2004). In contrast, Burek et al. showed that co-expression of either Bcl-2 or 
Bcl-xL with Apoptin protects MCF-7 breast cancer cells from cell death, while the 
overexpression of Bax promotes Apoptin-induced apoptosis (Burek et al. 2006). These 
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opposing effects of Bcl-2 seem to be cell type-specific and might be due to the 
differential activity of other cellular signalling factors that control Bcl-2 function.  
Nur77 is an orphan receptor, which translocates from the nucleus to the mitochondria 
upon various apoptotic stimuli. At the mitochondria Nur77 can activate the intrinsic 
apoptotic pathway by changing the conformation of Bcl-2 to promote apoptosis instead 
of suppressing it (Lin et al. 2004a). Shuttling of Nur77 to the mitochondria was 
observed in MCF-7 cells treated with Apoptin fused to the HIV TAT protein transduction 
domain (TAT-Apoptin) while inhibition of Nur77 expression conferred protection 
against Apoptin-induced cell death (Maddika et al. 2005). These data indicate a 
potential link between nuclear expression of Apoptin and induction of apoptosis at the 
mitochondria through modification of Bcl-2 function by Nur77 but still require further 
evidence. 
1.3.2.5.2 Role of the p73 tumour suppressor protein 
Apoptin is able to induce apoptosis even in tumour cells with mutations in the TP53 
tumour suppressor gene (Zhuang et al. 1995b), which represents an important aspect 
for its potential as a future anti-cancer therapeutic agent. The p53 family member p73 
shares significant structural and functional homology with p53, in particular in the 
DNA-binding domain (63% sequence identity) and to a lesser extent in the 
transactivation (29%) and oligomerisation (42%) domains (Oren 1997). It is expressed 
as multiple isoforms that result from alternative splicing in the C-terminus as well as 
the use of two distinct promoters, generating either transactivation-competent (TA) or 
N-terminally truncated (ΔN) forms. Whereas TAp73 isoforms are able to induce the 
transcription of genes involved in apoptosis and cell cycle arrest similarly to p53, 
ΔNp73 isoforms function as dominant negative inhibitors of TAp73 or p53 activity in a 
negative feedback loop (Grob et al. 2001; Melino et al. 2002). In response to genotoxic 
stress TAp73 isoforms become stabilised due to reduced degradation and activated 
while ΔNp73 levels decrease, changing the equilibrium between pro- and anti-apoptotic 
isoforms to induce apoptosis. This process is controlled by a network of post-
translational modifications of p73, including phosphorylation, acetylation and 
ubiquitination (Oberst et al. 2005).  
Expression of Apoptin in p53-deficient head and neck squamous cell carcinoma 
(HNSCC) cells resulted in increased protein levels of TAp73α and the p73 target PUMA 
while reducing the levels of ΔNp73α. Exogenous expression of TAp73 but not ΔNp73 
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further enhanced the sensitivity of Saos-2 osteosarcoma cells to Apoptin-induced cell 
death (Klanrit et al. 2008). A recent study showed that siRNA-mediated downregulation 
of p73 or PUMA significantly protects against Apoptin-induced cell death (Taebunpakul 
et al. 2012). Furthermore it was shown that the initial Apoptin-induced induction and 
activation of TAp73α results in induction of p73-induced RING finger protein 2 (PIR2). 
PIR2 was previously identified as a transcriptional target of p73 and functions as an 
ubiquitin ligase to mediate the preferential ubiquitination and degradation of ΔNp73 
isoforms to regulate p73 function (Sayan et al. 2010). Expression of Apoptin led to the 
PIR2-dependent degradation of ΔNp73 isoforms, relieving their inhibitory effect on 
TAp73 and thus facilitating the induction of apoptosis. These data suggest a novel 
mechanism of Apoptin-induced changes in the equilibrium between pro- and anti-
apoptotic p73 isoforms to induce cancer cell death.  
1.3.2.5.3 Ceramide signalling 
Liu et al. have proposed that Apoptin signalling involves modulation of the 
sphingolipid-ceramide metabolism, representing a further potential mechanism 
involved in Apoptin-mediated apoptosis (Liu et al. 2006a; Liu et al. 2006b). Apoptin-
treated prostate cancer cells displayed elevated ceramide levels due to increased or 
decreased activities of acid sphingomyelinase or acid ceramidase (ACDase), 
respectively. Ceramide is upregulated in response to several cellular stress signals such 
as TNFα stimulation or irradiation and functions as a second messenger to activate 
pro-apoptotic pathways. Cancer cells often overexpress enzymes that metabolise 
ceramide such as ACDase to promote their survival, making it a potential therapeutic 
target.  
1.3.2.5.4 Induction of G2/M arrest 
Cell cycle arrest at the G2/M checkpoint allows for the repair of damaged DNA prior to 
the initiation of mitosis and may eventually lead to apoptosis of arrested cells. Teodoro 
et al. reported that Apoptin expression in cells containing mutated p53 results in G2/M 
arrest and apoptosis through association with the APC/C and inhibition of its function 
(Teodoro et al. 2004). Similarly, in two recent studies Apoptin was shown to induce 
accumulation of p53-deficient osteosarcoma or gastric cancer cells in G2/M phase 
leading to induction of apoptosis (Taebunpakul et al. 2012; Li et al. 2013). 
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1.3.2.5.5 Mitotic catastrophe 
Mitotic catastrophe is considered a protective mechanism against genetic or 
chromosomal instability and thus suppresses tumour progression (Castedo et al. 2004). 
Recently it was suggested that Apoptin triggers mitotic catastrophe and subsequently 
cell death by sensing inaccuracies in the spindle assembly checkpoint (Lanz et al. 
2013). A majority of osteosarcoma cells expressing Apoptin displayed abnormal spindle 
formation and slower progression through mitotic phases compared to control cells. 
This eventually resulted in cell death either during mitosis or the following interphase, 
which showed characteristic features of apoptosis such as membrane blebbing and 
DNA fragmentation. However, the death-inducing activity of Apoptin was not confined 
to cycling cells and mitotic catastrophe might therefore represent only one aspect of 
Apoptin-induced cell death. 
1.3.2.6 Therapeutic potential of Apoptin 
The ability of Apoptin to induce tumour cell-specific apoptosis in vitro has been 
demonstrated in many independent studies. Moreover, treatment with Apoptin has also 
shown promising results in vivo in several mouse tumour models. A major obstacle in 
pre-clinical studies is the fact that Apoptin expression levels need to reach a certain 
threshold to efficiently induce apoptosis in cancer cells. This highlights the need for an 
efficient and accurate delivery system of Apoptin to tumour cells in vivo. 
Several groups have used intratumoural injection of adenoviral vectors to express 
Apoptin in tumours. In a pilot study a single injection of adenoviral Apoptin into 
tumours generated by xenografting HepG2 human hepatoma cells into nude mice 
resulted in significant reduction of tumour growth. Administration of the adenovirus by 
intraperitoneal, subcutaneous or intravenous injection in healthy rats did not cause any 
serious side effects on normal tissues (Pietersen et al. 1999). A follow-up study 
demonstrated that the majority of tumour-bearing mice injected multiple times 
intratumourally with adenoviral Apoptin responded at least partially to treatment. This 
was associated with significantly improved overall survival and tumour reduction up to 
complete tumour regression. Apoptin-treated tumours showed disruption of tissue 
integrity and reduced proliferation (van der Eb et al. 2002). Moreover, a single 
intratumoural injection of adenoviral Apoptin into primary oral tumours induced by the 
carcinogen 4NQO resulted in significant apoptosis of tumour cells (Schoop et al. 2008). 
In order to enhance tumour specificity and transduction efficiency the Apoptin gene 
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was combined with a tumour-specific human telomerase reverse transcriptase 
promoter (hTERT) in a conditional replication-competent adenovirus. Intratumoural or 
systemic delivery of this Ad-hTERT-E1a-Apoptin vector in xenograft models of 
melanoma or gastric cancer resulted in reduced tumour mass and increased survival (Li 
et al. 2010; Liu et al. 2012a). Similarly, injection of an AD55 oncolytic adenovirus 
expressing the Apoptin gene reduced the growth of liver tumour xenografts in nude 
mice (Zhang et al. 2012). 
Several studies employed other non-replicative viral vectors to enhance transduction 
efficiency and immunogenicity. Multiple injections of a replication-deficient fowlpox 
virus vector to express Apoptin in hepatoma xenografts induced significant anti-tumour 
effects and enhanced the survival of tumour-bearing mice (Li et al. 2006). A single 
injection with a recombinant oncolytic Newcastle disease virus containing the Apoptin 
gene reduced the growth of A549-induced tumours to a significantly greater extent 
than the parental virus alone and did not show any toxic effects in healthy mice (Wu et 
al. 2012). A recent study employed a lentiviral vector containing the Apoptin gene 
under control of the human survivin gene promoter. Transduction with this lentivirus 
had a pro-apoptotic effect on several cancer cell lines in vitro and significantly reduced 
the growth of virus-infected SW480 colon cancer cells xenografted into nude mice in 
vivo (Ye et al. 2013).  
An alternative approach to virus-mediated expression of Apoptin is the direct delivery 
of a recombinant Apoptin protein fused to protein transduction domains to tumour 
cells. In vitro, TAT-Apoptin was shown to translocate to the nucleus of cancer cells and 
induce cell death while not affecting normal cells (Guelen et al. 2004). To deliver 
TAT-Apoptin to tumours in vivo it was inserted into a lentiviral construct fused to a 
secretory signal peptide, enabling its secretion from infected cells to neighbouring 
cells. Systemic delivery of this TAT-Apoptin lentivirus reduced the growth of 
hepatocellular carcinoma xenografts in nude mice while displaying only low general 
toxicity (Ma et al. 2012). Similarly, recombinant Apoptin fused to the artificial protein 
transduction domain 4 (PTD4-Apoptin) was shown to inhibit tumour growth in 
xenografts derived from various cancer cell lines when applied to the epidermis 
covering the tumour (Sun et al. 2009).  
Several non-viral gene delivery systems have been investigated to deliver a therapeutic 
gene such as Apoptin to tumour cells, often specifically targeting a certain type of 
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cancer. In a recent study, wheat histone 4 with its natural DNA binding ability was 
fused to TAT and luteinising hormone-releasing hormone (LHRH) to generate H4TL 
which exhibits an enhanced transduction efficiency and specificity for LHRH-positive 
cancer cells. Transfer of the Apoptin gene using H4TL into ovarian carcinoma cells 
resulted in decreased proliferation and apoptosis in vitro (Wang and Zhang 2011). To 
specifically target liver cancer a plasmid encoding Apoptin was linked to the 
asialoglycoprotein that binds its respective receptor on normal or transformed 
hepatocytes to enable endocytosis. Injection of this Apoptin/asialoglycoprotein complex 
into the tail vein of mice bearing HepG2 tumours resulted in expression of Apoptin in 
both normal liver cells and hepatocarcinoma cells. While this induced regression of 
HepG2 tumours it did not affect the integrity of normal tissues surrounding the 
tumours (Peng et al. 2007). PAM-RG4 is a polyamidoamine dendrimer derivative that 
has shown high transfection efficiency in neuronal cells. Treatment with a 
PAM-RG4/Apoptin polyplex triggered apoptosis in glioma cells in vitro. Moreover, 
intratumoural injection of these polyplexes into brain tumour xenografts reduced 
tumour growth without any adverse effects on surrounding tissues (An et al. 2013). 
Apoptin has also shown potential in combination with other anti-cancer treatments 
both in vitro and in vivo. The combination of adenoviral Apoptin with chemotherapeutic 
agents such as etoposide and paclitaxel had an additive cytotoxic effect in several 
cancer cell lines independently of their p53 status (Olijslagers et al. 2007). 
Furthermore, concurrent exposure of radio-resistant HNSCC cells to irradiation and 
Apoptin resulted in enhanced apoptosis compared to radiotherapy alone (Schoop et al. 
2010). In a xenograft model of human or murine melanoma cells epidermal application 
of PTD4-Apoptin displayed a synergistic anti-tumour effect when combined with 
dacarbazine even at low doses with reduced haematological side effects (Jin et al. 
2011). Treatment of mice bearing prostate cancer xenografts with the acid ceramidase 
inhibitor LCL204 and adenoviral Apoptin significantly reduced tumour growth as a 
potential combination therapy for prostate cancer (Liu et al. 2006a). 
Several other tumour-specific agents have been combined with Apoptin and have 
displayed an increased anti-tumour effect compared to single treatments alone. 
Combination with Apoptin enhanced the oncolytic effect of a recombinant H1 
parvovirus in tumour cells but not in normal cells in vitro (Olijslagers et al. 2001). 
Using attenuated Salmonella typhimurium as a gene delivery system, co-expression of 
Apoptin and TRAIL had a significant inhibitory effect on the growth of xenografts 
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derived from gastric cancer cells (Cao et al. 2010). Simultaneous intratumoural 
administration of plasmids encoding Apoptin and the interleukin-18 was reported to 
result in increased lung tumour regression and induction of an anti-tumour immune 
response (Lian et al. 2007). A recent study combined Apoptin and mda-7 using an 
adenovirus-associated viral vector, which synergistically reduced the growth of HepG2 
xenografts through increased induction of apoptosis (Yuan et al. 2013).  
1.4 Protein kinases 
Protein kinases are enzymes that facilitate substrate phosphorylation - the transfer of a 
phosphate group from ATP to serine, threonine or tyrosine residues of other proteins. 
A study from 2002 proposed that the human genome contains 518 putative protein 
kinase genes which constitute approximately 1.7% of all human genes (Manning et al. 
2002). Phosphorylation represents one of the major mechanisms of post-translational 
regulation that is involved in the control of many cellular signalling pathways. 
Approximately a third of all proteins in a cell are thought to be regulated by 
phosphorylation (Sefton 2001). The addition of a negatively charged phosphate group 
can induce a conformational change of the substrate to inhibit or activate its function 
while phosphorylated residues can serve as a recognition site for other proteins or 
influence a protein’s cellular localisation. Many of the major signalling pathways in a 
cell such as MAPK, PI3K/Akt or JAK/STAT rely on a series of phosphorylation events. 
Moreover, essential processes such as cell cycle progression, apoptosis or proliferation 
are controlled by phosphorylation of regulatory proteins. 
1.4.1 Kinases and cancer 
Aberrant kinase activity can disrupt the control of major signalling pathways and 
consequently dysregulation of protein kinases has been linked to many pathological 
processes including tumourigenesis. As a prominent example, the constitutively active 
BCR-Abl tyrosine kinase, generated by a chromosomal translocation, has been 
implicated in the pathogenesis of more than 90% cases of chronic myelogenous 
leukaemia (CML) (Cortez et al. 1995; Advani and Pendergast 2002). The tyrosine 
receptor kinase human epidermal growth factor receptor 2 (HER2) is amplified in 
approximately 20% of breast cancers as well as in other solid malignancies resulting in 
hyperactivation of the PI3K and MAPK pathways (Gusterson et al. 1992). 
Consequently, inhibitors of protein kinases represent a promising class of anti-cancer 
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agents and several kinase-specific small molecule inhibitors are in development or have 
already been approved by the Food and Drug Administration (FDA) (Zhang et al. 
2009b; Giamas et al. 2010). 
Imatinib was the first small molecule inhibitor approved for the treatment of 
BCR-Abl-positive CML (Buchdunger et al. 2002; O'Dwyer et al. 2003). It inhibits the 
cancer-specific activity of BCR-Abl, resulting in an approximately 90% haematologic 
response with only minor side effects in CML patients (Deininger et al. 2005; Druker et 
al. 2006). Due to emerging imatinib resistance several other BCR-Abl inhibitors such as 
dasatinib and nilotinib are now in clinical use for imatinib-resistant CML cases 
(Kantarjian et al. 2006; Talpaz et al. 2006).  
Neutralising monoclonal antibodies for receptor tyrosine kinases such as cetuximab or 
trastuzumab are in clinical use for certain cancers overexpressing EGFR or HER2 
including colorectal, breast or head and neck cancer (Harris 2004). While they target 
extracellular receptor domains inhibitors for the intracellular tyrosine kinase domain 
have been developed and approved by the FDA. Lapatinib blocks downstream 
signalling from both EGFR and HER2, reducing activation of Akt and MAPK signalling, 
and is currently used for the treatment of advanced breast cancer patients as well as in  
several clinical trials for other solid tumours (Rusnak et al. 2001; Xia et al. 2002). Two 
other selective EGFR inhibitors gefitinib and erlotinib have been approved for the 
treatment of non-small-cell lung cancer (Moyer et al. 1997; Wakeling et al. 2002). 
The small molecule inhibitor sorafenib has several cellular targets, including vascular 
endothelial growth factor receptor (VEGFR), MAPK and Raf. Treatment with sorafenib 
is associated with reduced tumour proliferation and angiogenesis in pre-clinical models 
and it has been approved for treatment of advanced renal cancer and hepatocellular 
carcinoma (Wilhelm et al. 2004; Wilhelm et al. 2006). Similarly, the multi-kinase 
inhibitor sunitinib is used to treat patients with advanced renal cancer or 
gastrointestinal stromal tumours (Chow and Eckhardt 2007). Novel small molecule 
kinase inhibitors targeting other kinases, including mammalian target of rapamycin 
(mTOR), JAK, c-Kit, MAPK or Raf, are still under pre-clinical investigation or have 
already received FDA approval for the treatment of specific cancer types. 
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1.4.2 Protein Kinase C (PKC) 
Protein Kinase C (PKC) refers to a group of serine-threonine kinases which comprises 
at least 12 distinct isoforms described so far (Mellor and Parker 1998). While they 
share a similar structure PKC isozymes differ regarding their tissue distribution, 
subcellular localisation, regulatory mechanisms and biological function.  
1.4.2.1 Domain organisation of Protein Kinase C 
The common architecture consists of a C-terminal catalytic domain linked by a flexible 
hinge region to the N-terminal domain (Figure 1-4). This contains regulatory modules 
as well as an autoinhibitory pseudosubstrate sequence which binds to the substrate 
binding pocket maintains PKC in an inactive state in the absence of activating stimuli 
(Pears et al. 1990).  
Based on the composition of the regulatory domains PKC isoforms are divided into 
three different subclasses. Conventional isoforms (PKCα, PKCβI, PKCβII, PKCγ) contain 
a tandem C1 domain, activated by binding of diacylglycerol (DAG) and 
phosphatidylserine (PS), as well as a calcium-dependent C2 domain, which targets 
them to the plasma membrane in the presence of phosphatidyl-4,5-biphosphate (PIP2) 
or other anionic phospholipids (Johnson et al. 2000). In contrast, novel isoforms 
(PKCδ, PKCε, PKCη, PKCθ) contain a novel C2 domain that is insensitive to cellular 
calcium levels. Instead their C1 domain exhibits a two magnitudes higher binding 
affinity for DAG which is conferred by a single changed residue in the C1 domain 
(Giorgione et al. 2006; Dries et al. 2007). Atypical isozymes (PKCζ, PKCι) lack binding 
domains for either calcium or DAG but are regulated by PS and, more importantly, 
protein-protein interactions. The three-dimensional crystal structure of the 
conventional PKCβII isoform, comprising regulatory and catalytic domains, is shown in 
Figure 1-5. 
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Figure	  1-­‐4:	  Domain	  Organisation	  of	  Protein	  Kinase	  C	  Isoforms	  PKC	   family	  members	   can	  be	   subdivided	   into	   three	   subclasses	   -­‐	   conventional	  novel	  and	  atypical	  PKCs	  -­‐	  sharing	  a	  similar	  domain	  structure.	  In	  addition	  to	  a	  conserved	  kinase	  domain,	   conventional	   PKCs	   contain	   a	   pseudosubstrate	   (P),	  two	   C1	   domains	   that	   mediate	   binding	   to	   diacylglycerol	   (DAG)	   or	  phosphatidylserine	   (PS)	   and	   a	   calcium-­‐sensitive	   C2	   domain.	   The	   novel	   C2	  domain	   of	   novel	   PKCs	   does	   not	   bind	   calcium	   but	   mediates	   protein-­‐protein	  interactions.	  Atypical	  PKCs	  contain	  only	  a	  C1	  domain	  and	  are	  mainly	  regulated	  by	   binding	   to	   other	   proteins	   (RACKs).	   Interaction	   with	   other	   proteins	   or	  second	  messengers	  as	  well	  as	  phosphorylation	  sites	   in	   the	  C-­‐terminal	  region	  required	  for	  PKC	  maturation	  are	  indicated.	  
 
Figure	  1-­‐5:	  Crystal	  Structure	  of	  Protein	  Kinase	  C	  βII	  Three-­‐dimensional	  structure	  of	  full-­‐length	  rat	  PKCβII	  showing	  the	  C1B	  (blue),	  C2	  (green)	  and	  kinase	  (yellow	  /	  magenta)	  domains	  as	  well	  as	  phosphorylation	  motifs	  (adapted	  from	  Leonard	  et	  al.	  (2011).	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1.4.2.2 Regulation of Protein Kinase C 
All PKC isoforms undergo maturation involving several ordered priming phosphorylation 
steps at three motifs in the C-terminal region in order to acquire stability and 
catalytical competence (Keranen et al. 1995). These motifs are conserved among 
members of the PKC family but also other AGC kinases such as Akt. In a first step, 
phosphorylation at the activation loop, generating a catalytically competent enzyme, is 
mediated by PDK1 (Chou et al. 1998; Dutil et al. 1998; Le Good et al. 1998; 
Sonnenburg et al. 2001). Phosphorylation on the turn motif is required for stabilisation 
of mature PKC and was recently shown to depend on the mTORC2 complex as 
depletion of mTORC2 resulted in reduced levels of PKC due to lack of turn motif 
phosphorylation and degradation of unstable proteins (Facchinetti et al. 2008). 
Following phosphorylation at the turn motif, the hydrophobic motif of PKC is 
autophosphorylated in an intramolecular reaction (Dutil et al. 1994; Behn-Krappa and 
Newton 1999). Recently, the binding of heat shock protein 90 and its co-chaperone 
Cdc37 to a molecular clamp formed by the C-terminal PXXP motif and the catalytic 
domain of PKC was shown to control the phosphorylation of conventional and novel 
PKC isoforms (Gould et al. 2009).  
Sustained activation of conventional and novel PKC isoforms, for instance after 
prolonged treatment with phorbol esters, results in degradation of activated PKC 
enzymes (Young et al. 1987). In their membrane-bound, active conformation, PKC 
isoforms are sensitive to dephosphorylation by phosphatases such as PH domain and 
leucine rich repeat protein phosphatases (PHLPP) and PP2A (Hansra et al. 1996; Gao 
et al. 2008). Dephosphorylation in turn was shown to promote their ubiquitination and 
proteasomal degradation, determining the half-life of PKC (Lee et al. 1997; Hansra et 
al. 1999). Occupancy of the active site by peptide substrates, the pseudosubstrate 
sequence or active site inhibitors protects mature PKC from dephosphorylation and 
thus degradation (Cameron et al. 2009; Gould et al. 2011). In a recent study the 
peptidyl-prolyl isomerase Pin1 was identified as a regulator of conventional PKC 
lifetime by binding to the phosphorylated enzyme and inducing a conformational 
change that promotes dephosphorylation of PKC (Abrahamsen et al. 2012). Moreover, 
PKCα can be degraded via a non-proteasomal mechanism involving its internalisation 
into endolysosomes but not dephosphorylation (Lum et al. 2013). 
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With the exception of atypical isoforms, PKCs are regulated by the lipid second 
messenger DAG, as well as calcium for conventional isoforms, which are generated by 
hydrolysis of PIP2 downstream of G-protein coupled receptors or tyrosine kinase 
receptors that activate phospholipase C (Figure 1-6). Binding of calcium to the C2 
domain targets conventional PKC isoforms to the plasma membrane where binding to 
DAG triggers a conformational change and the release of the pseudosubstrate, thus 
allowing substrate binding and phosphorylation (Newton 2009). The C1 domain of 
novel PKC isoforms has a higher affinity for DAG and can therefore bind to membranes 
enriched in DAG without prior activation by calcium (Dries et al. 2007). In a recent 
study the crystal structure of PKCβII has provided further insights into the allosteric 
regulation of PKC activation in a multistep model (Leonard et al. 2011). 
 
Figure	  1-­‐6:	  Maturation	  and	  Activation	  of	  Conventional	  PKC	  Isoforms	  PKC	   isozymes	   undergo	   a	   priming	   process,	   involving	   three	   phosphorylation	  steps	   at	   the	   activation	   loop,	   the	   turn	   motif	   and	   the	   hydrophobic	   motif.	  Increased	   intracellular	   calcium	   and	   diacylclycerol	   (DAG)	   levels	   recruit	   the	  mature	   enzyme	   to	   the	   membrane	   and	   induce	   a	   conformational	   change	  releasing	   the	   pseudosubstrate	   (PS)	   and	   allowing	   substrate	   phosphorylation.	  	  Sustained	  activation	  of	  PKC	  results	  in	  its	  dephosphorylation	  and	  degradation.	  	  	  
(PDK1:	   phosphoinositide-­‐dependent	   kinase	   1,	   PHLPP:	   PH	   domain	   and	   leucine	  
rich	   repeat	   protein	   phosphatases,	   mTORC2:	   mammalian	   target	   of	   rapamycin	  
complex	   2,	   PLC:	   phospholipase	   C,	   PIP2:	   phosphatidylinositol	   4,5-­‐bisphosphate,	  
IP3:	  inositol	  1,4,5-­‐triphosphate)	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1.4.2.3 Protein Kinase C in cancer 
PKC was originally identified as the target of tumour-promoting phorbol esters such as 
TPA (Castagna et al. 1982; Kikkawa et al. 1983; Blumberg et al. 1984). Many PKC 
isoforms are therefore considered to contribute to tumour formation and progression 
as well as invasion or metastasis of cancer cells. Several PKC isoforms have been 
shown to activate other cellular signalling pathways or factors that promote 
proliferation and survival such as MAPK, Akt or AP-1 via inactivation of GSK-3β (Goode 
et al. 1992; Hsieh et al. 2007; Yang et al. 2010). However, each isoform can exert 
distinct cell type-dependent effects on pathways controlling cell death, survival or 
proliferation. Consequently, PKC isoforms have partially contrasting roles in 
tumourigenesis which will be discussed below. Although dysregulated expression of 
PKC has been demonstrated in different cancer types the causal relationship between 
altered PKC levels and malignant transformation remains partially unclear.  
Overexpression of PKCα has been shown in breast cancer, promoting proliferation, 
invasion and tumour growth (Ways et al. 1995; Tan et al. 2006). A recent study 
demonstrated increased levels of PKCα in breast cancer stem cells after epithelial-
mesenchymal transition which was associated with aggressive triple-negative breast 
cancers (Tam et al. 2013). In contrast, in colorectal cancer, lung cancer or invasive 
ductal carcinoma PKCα was shown to reduce proliferation and suppress tumour 
formation in vivo (Ainsworth et al. 2004; Oster and Leitges 2006; Gwak et al. 2009; Hill 
et al. 2014). Similarly, PKCα can suppress both proliferation through p21-dependent 
cell cycle arrest in intestinal epithelial cells (Frey et al. 2000) and apoptosis through 
Bcl-2 phosphorylation (Ruvolo et al. 1998; Jiffar et al. 2004). 
PKCβ is expressed as two variants, PKCβI and PKCβII, generated by alternative splicing 
from the same gene, which differ in the C-terminal region (Ono et al. 1987; Blobe et 
al. 1993). Despite their similarity they are differentially involved in proliferation and 
apoptosis. PKCβII plays an important role during colon carcinogenesis as elevated 
levels of PKCβII have been detected in early preneoplastic lesions and colon tumours 
with a concurrent decrease in expression levels of PKCβI and PKCα (Gokmen-Polar et 
al. 2001). Transgenic mice overexpressing PKCβII are characterised by 
hyperproliferation of the intestinal epithelium and increased susceptibility to tumour 
formation (Murray et al. 1999; Yu et al. 2003; Murray et al. 2009). Moreover colon 
cancer cells stably expressing PKCβII were shown to acquire an invasive phenotype 
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through activation of KRAS, Rac-1 and Mek (Zhang et al. 2004a). By contrast, the role 
of PKCβI in different cancer types is less clear. Both reduced and elevated levels have 
been demonstrated in colon cancer (Kahl-Rainer et al. 1996; Gokmen-Polar et al. 
2001), while antisense targeting of PKCβI suppressed gastric carcinogenesis (Jiang et 
al. 2004). Similarly, overexpression of PKCβI in breast cancer cells has been linked to 
either a less or more aggressive phenotype (Manni et al. 1996; Li and Weinstein 2006).  
PKCβ represents an essential signalling component downstream of the B cell receptor 
to promote NF-κB activation and the survival of lymphocytes while suppressing 
apoptosis (Su et al. 2002; zum Buschenfelde et al. 2010). Consequently, high levels of 
PKCβ have been detected in patient samples from various haematological malignancies 
including CLL, acute lymphoblastic leukaemia (ALL) and follicular lymphoma (Abrams 
et al. 2007; Holler et al. 2009; Saba and Levy 2011).  Moreover, elevated levels of 
PKCβ in diffuse large B cell lymphoma were associated with decreased 5-year survival 
rates and overall poor prognosis (Shipp et al. 2002; Li et al. 2007). More recently, 
PKCβII-dependent activation of NF-κB in cancer-associated fibroblasts was shown to 
promote the survival of CLL cells in vitro. Mice lacking PKCβII were resistant to 
transplantation of CLL cells, highlighting an important role of PKCβ not only in cancer 
cells but also the tumour microenvironment (Lutzny et al. 2013). Moreover, PKCβ is 
activated downstream of VEGFR to promote the proliferation of endothelial cells and 
thus angiogenesis (Xia et al. 1996; Suzuma et al. 2002). Activation of PKCβ has also 
been associated with resistance to chemotherapy or death receptor-induced apoptosis 
in several studies (Zhu et al. 2000; Cesaro et al. 2001; Meng et al. 2010). 
PKCδ is generally considered a pro-apoptotic PKC isoform and has a tumour suppressor 
function with few exceptions (Brodie and Blumberg 2003; Zhao et al. 2012). During 
apoptosis PKCδ is a direct target for proteolytic cleavage by caspase-3, generating the 
constitutively active catalytic fragment which accumulates in the nucleus and is 
required for the induction of apoptosis (DeVries-Seimon et al. 2007). Cleavage of PKCδ 
has been observed following treatment with DNA damaging agents such as 
UV irradiation or etoposide (Denning et al. 1998; Basu et al. 2001; Denning et al. 
2002). Subsequently, active PKCδ phosphorylates a number of target proteins including 
p73, p53 and Mcl-1 to promote apoptosis (Ren et al. 2002; Sitailo et al. 2006; Yoshida 
et al. 2006). In vivo, knockout mice lacking PKCδ display resistance to DNA damage-
induced apoptosis (Humphries et al. 2006). 
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Prolonged treatment with TPA was shown to result in downregulation of PKCδ and 
subsequent transformation of rat fibroblasts (Lu et al. 1997). Transgenic mice 
overexpressing PKCδ are less susceptible to TPA-induced skin tumour formation 
(Reddig et al. 1999). PKCδ is downregulated in several cancer types including 
squamous cell carcinomas and colon cancer and its overexpression was associated with 
reduced proliferation and tumourigenicity in vitro and in vivo (D'Costa et al. 2006; 
Hernandez-Maqueda et al. 2013). On the other hand, PKCδ was found to enhance the 
proliferation and survival of murine mammary epithelial cells in a single study 
(Grossoni et al. 2007). 
PKCε mainly promotes cell survival and proliferation and is considered an oncogene 
(Gorin and Pan 2009). It is upregulated in several types of cancer, including gliomas, 
breast cancer and HNSCC, and is associated with more aggressive tumours and poor 
prognosis (Sharif and Sharif 1999; Pan et al. 2005; Pan et al. 2006). Moreover, PKCε 
expression has been linked to suppression of apoptosis in response to genotoxic stress, 
growth factor withdrawal or death receptor ligation (Gubina et al. 1998; Ding et al. 
2002; Gillespie et al. 2005; Lau et al. 2012). A recent study also identified an important 
role for PKCε in TNF signalling by phosphorylation of TNF receptor-associated factor 2 
(TRAF2) which facilitated its ubiquitination to recruit the IκB kinase (IKK) complex and 
promote NF-κB activation (Li et al. 2009). 
Similarly, PKCι has been proposed as an oncogene in several types of cancer (Murray 
et al. 2011). It is an essential downstream effector of oncogenic Ras during colon 
carcinogenesis and is overexpressed in non-small cell lung cancer or ovarian 
carcinoma, correlating with tumour stage and poor survival (Murray et al. 2004; Regala 
et al. 2005; Zhang et al. 2006). PKCζ was identified as a mediator in the activation of 
MAPKs downstream of EGFR, promoting the growth of head and neck tumours (Cohen 
et al. 2006). While it is overexpressed in follicular lymphomas resulting in abnormal 
regulation of the mTOR complex and in pancreatic tumours activating STAT-3, it 
suppresses the growth of lung tumours through repression of the IL-6 promoter 
(Leseux et al. 2008; Galvez et al. 2009; Butler et al. 2013). 
In summary, these studies highlight the diverse functions of several PKC isoforms in 
different types of cancers. Overexpression and activation of PKC might contribute to 
many tumour-specific characteristics such as abnormal proliferation or resistance to 
apoptosis as opposed to normal tissues.  
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1.4.3 FRET-based kinase activity reporters 
Due to their crucial role in cellular signalling pathways and their dysregulation in 
various disorders, protein kinases have become a major therapeutic target in the past 
decade. In order to develop effective therapeutic agents it is necessary to understand 
the spatiotemporal regulation of kinase activity within cells. In vitro approaches to 
investigate kinase activation include the use of phosphorylation-specific antibodies or 
radioactivity to monitor substrate phosphorylation, antibodies specifically detecting 
activating phosphorylations on kinases or monitoring kinase translocation. However, 
these assays do not necessarily reflect the activation of kinases in their biological 
context. Biosensors based on intramolecular fluorescence resonance energy transfer 
(FRET, also referred to as Förster resonance energy transfer) provide a novel tool to 
monitor the dynamic changes of kinase activation and their regulation in fixed or living 
cells (Zhang and Allen 2007).  
1.4.3.1 FRET imaging 
FRET describes a process during which energy is transferred from a donor to an 
acceptor fluorophore through non-radiative dipole-dipole coupling. The efficiency of 
this energy transfer is inversely proportional to the sixth power of the distance 
separating the two fluorophores as described by the Förster equation: 
𝐸 = 𝑅!!𝑅!! +   𝑟! =   1 −   𝜏!"#"$/!""#$%&'𝜏!"#"$  
E = FRET efficiency, R0 = Förster radius, r = distance between fluorophores 
τdonor/acceptor = fluorescence lifetime of the interacting fraction 
τdonor = lifetime of the donor in the absence of the acceptor 
FRET therefore only occurs when donor and acceptor are within a certain distance to 
each other, approximately 100 Å, which is an important feature for its use in molecular 
biology as described below. Moreover, the fluorophores have to share a sufficiently 
large spectral overlap between the donor emission spectrum and the acceptor 
absorption spectrum in order for energy transfer to occur.  
Fluorescence can be defined as the result of a three-stage process (Figure 1-7). In a 
first step photon energy, supplied by an external source such as a laser, is absorbed by 
the fluorophore, exciting it from the ground state (S0) to a higher electronic state (S1). 
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From there it returns to the ground state after a finite amount of time, releasing its 
energy via radiative or non-radiative processes. The average length of time spent in 
the excited state is referred to as fluorescence lifetime τ. Radiative energy transfer 
results in fluorescent emission of a photon (Figure 1-7a). In the presence of a suitable 
acceptor fluorophore in close proximity, energy will be transferred from the excited 
donor to the acceptor molecule by FRET, generating an excited acceptor which will in 
turn return to its ground state emitting a photon (Figure 1-7b).  
 
Figure	  1-­‐7:	  Jablonski	  Representation	  of	  FRET	  Fluorescence	   resonance	   energy	   transfer	   (FRET)	   refers	   to	   the	   non-­‐radiative	  transfer	   of	   energy	   from	   an	   excited	   donor	   fluorophore	   in	   to	   an	   acceptor	  fluorophore	   in	   close	   proximity.	   (a)	   The	   donor	   fluorophore	   is	   excited	   by	  absorption	   of	   photon	   energy	   and	   transferred	   to	   a	   higher	   energy	   level	   (S1).	  After	  a	  certain	  length	  of	  time	  (average	  fluorescence	  lifetime	  τ)	  it	  returns	  to	  the	  ground	  state	  (S0)	  emitting	  fluorescent	   light.	  (b)	   In	  the	  presence	  of	  a	  suitable	  acceptor,	   energy	   is	   transferred	   from	   the	   excited	   donor	   fluorophore	   to	   the	  acceptor	  by	  FRET.	  This	  shortens	  the	  fluorescence	   lifetime	  τ	  of	   the	  donor	  and	  generates	   an	   excited	   acceptor	   fluorophore	   which	   in	   turn	   will	   return	   to	   the	  ground	  state	  emitting	  fluorescence	  (adapted	  from	  Kelleher	  et	  al.	  (2009)).	  
Several imaging techniques have been developed to measure FRET between two 
fluorophores in living cells (Jares-Erijman and Jovin 2003; Day and Davidson 2012; 
Padilla-Parra and Tramier 2012). These include intensity-based methods such as 
ratiometric FRET, acceptor photobleaching or photoactivation and spectral imaging, 
which detect quenching of donor fluorescence as well as sensitisation of acceptor 
emission due to FRET (Xia and Liu 2001; Zimmermann et al. 2003; van Rheenen et al. 
2004). However, these methods have disadvantages, for instance emission crosstalk or 
(a) (b) 
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susceptibility to fluorophore concentrations, and require extensive controls and 
correction algorithms.  
Alternatively, fluorescence lifetime imaging microscopy (FLIM) provides a tool to image 
the distribution of fluorescence lifetimes within a cell (Bastiaens and Squire 1999; 
Becker 2012). The fluorescence lifetime of a fluorophore depends on the rate of decay 
and is shortened by FRET. Mapping of fluorescence lifetimes across a cell is therefore 
indicative of the occurrence as well as the amount of FRET. There are two main 
approaches to measure fluorescence lifetimes (Gratton et al. 2003). In the time 
domain method samples are excited by a short pulse of light and the intensity of the 
resulting fluorescent signal is measured as a function of time from which fluorescence 
lifetimes can be extracted. Frequency domain FLIM uses sinusoidally modulated light to 
excite the sample, resulting in a similarly modulated emission of fluorescence. 
Fluorescence lifetimes can be calculated from the detected phase-shift and 
demodulation of the signal compared to the excitation light. Overall, time domain FLIM 
of donor fluorophore lifetime represents a state-of-the-art technique that is 
independent of fluorophore concentrations and donor-acceptor stoichiometry and 
requires no corrections for emission crosstalk. It allows for high spatial and temporal 
resolution imaging of molecular interactions or signalling processes.  
1.4.3.2 Application of FRET imaging 
In the context of molecular biology measurement of FRET has become a widely used 
approach to analyse molecular dynamics in cells such as protein interactions, 
conformational changes and subcellular localisation (Tsien et al. 1993; Lippincott-
Schwartz et al. 2001; Peter and Ameer-Beg 2004; Wallrabe and Periasamy 2005).  
For instance, measurement of FRET by FLIM has been applied to study the interaction 
of PKCα and cellular proteins including β-integrin and the actin-binding protein ezrin to 
stimulate β-integrin-related cell migration in physiological contexts such as wound 
healing (Ng et al. 1999a; Ng et al. 2001). PKCα was also shown to bind to the CXCR4 
chemokine receptor and caveolin following stimulation with phorbol esters, highlighting 
the involvement of PKCα in many cellular processes (Peter et al. 2005; Stubbs et al. 
2005). In a recent study the binding of pro-apoptotic BH3-only proteins to Bcl-2 and 
Bcl-xL was monitored in live cells, testing the effect of mutations in the BH3-only 
domains or the presence of BH3 mimetics on binding efficiencies (Liu et al. 2012b). By 
measuring FRET between cyan fluorescent protein (CFP) targeted to mitochondria and 
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PKC isoforms labelled with yellow fluorescent protein (YFP) it was shown that PKCδ 
translocates to mitochondria in an isoform-specific manner after stimulation with 
phorbol esters. This translocation was dependent on both regions in the C1 and C2 
regulatory domains and promoted mitochondrial respiratory activity (Wu-Zhang et al. 
2012). Using fusion proteins of Fas and CFP or YFP respectively it was shown that Fas 
already exists as a trimer on the cell surface prior to ligand binding. This pre-assembly 
is mediated by an extracellular assembly domain and required for downstream 
apoptotic signalling following ligand binding (Siegel et al. 2000). Other members of the 
TNF-R family share homology in this domain and also undergo ligand-independent 
pre-assembly as detected by FRET imaging (Chan et al. 2000).  
FRET imaging can also be employed to study downstream signalling events or detect 
post-translational modifications. Combining a green fluorescent protein (GFP) fusion 
protein of interest with a fluorescently labelled antibody allowed for the visualisation of 
PKCα autophosphorylation and ligand-induced phosphorylation of EGFR by FLIM in 
fixed and living cells (Ng et al. 1999b; Wouters and Bastiaens 1999). Subsequently it 
was shown that focal stimulation of the EGFR resulted in ligand-independent lateral 
propagation of receptor activation across the plasma membrane (Verveer et al. 2000).  
FRET and FLIM are suitable as well for use in fresh or formalin-fixed paraffin-
embedded tissue samples (Kelleher et al. 2009). They might therefore provide novel 
tools to screen for cancer-specific protein interactions or modulations with the aim to 
improve cancer treatment and diagnosis. As one example, phosphorylation of EGFR 
was detected by FRET imaging in head and neck tumour samples and FRET efficiency 
could be correlated with a decrease in disease-free survival (Kong et al. 2006).  
1.4.3.3 FRET-based biosensors 
A variety of biosensors to study specific intracellular signalling events have been 
developed on the basis of intramolecular FRET, which is altered upon activation of the 
enzyme or other changes in the environment (Table 1-2). These reporters usually 
contain two functional units: a sensor for detection of the respective signalling activity, 
such as a molecular switch of a peptide substrate linked to a phospho-serine- or 
phospho-threonine-binding domain, and a FRET pair of donor and acceptor 
fluorophores. Enzymatic activity induces a conformational change of the reporter, 
altering the distance between the donor and acceptor fluorophore, which results in a 
detectable change of FRET. 
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Name Target FRET Pair References 
AKAR PKA mCFP / mYFP (Zhang et al. 2001) 
AKAR2 PKA eCFP / Citrine (Zhang et al. 2005) 
AKAR3 PKA eCFP / Venus (Allen et al. 2006) 
BKAR Akt mCFP / mYFP (Kunkel et al. 2005) 
CKAR PKC mCFP / mYFP (Violin et al. 2003) 
δCKAR PKCδ mCFP / mYFP (Kajimoto et al. 2010) 
DKAR PKD mCFP / mYFP (Kunkel et al. 2007) 
Aktus Akt mCFP / mYFP (Sasaki et al. 2003) 
Picchu EGFR mCFP / mYFP (Kurokawa et al. 2001) 
Picchu-Z EGFR mCFP / mYFP (Itoh et al. 2005) 
EKAR Erk eGFP / mRFP1 (Harvey et al. 2008) 
Cameleon Ca2+ 
eCFP / eYFP 
eBFP / eGFP 
(Miyawaki et al. 1997) 
Raichu-Ras Ras mCFP / mYFP (Mochizuki et al. 2001) 
(Nakamura et al. 2005) 
Raichu-Rap1 Rap1 mCFP / mYFP (Mochizuki et al. 2001) 
(Nakamura et al. 2005) 
Raichu-Cdc42 Cdc42 mCFP / mYFP (Itoh et al. 2002) 
(Nakamura et al. 2005) 
Raichu-Rac Rac mCFP / mYFP (Itoh et al. 2002) 
ATOMIC ATM mCFP / mYFP (Johnson et al. 2007) 
Phocus-2nes Insulin Receptor mCFP / mYFP (Sato et al. 2002) 
Pickles BCR-Abl eCFP / Venus (Mizutani et al. 2010) 
FRas / FRas-F Ras eGFP / mRFP (Yasuda et al. 2006) 
(Oliveira and Yasuda 2013) 
Cygnet-1/2 cGMP eCFP / eYFP (Honda et al. 2001) 
AktAR Akt eCFP / Venus (Gao and Zhang 2008) 
Miu2 Erk mCFP / mYFP (Fujioka et al. 2006) 
ICAP CREB mCFP / Citrine (Friedrich et al. 2010) 
GTRCOS Caspases 
eCFP / eYFP 
eBFP / eGFP 
(Mahajan et al. 1999) 
fllip PtdInsP3 mCFP / mYFP (Sato et al. 2003) 
CYPHR PLC mCFP / mYFP (Violin et al. 2003) 
DAGR DAG mCFP / mYFP (Violin et al. 2003) 
ICUE1 cAMP eCFP / Citrine (DiPilato et al. 2004) 
CaNAR1 Calcineurin eCFP / Venus (Newman and Zhang 2008) 
Apoliner Caspase eGFP / mRFP (Bardet et al. 2008) 
	  
Table	  1-­‐2:	  FRET-­‐based	  Biosensors	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Kinase activity reporters (KARs) such as the PKC activity reporter CKAR are a subgroup 
of FRET-based biosensors designed to detect phosphorylation of specific kinase 
substrate sequences and translating it into a change of FRET. These reporters 
comprise two fluorophores, usually CFP and YFP, linked by a kinase substrate domain 
and a suitable phospho-serine- or phospho-threonine-binding domain (Figure 1-8). 
Phosphorylation of the substrate results in a molecular clamp due to its binding to the 
phospho-binding domain, changing the distance between CFP and YFP. Depending on 
the substrate sequence and binding domain, KARs have been designed to specifically 
monitor the activation of various serine/threonine and tyrosine kinases.  
 
Figure	  1-­‐8:	  Structure	  and	  Function	  of	  CKAR	  The	  PKC	  activity	  reporter	  CKAR	   is	  comprised	  of	   the	   two	   fluorophores	   linked	  by	   a	   PKC	   substrate	   sequence	   and	   the	   FHA2	   phospho-­‐threonine-­‐binding	  domain	  of	  Rad53p	  (adapted	  from	  Violin	  et	  al.	  (2003)).	  
CKAR was used to detect oscillations in PKC activity after treatment with histamine, 
corresponding to concurrent changes in calcium levels (Violin et al. 2003). Moreover, 
CKAR was targeted to other subcellular compartments, including the plasma 
membrane, the mitochondria, the Golgi apparatus, the cytoplasm or the nucleus, by 
fusion with short targeting motifs. Ratiometric FRET imaging of live cells expressing 
these targeted CKAR constructs after treatment with known PKC agonists or inhibitors 
revealed specific activation of PKC in distinct regions of the cells (Gallegos et al. 2006). 
Recently, a reporter specifically detecting activity of PKCδ was generated and used to 
show differences in PKCδ activation depending on the agonist used. While DAG or 
phorbol esters initiated PKCδ signalling at the plasma membrane, mitochondria or the 
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Golgi apparatus, nuclear activation of PKCδ was independent of phorbol ester 
stimulation but required the activity of Src kinase (Kajimoto et al. 2010).  
FRET-based biosensors might also represent tools for use in clinical diagnosis or 
high-throughput drug screens of compounds to identify novel modulators of signalling 
pathways. A recently developed biosensor for BCR-Abl activity showed potential to 
detect malignant cells expressing the BCR-Abl oncogene in blood samples as well as to 
predict and evaluate the response of CML patients to treatment with specific kinase 
inhibitors (Mizutani et al. 2010). A reporter of caspase activity, comprising CFP and YFP 
linked by an exchangeable endoprotease sequence, was used in live cells to identify 
small molecules inducing apoptosis and to monitor apoptosis in real-time (Jones et al. 
2000). AKAR3, an improved reporter for protein kinase A (PKA) activity led to the 
identification of known and novel modulators of PKA signalling from a collection of 
clinical compounds in a live cell high-throughput approach (Allen et al. 2006). 
Recent studies are focusing on the optimisation of existing biosensors aiming to reduce 
basal FRET and make the reporters completely distance-dependent by introducing a 
long flexible linker between the fluorophores (Komatsu et al. 2011). Moreover, 
advances in imaging methods and the design of novel fluorophores provide the 
possibility to detect several signalling events in parallel using up to three probes 
simultaneously (Piljic and Schultz 2008; Carlson and Campbell 2009; Woehler 2013).  
Overall, FRET imaging, in particular using specific genetically encoded reporters, 
represents a novel and widely used technique to monitor signalling events in single 
cells.  
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1.5 Objectives of this study 
The overall aim of this study was to further investigate the tumour-selective function of 
Apoptin and its regulation by PKC, in particular PKCβI, in cancer cells. This will not only 
contribute to a better understanding of the mechanism of Apoptin-induced cell death 
but also potentially identify a novel role of PKC isoforms in the cellular response to a 
tumour-selective anti-cancer agent. Specifically the aims of the study were as follows: 
! to compare the function of the novel HGyV-Apoptin variant to CAV-Apoptin using 
a variety of methods, in particular with regard to its cytotoxicity and tumour-
selective properties 
! to investigate the interaction and co-localisation of CAV- or HGyV-Apoptin and 
PKCβI in different cancer types and identify regions of Apoptin that mediate 
binding to PKCβI 
! to establish a model for studying the function of Apoptin in relation to PKCβI 
expression both in cell lines showing differential endogenous PKCβI expression 
and using transient knockdown or overexpression studies using the established 
cell line model 
! to establish and optimise a FLIM imaging setup in order to measure changes in 
PKC activity in response to pharmacological stimuli or Apoptin expression in 
cancer and normal cells using the FRET-based biosensor CKAR  
! to investigate pathways related to PKC activation and Apoptin signalling that 
might regulate cell death or survival in response to Apoptin expression 
The work presented here demonstrates an important role for PKC, in particular PKCβI, 
for the function of Apoptin in cancer cells. The complete results will be discussed in 
detail in Chapters 3 to 6. 
Moreover the combinatory effect of the targeted anti-cancer agent TRAIL and the 
proteasome inhibitor Bortezomib in a panel of human papillomavirus (HPV) related 
HNSCC cell lines was investigated as described in Chapter 7. 





Materials and Methods 
 
2.1 Materials 
Plasticware used in tissue culture was purchased from Greiner Bio-One or PAA 
Laboratories. All chemicals used were obtained from Sigma-Aldrich unless stated 
otherwise. Solutions and buffers were kept at room temperature unless specified and 
reagents were stored according to instructions. 
2.1.1 Solutions, buffers and media 
Agarose Gel 
A 1% (w/v) solution of agarose was made up in 100 ml 1 x TAE buffer and boiled to 
dissolve the powder completely. The solution was cooled down and ethidium bromide 
was added to a final concentration of 0.5 µg/ml. 
10% APS (10% Ammonium Persulfate) 
10% (w/v) ammonium persulfate 
The solution was made up in dH2O and stored at 4°C for up to 4 weeks. 
1 x Annexin V Binding Buffer 
10 mM HEPES adjusted to pH 7.4 
140 mM NaCl 
2.5 mM CaCl2 
Annexin V Staining Solution 
Annexin V-APC (Molecular Probes, A35110) or Annexin V-FITC (BD Pharmingen, 
556420) were diluted 1:100 or 1:50 in 100 µl Annexin V Binding buffer respectively. 
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Antibiotics 
Carbenicillin was purchased from Bioline (BIO-87026), stored at -20°C and used at a 
working concentration of 100 µg/ml. 
Kanamycin was purchased from Bioline (BIO-87028), stored at -20°C and used at a 
working concentration of 50 µg/ml. 
Blocking Buffer 
for Immunofluorescence  3% (w/v) BSA in 1 x PBS 
for Western blot analysis 5% (w/v) dry milk or 3% (w/v) BSA in 1 x TBS-T 
Cell Culture Media 
All cell culture media were stored at 4°C. 
DMEM (PAA Laboratories, E15-810) 
10% or 15% FBS (Sigma-Aldrich, F7524) and 5 ml 100 x Penicillin/Streptomycin to a 
final concentration of 100 µg/ml penicillin and 50 µg/ml streptomycin (PAA 
Laboratories, P11-010) were added into 500 ml of medium prior to use. 
McCoy’s 5A (PAA Laboratories, E15-823) 
10% FBS and 5 ml 100 x Penicillin/Streptomycin were added into 500 ml of medium 
prior to use. 
RPMI1640 (PAA Laboratories, E15-840) 
10% or 20% FBS and 5 ml 100 x Penicillin/Streptomycin were added into 500 ml of 
medium prior to use. 
MEM with Earle’s Salts (Lonza, BE12-611F) 
10% FBS, 5 ml 100 x non-essential Amino Acids (PAA Laboratories, M11-003), 5 ml 
200 mM L-Glutamine (PAA Laboratories, M11-004) and 550 µl Gentamicin to a final 
concentration of 100 µg/ml (PAA Laboratories, P11-004) were added into 500 ml of 
medium prior to use. 
Cell Lysis Buffer 
2 mM MgCl2 
25 mM HEPES KOH pH 7.4 
2 mM EGTA 
Prior to use cell lysis buffer was diluted 1:1 in 2% Triton X-100 and the following 
components were added: protease inhibitors aprotinin and leupeptin both at a final 
concentration of 1 µg/ml and PMSF at a final concentration of 100 µg/ml. 
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Coumaric Acid 
90 mM p-coumaric acid  
The solution was made up in DMSO, aliquoted (25 µl) and stored at -20°C. 
Doxycycline 
A stock solution of 1 g/ml doxycycline (Sigma-Aldrich, D9891) was made up in dH2O, 
sterilised by filtering through a 0.2 µm filter and stored at -20°C. Prior to use it was 
diluted in appropriate culture medium to a final concentration of 1 µg/ml. 
ECL Buffer (Enhanced Chemiluminescence Buffer) 
100 mM Tris-HCl pH 8.5 
Stored at 4°C 
Prior to use 10 ml of ECL buffer was mixed with 3 µl hydrogen peroxide, 25 µl 90 mM 
coumaric acid and 50 µl 250 mM luminol. 
0.5 M EDTA Solution pH 8.0 
0.5 M ethylenediaminetetraacetic acid (EDTA)  
The solution was made up in dH2O, adjusted to pH 8.0 with NaOH and sterilised by 
autoclaving. 
Freezing Medium 
10% dimethyl sulfoxide (DMSO) 
40% FBS 
50% culture medium 
3 x LSB (3 x Laemmli Sample Buffer) 




The buffer was made up in dH2O and stored at -20ºC.  
Prior to use, the following components were added: protease inhibitors aprotinin and 
leupeptin both at a final concentration of 1 µg/ml, PMSF at a final concentration of 
100 µg/ml and saturated bromophenol blue. 
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LB Medium (Luria-Bertani Medium) 
1% NaCl 
0.5% Bacto-yeast extract 
1% Bacto-tryptone 
The medium was made up in dH2O, adjusted to pH 7.0 with NaOH and sterilised by 
autoclaving. 
LB Agar Plates 
1.5% (w/v) agar was dissolved in LB medium, sterilised by autoclaving and cooled 
down to 50°C. The plates were poured after adding antibiotic to the desired final 
concentration and allowed to set. Plates were stored for several months at 4°C. 
Luminol 
250 mM Luminol 
The solution was made up in DMSO, aliquoted (50 µl) and stored at -20°C in the dark. 
MTT  Solution 
5 mg/ml MTT (Calbiochem 475989, 3-(4,5-Dimethylthiazolyl-2)-2,5-diphenyltetrazolium 
bromide) was prepared in 1 x PBS and sterilised by filtering through a 0.2 µm filter. 
The solution was stored for several months at -20°C protected from light. 
MTT Solubilisation Solution 
50% dimethylformamide 
0.2% glacial acetic acid 
20 mM HCl 
20% SDS 
The solution was made up in dH2O. 
4% PFA (4% Paraformaldehyde) 
8 g of PFA powder was dissolved in 100 ml dH2O and carefully heated to 60°C while 
stirring in a fume hood. A few drops of 3 M NaOH were added while mixing until the 
solution became clear, then 20 ml of 10 x PBS was added as well as dH2O to a final 
volume of 200 ml. Aliquots were stored at -20°C or 4°C for working solutions. 
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10 x PBS (10 x Phosphate-Buffered Saline) 
1.4 M NaCl 
27 mM KCl 
80 mM Na2HPO4 
15 mM KH2PO4 
The solution was made up in dH2O and sterilised by autoclaving. 
For 1 x PBS the 10 x PBS stock solution was diluted 1:10 in dH2O and sterilised by 
autoclaving. 
PMSF (Phenylmethylsulfonyl fluoride) 
10 mM PMSF was made up in isopropanol and stored at -20°C. 
Propidium Iodide Solutions (PI Solutions) 
PI Stock Solution (1 mg/ml) 
1 mg PI (Sigma-Aldrich, P4170) was dissolved in 1 ml 1 x PBS and sterilised by filtering 
through a 0.2 µm filter. The solution was stored at 4°C protected from light. 
PI Staining Solution (Cell Death) 
For cell death analysis the PI stock solution was diluted 1:10 in 1 x PBS and stored at 
4°C for up to a month. 10 µl of staining solution was added to the cell suspension 
directly before analysis. 
PI Staining Solution (Cell Cycle) 
For 10 ml of staining solution, 200 µl PI stock solution and 200 µl RNAse A stock 
solution were added to 10 ml of 0.1% Triton X-100 in 1 x PBS directly before use.  
ReBlot Plus Stripping Buffer 
ReBlot Plus 10 x solution (Millipore, 2504) was diluted 1:10 in dH2O and stored at 4°C. 
Working solutions were re-used up to five times according to the manufacturer’s 
instructions.  
RNAse A Stock Solution (Ribonuclease A Stock Solution) 
333 µl of DNAse-free RNAse A (Sigma-Aldrich, R4642) was diluted in 666 µl 1 x PBS for 
a 10 mg/ml RNAse A stock solution and stored at -20°C. 
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1 x RIPA Buffer (Radioimmunoprecipitation Assay Buffer) 
1 ml of 10 x RIPA Buffer (Cell Signaling, #9806) was diluted 1:10 in dH2O and 
supplemented with one Complete Protease Inhibitor Cocktail tablet (Roche Applied 
Sciences, 11719416001) and 10 µl PMSF. 
10 x Running/Transfer Buffer 
250 mM Tris base 
2.5 M Glycine 
1% SDS 
The solution was made up in dH2O. 
1 x Running Buffer for SDS-PAGE 
10% 10 x Running/Transfer buffer 
90% dH2O 
10% SDS (10% sodium dodecyl sulfate) 
A 10% (w/v) solution of SDS was made up in dH2O, heated to 68°C to dissolve and the 
pH was adjusted to 7.2 with concentrated HCl. 
SDS Polyacrylamide Gels 
Protogel 30% Acrylamide Mix (37.5:1 acrylamide to bisacrylamide stabilised solution) 
was purchased from National Diagnostics, all other chemicals were obtained from 
Sigma-Aldrich. 
Resolving gel 10% 12% 15%  Stacking gel 4% 
1.5 mM Tris pH 8.8 5.0 ml 5.0 ml 5.0 ml  1.0 mM Tris pH 6.8 750 µl 
30% Acrylamide 6.7 ml 8.0 ml 10.0 ml  30% Acrylamide 1.0 ml 
ddH2O 7.9 ml 6.6 ml 4.6 ml  ddH2O 4.1 ml 
10% SDS 200 µl 200 µl 200 µl  10% SDS 60 µl 
10% APS 8 µl 8 µl 8 µl  10% APS 60 µl 
TEMED 200 µl 200 µl 200 µl  TEMED 6 µl 
 




! ON-TARGET plus GAPDH Control siRNA – Human 
! Thermo Scientific, Cat# D-001830-01-05 
siRNA PKCβI 
! siGENOME Human siRNA SMARTpool 
! Thermo Scientific Dharmacon, Cat# M-003758-04-0005 
! Targeting Sequences: GAACCAAGGUCCCGGAAGA, GGAUGAAACUGACCGAUUU, 
CCAAGUCUAUGUCCAAGGA, AGAGUAAGGGCAUCAUUUA 
50 x TAE Buffer (Tris-acetate/EDTA Buffer) 
242 g Tris base 
57.1 ml glacial acetic acid 
37.2 g Na2EDTA*2H2O 
The solution was made up in 1 litre dH2O, adjusted to pH 8.5 and sterilised by 
autoclaving. For 1 x TAE buffer the concentrated stock solution was diluted 1:50 in 
dH2O. 
10 x TBS (10 x Tris-Buffered Saline) 
250 mM Tris base 
1.5 M NaCl 
The solution was made up in dH2O and adjusted to pH 7.4 with concentrated HCl. 
1 x TBS-T (1 x TBS-Tween) 
0.05% Tween 20 in 1 x TBS 
1 x Transfer Buffer for Western blotting 
10% 10 x Running/Transfer Buffer 
20% Methanol 
70% dH2O 
0.2% Triton X-100 
0.1 ml of Triton X-100 was dissolved in 49.9 ml of 1 x PBS. 
  Chapter 2: Materials and Methods 
 67 
1 x Trypsin 
10% 10 x Trypsin (PAA Laboratories, L11-003) in Versene 
Versene 
0.270 mM EDTA pH 8.0 
The solution was made up in 1 x PBS and sterilised by autoclaving. 
2.1.2 Reagents 
Bortezomib 
! proteasome inhibitor (PS-341, Velcade ®) 
! stock solution 2.5 mg/ml in DMSO, stored at -20°C / -70°C 
! provided by Guy’s Hospital Pharmacy 
Cisplatin 
! chemotherapeutic drug, causes crosslinking of DNA 
! stock solution 1 mg/ml, stored at room temperature 
! provided by Guy’s Hospital Pharmacy 
Gö6976 
! protein kinase C inhibitor 
! stock solution 500 µg/ml in DMSO, working solution 25 µg/ml, stored at -20°C 
! purchased from Calbiochem (365253) 
MG132 
! proteasome inhibitor (Z-Leu-Leu-Leu-al) 
! stock solution 50 mM in DMSO, stored at -20°C 
! purchased from Sigma-Aldrich (C2211) 
Nec-1 (Necrostatin-1) 
! inhibitor of necroptosis / RIP1 kinase 
! stock solution 30 mM in DMSO, stored at -20°C 
! purchased from StressMarq Biosciences (SIH-213) 
TNFα  (Tumour Necrosis Factor alpha) 
! stock solution 1.5 mg/ml, stored at -70°C 
! provided by Prof. Henning Walczak, UCL Cancer Institute, London 
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TPA (2-O-Tetradecanoylphorbol-13-Acetate, PMA) 
! protein kinase C activator, phorbol ester 
! stock solution 200 µM, stored at -20°C 
! purchased from Cell Signaling (#4174) 
TRAIL (TNF-related Apoptosis-Inducing Ligand) 
! stock solution 1 mg/ml, stored at -70° 
! provided by Prof. Henning Walczak, UCL Cancer Institute, London 
z-VAD-fmk (zVad) 
! pan-caspase inhibitor 
! stock solution 20 mM in DMSO, stored at -20°C 
! purchased from Promega (G7231) 
2.1.3 Cell lines 
1BR3 
! normal human fibroblasts 
! provided by Prof. Alan Lehmann, Sussex Centre for Genome Damage and Stability, 
University of Sussex 
Ad-293  
! derived from HEK293 cells; improved cell adherence and plaque formation properties for 
adenovirus production 
! purchased from Stratagene 
HCT116  
! human colorectal carcinoma cells 
! provided by Prof. Bert Vogelstein, The Howard Hughes Medical Institute and Sidney 
Kimmel Comprehensive Cancer Centre, Johns Hopkins University, Baltimore, MD 
HCT116 p53-/-  
! HCT116 cells with homozygous p53 knockout 
! provided by Prof. Bert Vogelstein, The Howard Hughes Medical Institute and Sidney 
Kimmel Comprehensive Cancer Centre, Johns Hopkins University, Baltimore, MD 
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HEK293T 
! derived from HEK293 cells; expressing the SV40 large T antigen allowing for replication 
of plasmids containing the SV40 origin of replication for lentivirus production 
! provided by Dr. Lucas Chan, Rayne Institute, King’s College London 
HeLa 
! human cervical carcinoma cells, HPV positive 
! purchased from American Type Culture Collection 
Hke-3 
! HCT116 cells containing only wild type KRAS 
! provided by Dr. Gregory Weitsman, Cancer Cell Biology & Imaging, King’s College 
London 
KMS-12-BM 
! human multiple myeloma cells 
! provided by Prof. Farzin Farzaneh, Rayne Institute, King’s College London 
KMS-12-PE 
! human multiple myeloma cells 
! provided by Prof. Farzin Farzaneh, Rayne Institute, King’s College London 
MM1.R 
! dexamethasone-resistant human multiple myeloma cells, derived from MM1.S 
! provided by Dr. Yu-Tzu Tai, Dana-Farber Cancer Institute, Boston, MA 
MM1.S 
! dexamethasone-sensitive human multiple myeloma cells 
! provided by Dr. Yu-Tzu Tai, Dana-Farber Cancer Institute, Boston, MA 
NCM356 
! normal human colon mucosa cells 
! purchased from INCELL Corporation 
NCM460 
! normal human colon mucosa cells 
! purchased from INCELL Corporation 
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RPMI8226 
! human multiple myeloma cells 
! provided by Prof. Farzin Farzaneh, Rayne Institute, King’s College London 
Saos-2 
! human osteosarcoma cells 
! purchased from American Type Culture Collection 
U266 
! human multiple myeloma cells 
! provided by Prof. Farzin Farzaneh, Rayne Institute, King’s College London 
UD-SCC2 (UD2) 
! HPV positive HNSCC cells 
! provided by Dr. Selvam Thavaraj, Oral Pathology, King’s College London 
UPCI-SCC072 (072) 
! HPV negative HNSCC cells 
! provided by Dr. Selvam Thavaraj, Oral Pathology, King’s College London 
UPCI-SCC089 (089) 
! HPV negative HNSCC cells 
! provided by Dr. Selvam Thavaraj, Oral Pathology, King’s College London 
UPCI-SCC090 (090) 
! HPV positive HNSCC cells 
! provided by Dr. Selvam Thavaraj, Oral Pathology, King’s College London 
UPCI-SCC152 (152) 
! HPV positive HNSCC cells 
! provided by Dr. Selvam Thavaraj, Oral Pathology, King’s College London 
UPCI-SCC154 (154) 
! HPV positive HNSCC cells 
! provided by Dr. Selvam Thavaraj, Oral Pathology, King’s College London 
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VU-147T (147T) 
! HPV positive HNSCC cells 
! provided by Dr. Selvam Thavaraj, Oral Pathology, King’s College London 
2.1.4 Plasmid constructs 
pBabe-puro 
! provided by Dr. Joop Gäken, Department of Haemato-Oncology, King’s College London 
pBabe-puro PKCβI 
! provided by Dr. Joop Gäken, Department of Haemato-Oncology, King’s College London 
pcDNA3 3x Flag-tagged CAV-Apoptin 
! provided by Prof. Jose G. Teodoro, Rosalind and Morris Goodman Cancer Center and 
Department of Biochemistry, Montreal, Quebec, Canada 
pcDNA3 3x Flag-tagged HGyV-Apoptin  
! generated by Dr. Joop Gäken, Department of Haemato-Oncology, King’s College London 
pCMV-CAV-Apoptin 
! provided by Dr. Lars Guelen, Head and Neck Oncology Group, King’s College London 
pCMV-CAV-GFP-Apoptin 
! provided by Dr. Lars Guelen, Head and Neck Oncology Group, King’s College London 
peGFP-C1 
! provided by Dr. Joop Gäken, Department of Haemato-Oncology, King’s College London 
peGFP-C1 HGyV-Apoptin  
! generated by Dr. Joop Gäken, Department of Haemato-Oncology, King’s College London 
pEPI-GFP-Apoptin (1-121) 
! provided by Dr. Gualtiero Alvisi, Department of Biochemistry and Molecular Biology, 
Monash University, Clayton, Victoria, Australia 
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pEPI-GFP-Apoptin (74-121) 
! provided by Dr. Gualtiero Alvisi, Department of Biochemistry and Molecular Biology, 
Monash University, Clayton, Victoria, Australia 
pEPI-GFP-Apoptin (74-121 T108A) 
! provided by Dr. Gualtiero Alvisi, Department of Biochemistry and Molecular Biology, 
Monash University, Clayton, Victoria, Australia 
pGFP-PKCα  
! provided by Dr. Gregory Weitsman, Cancer Cell Biology & Imaging, King’s College 
London 
pGFP/RFP-CKAR 
! generated from pCFP/YFP CKAR obtained from Prof. Alexandra Newton, University of 
California, San Diego, CA 
! provided by Dr. Melanie Keppler, Cancer Cell Biology & Imaging, King’s College London 
pHA-PKCβI 
! provided by Prof. Alexandra Newton, University of California, San Diego, CA 
pNF-κB-fosp Luciferase 
! provided by PD Dr. Dagmar Kulms, Experimental Dermatology, University of Dresden, 
Germany 
pRFP-PKCβII 
! provided by Prof. Alexandra Newton, University of California, San Diego, CA 
pTK-Ren Luciferase 
! provided by Dr. Richard Killick, Old Age Psychiatry, King’s College London 
2.1.5 Adenoviral expression constructs 
Ad-GFP 
! for expression of GFP 
! provided by Prof. Bert Vogelstein, Howard Hughes Medical Institute and Sidney Kimmel 
Comprehensive Cancer Centre, Johns Hopkins University, Baltimore, MD 
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Ad-Apoptin 
! for expression of CAV-Apoptin 
! generated by Dr. Patrayu Taebunpakul, Head and Neck Oncology Group, King’s College 
London 
2.1.6 Lentiviral expression constructs 
Lenti-GFP 
! for expression of GFP 
! provided by Dr. Joop Gäken, Department of Haemato-Oncology, King’s College London 
Lenti-CAV-GFP-Apoptin 
! for expression of CAV-Apoptin fused to GFP 
! provided by Dr. Joop Gäken, Department of Haemato-Oncology, King’s College London 
Lenti-HGyV-GFP-Apoptin 
! for expression of HGyV-Apoptin fused to GFP 
! generated as part of this study with Dr. Joop Gäken, Department of Haemato-Oncology, 
King’s College London 
Lenti-CAV-FLAG-Apoptin 
! for expression of CAV-Apoptin fused to 3xFLAG 
! generated as part of this study with Dr. Joop Gäken, Department of Haemato-Oncology, 
King’s College London 
2.1.7 Lentiviral shRNA constructs 
shRNA Bid / scr (Bid) 
! provided by Prof. Simone Fulda, Institute for Experimental Cancer Research in Pediatrics, 
University Hospital Frankfurt, Germany 
shRNA LacZ / XIAP 
! provided by Dr. Hamid Kashkar, Institute for Medical Microbiology, Immunology and 
Hygiene, University of Cologne, Germany 
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shRNA Caspase-8 / scr (Caspase-8) 
! provided by Prof. Pascal Meier, Division of Breast Cancer Research, Institute of Cancer 
Research, London 
2.1.8 Antibodies 
2.1.8.1 Primary antibodies 
β-Actin 
! Mouse monoclonal to β-Actin 
! Provider: Sigma-Aldrich (A5441) 
! Dilution: 1:5000 (WB) 
Apoptin, non-specific 
! Rabbit polyclonal to Apoptin, non-specific to T108 
! Provider: Eurogentec 
! Dilution: 1:1000 (WB) 
Apoptin, phospho-T108 (P-Apoptin) 
! Rabbit polyclonal to Apoptin, specific to phosphorylated T108 
! Provider: Eurogentec 
! Dilution: 1:1000 (WB), 1:500 (PLA) 
Bid 
! Rabbit polyclonal to Bid 
! Provider: Cell Signaling (#2002) 
! Dilution: 1:1000 (WB) 
Caspase-3 
! Rabbit polyclonal to Caspase-3 (full length and cleaved) 
! Provider: Cell Signaling (#9662) 
! Dilution: 1:1000 (WB) 
Caspase-8 
! Mouse polyclonal to Caspase-8 (full length and cleaved) 
! Provider: Enzo Life Sciences (ALX-804-242) 
! Dilution: 1:500 (WB) 
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Flag 
! Mouse monoclonal to Flag-Tag 
! Provider: Sigma-Aldrich (F1804) 
! Dilution: 1:2000 (WB), 1 µg per 1 ml of cell lysate (IP), 1:500 (IF, PLA) 
GFP 
! Rabbit polyclonal to GFP 
! Provider: Cell Signaling (#2555) 
! Dilution: 1:1000 (WB) 
GFP 
! Rabbit polyclonal to GFP 
! Provider: Abcam (ab290) 
! Dilution: 1:1000 (WB), 2 µg per 1 ml of cell lysate (IP), 1:500 (PLA) 
HA-Tag 
! Rabbit monoclonal to HA-Tag (C29F4) 
! Provider: Cell Signaling (#3724) 
! Dilution: 1:1000 (WB), 1 µg per 1 ml of cell lysate (IP) 
γH2AX 
! Rabbit polyclonal to γH2AX 
! Provider: Cell Signaling (#2577) 
! Dilution: 1:100 (IF) 
p21 
! Mouse monoclonal to p21 (clone DCS60) 
! Provider: Cell Signaling (#2946) 
! Dilution: 1:1000 (WB) 
p53  
! Mouse monoclonal to p53 (clone DO-7) 
! Provider: Novacastra Laboratories 
! Dilution: 1:2000 (WB) 
  Chapter 2: Materials and Methods 
 76 
PARP p85 
! mouse monoclonal to cleaved PARP p85 fragment (clone 7C9) 
! Provider: Cell Signaling (#9548) 
! Dilution: 1:2000 (WB) 
PKCβI 
! Mouse monoclonal to PKCβI (E-3) 
! Provider: Santa Cruz Biotechnology (sc-8049) 
! Dilution: 1:500 (WB), 1:200 (PLA) 
PKCβI 
! Rabbit polyclonal to PKCβI (C-16) 
! Provider: Santa Cruz Biotechnology (sc-209) 
! Dilution: 1:500 (WB), 1:200 (PLA), 2 µg per 1 ml cell lysate (IP) 
PKCβII 
! Rabbit polyclonal to PKCβII (C-18) 
! Provider: Santa Cruz Biotechnology (sc-10) 
! Dilution: 1:500 (WB) 
PKCδ  
! Rabbit polyclonal to PKCδ (C-20) 
! Provider: Santa Cruz Biotechnology (sc-937) 
! Dilution: 1:1000 (WB) 
Tubulin 
! Mouse monoclonal to Tubulin 
! Provider: Sigma-Aldrich (T9026) 
! Dilution: 1:5000 (WB) 
XIAP 
! Mouse monoclonal to XIAP 
! Provider: BD Transduction Laboratories (610762) 
! Dilution: 1:2000 (WB) 
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2.1.8.2 Secondary antibodies 
Mouse-HRP 
! Goat anti-mouse IgG conjugated to horseradish peroxidase 
! Provider: Sigma-Aldrich (A0168) 
! Dilution: 1:4000 (WB) 
Rabbit-HRP 
! Donkey anti-rabbit IgG conjugated to horseradish peroxidase 
! Provider: GE Healthcare (NA934) 
! Dilution: 1:2000 (WB) 
Mouse-FITC 
! Goat anti-mouse IgG (whole antibody) FITC conjugate 
! Provider: Sigma-Aldrich (F0257) 
! Dilution: 1:100 (IF) 
Rabbit-FITC 
! Goat anti-rabbit IgG (whole antibody) FITC conjugate 
! Provider: Sigma-Aldrich (F0382) 
! Dilution: 1:100 (IF) 
Mouse-TRITC 
! Goat anti-mouse IgG (whole antibody) TRITC conjugate 
! Provider: Sigma (T5393) 
! Dilution: 1:100 (IF) 
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2.2 Methods 
2.2.1 Cell culture methods 
2.2.1.1 Cultivation of cell lines 
Cells were grown on 10 cm dishes or in 75 cm² flasks in their corresponding medium 
and maintained at 37°C and 5% CO2. Derivative cell lines were cultured in the same 
medium as the respective parental cell line. 
HCT116, HCT116 p53-/-, Hke-3, NCM356 and NCM460 cells were cultured in 
McCoy’s 5A medium supplemented with 10% FBS, 50 µg/ml streptomycin and 
100 µg/ml penicillin. Saos-2, HEK293T, HeLa and Ad-293 cells were cultured in DMEM 
High Glucose supplemented with 10% FBS, 50 µg/ml streptomycin and 100 µg/ml 
penicillin. 1BR3 cells were cultured in DMEM High Glucose supplemented with 
15% FBS, 50 µg/ml streptomycin and 100 µg/ml penicillin. MM1.R, MM1.S, RPMI8226, 
KMS-12-BM and KMS-12-PE cells were cultured in RPMI medium supplemented with 
10% FBS, 50 µg/ml streptomycin and 100 µg/ml penicillin. U266 cells were cultured in 
RPMI medium supplemented with 20% FBS, 50 µg/ml streptomycin and 100 µg/ml 
penicillin. UPCI-SCC089 (089), UPCI-SCC072 (072), UPCI-SCC090 (090), UPCI-SCC152 
(152), UPCI-SCC154 (154) and UD-SCC2 (UD2) cells were cultured in MEM with Earle's 
salts supplemented with 10% FBS, 2 mM L-Glutamine, 100 µg/ml gentamicin and 
1 x MEM non-essential amino acids. VU147-T (147T) cells were cultured in DMEM High 
Glucose supplemented with 10% FBS, 50 µg/ml streptomycin, 100 µg/ml penicillin and 
1 mM sodium pyruvate. 
Cells were passaged every 2 to 5 days once confluent. To this end, adherent cells were 
washed with Versene and incubated with 1 ml trypsin at 37°C for several minutes. 
After detachment cells were resuspended in fresh medium to stop trypsinisation and 
split according to their further use.  
Suspension cells or semi-adherent cells were collected by scraping and centrifuged for 
5 min at 1,000 x g. The pellet was diluted in fresh medium and cells were split 
according to their further use. 
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2.2.1.2 Cell counting 
Cells in suspension were counted using a haemocytometer (Neubauer chamber). 
Approximately 10 µl of cell suspension was pipetted into the counting chamber under 
the cover slip and cells in the four outer squares were counted. The cell number was 
determined using the following formula:  
cells ml=     𝑐𝑜𝑢𝑛𝑡𝑒𝑑  𝑐𝑒𝑙𝑙𝑠4     ×104  
2.2.1.3 Cryopreservation and thawing of cells 
Cells were collected by trypsinisation and centrifuged for 5 min at 1,000 x g. The cell 
pellet was resuspended in fresh corresponding medium supplemented with 40% FBS 
and 10% DMSO and transferred to cryovials. These were slowly frozen down at -70°C 
in an isopropanol bath (Nalgene Cryoware) for at least 2 days before transfer to a 
liquid nitrogen tank for long term storage. 
For reculturing frozen cells were quickly thawed in a 37°C water bath, diluted in 10 ml 
of appropriate culture medium and centrifuged for 5 min at 1,000 x g. The cell pellet 
was resuspended in fresh medium and cells were plated on 10 cm dishes or in 75 cm² 
flasks. 
2.2.1.4 Mycoplasma testing 
Cell lines were regularly tested for the presence of mycoplasma using a PCR-based 
detection kit according to the manufacturer’s instructions (AppliChem, A3744). 
2.2.1.5 PBMC activation 
96-well plates were coated with anti-CD3 antibodies by adding 50 µl of a 0.1 µg/ml 
solution of anti-CD3 (eBioscience, 14-0038) in sterile 1 x PBS per well, covering the 
plate with parafilm to avoid evaporation and incubating the plate for 2 hours at 37°C. 
The antibody solution was removed and plates were rinsed several times with sterile 
1 x PBS. Freshly isolated peripheral blood mononuclear cells (PBMCs) in RPMI culture 
medium were added to the wells and incubated at 37°C and 5% CO2 before infection 
with lentiviruses. 
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2.2.2 Transfection methods 
2.2.2.1 Plasmid transfection 
Cells at 80 to 90% confluency were transfected with plasmid DNA using the 
X-tremeGENE HP reagent as recommended by the manufacturer (Roche Applied 
Science). In short, a mix of plasmid DNA and transfection reagent was prepared in 
OptiMEM reduced-serum medium (Life Technologies) and added dropwise to the cells 
after incubation for 20 min at room temperature.  
2.2.2.2 Plasmid nucleofection 
Alternatively, plasmid transfection was achieved by nucleofection according to the 
manufacturer’s instructions (Lonza). Cells were trypsinised and counted to prepare 
nucleofection samples of 1 x 106 cells. After centrifugation for 10 min at 100 x g cell 
pellets were resuspended in 100 µl pre-warmed nucleofector solution and 2 µg of 
plasmid DNA was added to each sample. The suspension was then transferred to a 
cuvette, inserted into the nucleofector machine and the cell type-specific program was 
started. After nucleofection cells were mixed carefully with pre-warmed culture 
medium and seeded on cell culture plates at the desired density. Culture medium was 
changed 16 hours later before collecting the cells for the respective assays at 
2 to 5 days after nucleofection. 
2.2.2.3 siRNA transfection 
Cells at 70% confluency were transfected with siRNA using the X-tremeGENE siRNA 
transfection reagent as recommended by the manufacturer (Roche Applied Science). In 
short, siRNA and transfection reagent were prepared separately in OptiMEM reduced-
serum medium, mixed carefully and added dropwise to the cells after incubation for 
20 min at room temperature. Successful knockdown was tested after 48 to 72 hours by 
Western blot analysis. 
2.2.3 Virus methods 
2.2.3.1 Adenovirus amplification 
Ad-293 cells were grown to 90% confluence in 10 cm dishes and infected with virus 
1:1 in a minimal amount of culture medium. Supernatant saved from previously 
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infected cells was also used to infect cells. Once a complete cytopathic effect was 
visible the cells were collected, centrifuged for 10 min at 900 x g and the pellet was 
resuspended in 2 ml culture medium. Viral particles were released into the medium by 
four freeze-thawing cycles in dry ice/methanol and a 37°C water bath and subsequent 
centrifugation for 10 min at 4°C and 16,000 x g after which the supernatant was 
collected, aliquoted and stored at -70°C. 
2.2.3.2 Adenovirus titration 
The tissue culture infectious dose50 (TCID50) is defined as the dilution of virus at which 
there is a 50% probability of an infectious particle being present. To determine virus 
titres Ad-293 cells were seeded on 96-well plates at a density of 5 x 103 cells per well 
in low-serum culture medium containing 5% FBS. After 24 hours cells were infected 
with adenovirus dilutions ranging between 10-3 and 10-10 that were added to ten wells 
in a row per dilution. Seven days later the number of wells displaying a cytopathic 
effect for each dilution was determined under a light microscope in and used to 
calculate the virus titre using the following formula based on the Spearman-Kärber 
method:  log!" titre = log!" D + 0.25 − 0.25  × #  wells  with  CPE  below  D10  
(CPE = cytopathic effect, # = number, D = lowest dilution with 100% CPE) 
2.2.3.3 Adenovirus infection 
Target cells were plated 24 hours before infection to reach about 80% confluency at 
the time of infection. Adenovirus stocks were diluted in medium to achieve the desired 
MOI and added to the cells after removal of old culture medium.  
µμ𝑙  𝑓𝑜𝑟  𝑖𝑛𝑓𝑒𝑐𝑡𝑖𝑜𝑛 = #  𝑐𝑒𝑙𝑙𝑠  ×  𝑀𝑂𝐼  ×  1000  𝑣𝑖𝑟𝑢𝑠  𝑡𝑖𝑡𝑟𝑒  
(MOI = multiplicity of infection, # = number, virus titre = TCID50) 
2.2.3.4 Lentivirus production 
HEK293T cells were plated on 10 cm dishes to reach around 60 to 70% confluency at 
the time of transfection. For transfection by calcium phosphate precipitation a vector 
mix of three plasmids was prepared in 250 µl sterile dH2O: 3.5 µg of lentiviral 
construct, 6.5 µg of envelope plasmid (pMD2.G) and 10 µg of packaging plasmid 
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(pCMV-dR8.91). After addition of 250 µl 2.5 M CaCl2 the vector mix was added 
dropwise to 500 µl of 2 x HeBS (pH 8.05) while vortexing. After 30 min incubation at 
room temperature the suspension was slowly added to the cells which were incubated 
overnight at 37°C and 5% CO2 before changing the medium. The virus-containing 
supernatant was harvested at 24 and 48 hours post-transfection, put through a 
0.45 µm filter and frozen at -70°C for long-term storage or 4°C overnight for 
subsequent lentivirus concentration.  
2.2.3.5 Lentivirus concentration 
To generate lentivirus stocks for Apoptin expression the viral supernatant was 
concentrated by centrifugation for 6 hours at 13,000 x g (Sorvall RC5C Plus). The 
resulting pellet was resuspended in target cell medium and virus aliquots were stored 
at -70°C. 
2.2.3.6 Lentivirus titration 
2.5 x 105 MM1.R cells were plated on 12-well plates and infected with several dilutions 
of concentrated virus supernatant in the presence of 5 µg/ml polybrene (Santa Cruz 
Biotechnology). After 5 days GFP-expressing cells were detected by flow cytometry to 
calculate the virus titre (transducing units, TU) according to the following formula: 
𝑇𝑈 µμ𝑙 = %  𝐺𝐹𝑃  𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒  𝑐𝑒𝑙𝑙𝑠/  100    ×  #  𝑐𝑒𝑙𝑙𝑠  ×  𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛  𝑓𝑎𝑐𝑡𝑜𝑟𝑣𝑜𝑙𝑢𝑚𝑒  𝑣𝑖𝑟𝑢𝑠  𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛  𝑖𝑛  µμ𝑙  
(TU = transducing units, # = number) 
2.2.3.7 Lentivirus infection 
Target cells were plated 24 hours before infection to reach around 80% confluency at 
the time of infection. Lentivirus stocks were diluted in a minimal amount of medium 
supplemented with 5 µg/ml polybrene to achieve the desired MOI and added to the 
cells. After 24 hours fresh medium was added and cells were collected at the indicated 
time points for the respective assays. 
µμ𝑙  𝑓𝑜𝑟  𝑖𝑛𝑓𝑒𝑐𝑡𝑖𝑜𝑛 = #  𝑐𝑒𝑙𝑙𝑠  ×  𝑀𝑂𝐼  𝑇𝑈/  µμ𝑙  
(TU = transducing units, # = number, MOI = multiplicity of infection) 
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2.2.3.8 Generation of stable knockdown cell lines 
Target cells were seeded approximately 24 hours before infection on 6 cm dishes to 
reach around 80% confluency at the time of infection. Cells were infected using 1 ml 
of viral supernatant supplemented with 5 µg/ml polybrene and 2 ml of fresh culture 
medium were added 8 hours after infection. After several days cells were selected 
depending on their acquired resistance to antibiotics. A control of non-transduced cells 
was treated in parallel to ensure toxicity of the antibiotic. 
2.2.4 Protein methods 
2.2.4.1 Protein extraction 
Cells were collected by trypsinisation in cold 1 x PBS and kept on ice. After 
centrifugation at 4°C and 1,000 x g for 5 min, the pellet was washed in 1 x PBS, 
centrifuged again and the obtained cell pellet was stored at -20°C until further use. 
Total cell lysates were prepared by resuspending the cell pellet in 20 to 80 µl cell lysis 
buffer containing the detergent Triton X-100 and protease inhibitors. After incubation 
for 10 min on ice the suspension was centrifuged at 4°C and 16,000 x g for 5 min. The 
supernatant containing the solubilised proteins was transferred to new tubes. 
Determination of protein concentration and preparation of samples in 3 x LSB was 
carried out immediately after cell lysis and cell lysates were stored at -20°C until 
further use. 
Alternatively, cells were lysed directly in 3 x LSB on the plates and used for gel 
electrophoresis without determining protein concentrations. All medium was removed 
and cells were washed once in cold 1 x PBS. Cells in a 6-well plate were lysed by 
scraping in 100 µl 3 x LSB with a sterile disposable cell scraper. Lysates were 
homogenised using a motor pestle and boiled for 5 min at 95°C before loading on the 
gel or storage at -20°C for later use.  
2.2.4.2 Bradford assay 
Protein concentrations were determined using the Bradford method. This assay is 
based on the shift of the dye Coomassie from a doubly-protonated red form to an 
unprotonated blue form with an absorbance maximum at 595 nm when binding to 
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proteins in the sample. The resulting increase in the absorbance at 595 nm is 
proportional to the protein concentration. 
Samples were diluted 1:500 to 1:1000 in dH2O and BSA (bovine serum albumin) 
standards with concentrations ranging between 0 and 20 µg/ml were prepared. 100 µl 
of every sample or standard were mixed on a 96-well plate with 100 µl Bradford 
reagent (BioRad). The absorbance of each well was measured at 595 nm on a LT-4000 
microplate reader (Labtech) to calculate the protein concentration in individual samples 
via the BSA standard curve. 
2.2.4.3 Immunoprecipitation 
This technique is used to isolate complexes of a protein and its binding partners (co-
immunoprecipitation) from a solution using a specific antibody. Here, the specific 
antibody was added into a sample and antibody/protein complexes were isolated using 
protein A/G beads. 
Cells on 6-well plates were collected by scraping and washing with cold 1 x PBS. After 
centrifugation at 4°C and 1,000 x g for 5 min, the pellet was washed and centrifuged 
again for 15 min at 16,000 x g. The obtained cell pellet was resuspended in 250 µl to 
500 µl RIPA buffer, sonicated and incubated for 1 hour on ice. After centrifugation at 
4°C and 16,000 x g for 10 min the supernatant was transferred to a new tube and 
used for immunoprecipitation of the target proteins. 
For immunoprecipitations using magnetic PAG beads the supernatant was directly 
incubated with 2 µg of antibody against the protein of interest for 30 min under 
agitation at 4°C. 20 µl of washed Bio-Adembeads PAG (Ademtech) was added and 
incubated with the sample for 3 hours at 4°C. Using a magnetic rack, beads were 
washed and isolated from the solution and proteins were removed from the beads by 
resuspending in 50 µl 2 x LSB and 20 µl 3 x LSB and boiling for 5 min at 95°C. The 
pulled down protein complexes were stored at -20°C for gel electrophoresis. 
For immunoprecipitations using Protein A-Agarose beads the supernatant was 
subjected to pre-clearance with 50 µl washed Protein A-Agarose beads (Roche Applied 
Science) for 1 hour under agitation at 4°C. After centrifugation for 1 min at 4°C and 
16,000 x g the supernatant was incubated with 2 µg of antibody against the protein of 
interest for 1 hour under agitation at 4°C. The samples were then incubated with 
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100 µl of washed Protein A-Agarose beads overnight under agitation at 4°C. The next 
day the beads were washed three times by incubation with 300 µl RIPA buffer for 
15 min at 4°C, centrifugation for 1 min at 16,000 x g and discarding the supernatant. 
After the final wash the pellet was resuspended in 50 µl 2 x LSB and 20 µl 3 x LSB, 
boiled for 5 min at 95°C and centrifuged for 1 min at 16,000 x g. The supernatant was 
transferred to a fresh vial and stored at -20°C until gel electrophoresis. 
2.2.4.4 SDS-PAGE (Sodium Dodecylsulfate Polyacrylamide Gel Electrophoresis) 
In general this type of gel electrophoresis is used to analyse proteins which are, after 
denaturation by the anionic detergent SDS, separated by size on a polyacrylamide gel. 
The smaller the protein and the higher its negative charge, the faster it migrates 
through the gel matrix driven by an electric current. After separation proteins can be 
visualised and analysed by Coomassie staining or Western Blot analysis. 
For SDS-PAGE equal amounts of protein were resuspended in 3 x LSB and heated at 
95°C for 5 min to allow denaturation. Samples were either stored at -20°C or directly 
used for gel electrophoresis. 
Depending on the size of the proteins of interest different gel percentages, 
corresponding to the percentage of polyacrylamide crosslinking of the resolving gel, 
were used. The gels were cast according to the manufacturer’s instructions in a gel-
casting apparatus included in the Mini-PROTEAN system (BioRad). Freshly cast SDS 
gels were put into the electrophoresis tank filled with 1 x running buffer to cover the 
gels entirely. The complete sample volume was loaded in the pockets next to 4 µl of a 
prestained protein ladder (PageRuler, Fermentas). Electrophoresis was started at 80 V 
allowing protein migration through the stacking gel, before the voltage was increased 
to 100 V for up to 2 hours. 
2.2.4.5 Western blot analysis 
This method is used to detect specific target proteins. It is based on the 
electrophoretic transfer of proteins from an SDS gel to a nitrocellulose or 
polyvinylidene fluoride membrane where they can be detected by specific antibodies. 
While the primary antibody directly binds to the protein of interest on the membrane, 
the secondary antibody is species-specific (e.g. mouse, rat, rabbit), detecting the 
bound first antibody and is linked to a reporter enzyme. Here, horseradish peroxidase 
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(HRP) coupled secondary antibodies were applied that catalyse the conversion of a 
peroxidase substrate contained in the enhanced chemiluminescence (ECL) solution. 
The light emitted during this reaction can be captured on photographic films, creating 
an image of the bound antibodies on the membrane. 
After separation by SDS-PAGE, the proteins were transferred onto Whatman Protran 
nitrocellulose membranes (Sigma-Aldrich) using the tank-blotting method. Both the gel 
and the membrane were placed in a sandwich arrangement between sponges and 
three filter papers on each side and placed in a transfer tank (BioRad Criterion Blotter) 
filled with 1 x transfer buffer. Blotting was then carried out at 400 mA for 90 min or at 
40 mA overnight. 
After the transfer membranes were blocked for 1 hour in 5% dry milk or 3% BSA in 
1 x TBS-T to prevent unspecific binding of the detecting antibody to the membrane, 
followed by incubation with specific antibodies overnight at 4°C. Blots were then rinsed 
three times for 10 min with 1 x TBS-T and incubated for 1 hour at room temperature 
with the corresponding secondary antibody. After a second washing step 
HRP-conjugated secondary antibodies were detected using the ECL method. The blot 
was incubated for 1 min in freshly prepared ECL solution, drained and sealed in cling 
film. An RX X-ray film (Fujifilm) was exposed to the nitrocellulose membrane for 
varying times depending on signal strength and subsequently developed on a JB-33 
X-ray film processor (JPI). All antibody incubations and washing steps, except for 
incubations overnight, were performed at room temperature on a rocking table. For a 
second probing procedure after ECL visualisation, the blot was stripped for 10 min in 
Reblot Plus Strong buffer (Millipore) and incubated twice for 5 min in blocking solution. 
2.2.5 Flow cytometry methods 
FACS (fluorescence activated cell sorting) is a method used to sort and count cells 
according to different criteria like cell size, granularity or fluorescence. Cells in the 
solution of interest individually pass through an orthogonally applied laser beam 
resulting in the scattering of light and, in the presence of fluorescent labels, emission 
of fluorescent impulses that can be detected by appropriate fluorescence detectors. 
Forward scatter (FSC) and side scatter (SSC) represent light deviated in a small or 
large angle and correlate to cell size and granularity, respectively. During this work 
FACS analysis was performed for three purposes: 
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! to quantify cell death by Annexin V/PI staining 
! to measure transfection or infection efficiency through GFP expression 
! to analyse the cell cycle by PI staining 
For all assays, cells were plated on 12-well plates, harvested by trypsinisation at 
specific time points after treatment, washed with cold 1 x PBS and centrifuged at 
1,000 x g for 5 min. Cell fluorescence was measured on a FACS Canto II machine (BD 
Biosciences) and data was analysed using FlowJo software (Tree Star Inc.). 
2.2.5.1 Annexin V/PI staining 
FACS analysis can be used to distinguish living from apoptotic or necrotic cells. This 
assay relies on the use of two different fluorescent dyes to stain cells of interest: a 
recombinant fusion protein of Annexin V and allophycocyanin (APC) or fluorescein 
isothiocyanate (FITC) fluorophores, and the fluorescent DNA-binding dye PI. It permits 
quantification of apoptosis because healthy cells remain unstained, apoptotic cells will 
show APC or FITC fluorescence only and necrotic cells will be double positive for both 
Annexin V and PI.  
The cell pellet was resuspended in 100 µl of a 1:100 solution of Annexin V-APC 
(Molecular Probes) or Annexin V-FITC (BD Pharmingen) in calcium-containing 
Annexin V binding buffer. After incubation for 20 min in the dark to allow Annexin V 
binding, 200 µl binding buffer was added together with 10 µl PI stock solution directly 
before measurement.  
Alternatively, cell death was quantified by staining with PI alone, which will penetrate 
only into dead cells. The cell pellet was resuspended in 400 µl 1 x PBS and stained by 
addition of 10 µl PI stock solution only. 
2.2.5.2 Cell cycle analysis 
To distinguish cells in different phases of the cell cycle by FACS analysis cells can be 
permeabilised and stained with DNA-binding fluorescent dyes such as PI. The 
fluorescence intensity of this dye correlates to the cellular DNA content, indicating the 
respective cell cycle phase. Cells in G0/G1 phase contain one copy of DNA which is 
replicated in S phase, resulting in the double amount of cellular DNA in G2/M phase. 
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Moreover, detection of cells in sub-G1 phase containing less DNA than healthy cells 
allows for quantification of apoptosis. 
In preparation for cell cycle staining using PI cells were collected and centrifuged for 
5 min at 1,000 x g. The pellet was resuspended in 500 µl 1 x PBS and 4.5 ml cold 
70% ethanol and fixed for a minimum of 2 hours at -20°C. Before staining with PI, the 
cells were centrifuged for 10 min at 1,000 x g, the ethanol was decanted and the cell 
pellet was suspended in 200 µl to 500 µl staining solution containing PI and RNAse A. 
The samples were incubated at 37°C for 30 min and analysed within 24 hours. 
2.2.6 Imaging 
2.2.6.1 Indirect immunofluorescence 
Cells were seeded in Falcon 8-chamber culture slides (BD Biosciences) at densities 
between 2 x 104 and 5 x 104 cells per well and treated the next day. After defined time 
points cells were washed in 1 x PBS, fixed in 4% PFA for 10 min, washed again in 
1 x PBS and permeabilised with 0.2% Triton X-100 for 10 min.  
After washing three times in 1 x PBS cells were blocked for 30 min in 3% BSA in 
1 x PBS at 37°C in a humidity chamber and incubated with a specific primary antibody 
diluted in 3% BSA in 1 x PBS for 90 min at 37°C in a humidity chamber or overnight at 
4°C. The primary antibody was removed by three washes in 1 x PBS, after which cells 
were incubated with a fluorophore-labelled secondary antibody diluted in 3% BSA in 
1 x PBS for 1 hour as before and washed again. Cells were mounted in Vectashield 
mounting medium (Vector Laboratories) containing 4’,6-diamidino-2-phenylindole 
(DAPI) to stain nuclei. Images were acquired on the Olympus BX61 automated 
fluorescence microscope using Cell^F software (Olympus). Confocal microscopy 
images were acquired on an A1R Si Confocal System and Eclipse Ti-E Inverted 
Microscope (Nikon). 
2.2.6.2 PLA (Proximity Ligation Assay) 
The Duolink In Situ kit (Olink) allows for the detection of protein interactions or 
co-localisations directly in cells. It is based on the binding of two primary antibodies 
raised in different species recognising the proteins of interest, which are subsequently 
bound by species-specific proximity probes. If they are in close proximity the DNA 
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strands attached to the probes can be ligated to form a complete DNA circle. These 
circles are then amplified via rolling circle amplification during which labelled 
oligonucleotides are incorporated. The resulting product can be detected on a 
fluorescence microscope as a bright dot indicating a site of protein interaction. 
In preparation for the assay cells were seeded in Falcon 8-chamber culture slides (BD 
Biosciences) at densities between 2 x 104 and 5 x 104 cells per well and transfected the 
next day. After 1 or 2 days cells were washed three times for 5 min in 1 x PBS, fixed in 
4% PFA for 10 min, washed again in 1 x PBS and permeabilised with 0.2% Triton 
X-100 for 10 min. After washing three times in 1 x PBS for 5 min cells were blocked in 
80 µl blocking solution for 30 min at 37°C in a humidity chamber and then incubated 
with primary antibodies diluted in antibody diluent to 80 µl for 2 hours at 37°C.  
All further steps were carried out according to the manufacturer’s instructions in a 
reaction volume of 80 µl per well (Duolink In Situ kit, Olink). After mounting in DAPI-
containing mounting medium images were acquired on the Olympus BX61 automated 
fluorescence microscope using Cell^F software (Olympus) and analysed using 
Blobfinder software (Olink) to automatically detect and quantify positive signals. 
2.2.6.3 FLIM (Fluorescence Lifetime Imaging Microscopy) 
The fluorescent biosensor CKAR (C kinase activity reporter) is a tool to detect 
PKC-catalysed phosphorylation and measure cellular PKC activity. The modified 
reporter consists of GFP and RFP, flexibly linked by a PKC substrate sequence and an 
FHA2 phospho-threonine-binding domain and is based on a change of FRET between 
the two fluorophores upon PKC activation (Figure 5-2). PKC activity triggers a 
conformational change of the reporter due to binding of the phosphorylated substrate 
sequence to the FHA2 domain, reducing the amount of FRET from GFP to RFP. 
Alterations of FRET were detected by measuring changes in the fluorescence lifetime τ 
of the donor fluorophore GFP using FLIM and time-correlated single-photon counting.   
Cells were seeded on sterile coverslips in 24-well plates at a low density and 24 hours 
later transfected with the CKAR plasmid as well as a GFP-only control (eGFP-C1 or 
GFP-PKCα). The next day cells were infected with Ad-Apoptin at an MOI of 10 to 
express Apoptin for 2 up to 24 hours before fixation. Control cells were treated with 
TPA (Cell Signaling) to activate PKC or the PKC inhibitor Gö6976 (Calbiochem) for the 
indicated periods of time. For siRNA knockdown studies cells were transfected with 
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GAPDH or PKCβI siRNA 24 hours prior to infection or treatment. After treatment cells 
were washed in 1 x PBS and fixed in 4% PFA for 10 min. To reduce autofluorescence 
fixed cells were treated with 1 mg/ml sodium borohydride (NaBH4) and mounted on 
slides in 8 µl FluorSave mounting medium (Calbiochem).  
Time-domain FLIM was performed using a home-built two-photon laser-scanning 
microscope based on the modified Nikon Eclipse Ti inverted microscope. A mode-
locked Ti:Sapphire laser (Coherent, Chameleon Vision) with repetition rate of 80 MHz 
and pulse width of ~140 fs was tuned to 890 nm providing a photoexcitation source 
for GFP. GFP fluorescence was detected with a 40x objective lens non-descanned 
approach using a hybrid photo multiplier tube (PMT, HPM-100) in conjunction with a 
time-correlated single-photon counting (TCSPC, SCP-150) card (both from Becker & 
Hickl). 500/40 nm bandpass and 694 nm shortpass filters were used to select GFP 
emission and to cut-off any back scattered excitation. Images were acquired at 
256 x 256 pixels with peak photon counting rates kept below 107 photons per second 
to avoid pulse pile-up.  
The fluorescence lifetime τ was calculated by fitting bi-exponential fluorescence decay 
models to the images using TRI2 software (Paul Barber, University of Oxford). Output 
files were analysed to produce a distribution of the GFP lifetime across the cells and 
calculation of average donor lifetimes in single cells. 
2.2.7 Molecular biology 
2.2.7.1 Bacteria transformation 
For plasmid amplification chemically competent E.Coli (Mach1™-T1R, Invitrogen or 
MAX Efficiency® Stbl2™, Invitrogen) were transformed by adding 1 µl of plasmid DNA, 
leaving them on ice for 30 min followed by a heat shock (30 sec at 42°C) and a cold 
shock (at least 2 min on ice). Bacteria were then cultured in 250 µl LB medium for 
1 hour at 37°C before they were spread on a pre-warmed LB agar plate supplemented 
with the appropriate antibiotic. The plates were incubated overnight at 37°C and then 
stored at 4°C. Single colonies were picked into an appropriate volume of LB medium 
with antibiotic and incubated at 37°C while shaking overnight before plasmid 
extraction.   
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2.2.7.2 Glycerol stocks 
Glycerol stocks were generated from bacterial cultures containing plasmid constructs. 
800 µl bacterial culture was added to 200 µl sterile glycerol. Glycerol stocks were 
stored at -70°C and were used to re-start cultures by streaking them out on LB plates 
containing the appropriate antibiotic. 
2.2.7.3 Plasmid extraction 
Plasmid DNA was purified from bacterial cultures using either a Plasmid Midi Kit 
(Qiagen), Wizard Plus SV Miniprep DNA Purification System (Promega) or GenElute HP 
Plasmid Maxiprep Kit (Sigma-Aldrich) according to the manufacturer’s instructions. 
2.2.7.4 Determination of DNA concentration 
DNA concentrations were measured on a NanoDrop 1000 spectrophotometer (Thermo 
Scientific). 
2.2.7.5 Restriction digestion 
Reaction mixtures for digestion of plasmid DNA contained 1 µl restriction 
endonucleases, 1/10 volume of the accompanying 10 x restriction endonuclease buffer 
(New England Biolabs), 1 x BSA if required, approximately 1 µg plasmid DNA and dH2O 
in a total volume of 20 or 30 µl. In case two restriction enzymes were used 
simultaneously in a reaction, the buffer in which both enzymes showed the highest 
activity was used.  Reaction mixtures were incubated at 37°C for 1 hour. Digested 
plasmid DNA was subsequently analysed by agarose gel electrophoresis. 
2.2.7.6 Dephosphorylation of DNA termini 
Prevention of self-ligation of digested vector DNA with compatible termini can be 
achieved by dephosphorylation. In a total volume of 40 µl, approximately 1 µg of 
digested DNA was mixed with 2 U of calf intestinal alkaline phosphatase in the 
presence of 1 x restriction buffer 3 (New England Biolabs). The mixture was incubated 
for 1 hour at 37°C. 
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2.2.7.7 Conversion to blunt end DNA  
The 5’→3’ DNA polymerase activity of the large (Klenow) fragment of E.coli DNA 
polymerase I, which has lost 5’→3’ exonuclease activity, was used to modify 5’ 
extended termini of digested DNA into blunt ends. To 20 µl of digested plasmid DNA 
10 µl of reaction mix, consisting of 5 U Klenow polymerase (Abgene), 1 x endonuclease 
restriction buffer and dNTPs (New England Biolabs) at a final concentration of 100 µM 
in dH2O were added. The mixture was incubated for 15 min at room temperature 
followed by 20 min at 75°C to heat-inactivate Klenow polymerase. 
T4 DNA polymerase was used for the conversion of both 3’ and 5’ extended termini 
into blunt ends. Using a primer and template, it catalyses the synthesis of DNA in the 
5’→3’ direction. In addition, T4 DNA polymerase has 3’→5’ exonuclease activity that 
can be exploited to remove 3’-overhangs to generate blunt ends. T4 DNA polymerase 
was added to digested DNA in the presence of any 1 x restriction endonuclease buffer 
and 100 µM dNTPs (New England Biolabs). The mixture was incubated for 15 min at 
12°C and the enzyme was inactivated by heating to 75°C for 15 min. 
2.2.7.8 Agarose gel electrophoresis 
To prepare agarose gels a suitable amount of agarose (e.g. 1% w/v) was dissolved in 
100 ml 1 x TAE buffer by heating the mixture to boiling. After cooling down, ethidium 
bromide was added to a final concentration of 0.5 µg/ml and the solution was poured 
into a sealed gel chamber with inserted combs. The gel was allowed to set, placed in 
the electrophoresis tank and covered with 1 x TAE buffer. DNA samples were prepared 
by addition of 6 x Orange Loading Dye (Fermentas) and loaded on the gel next to a 
DNA molecular weight marker as a reference (Fermentas). The gel was run at 100 V 
for about 1 hour before visualisation of DNA on a UV transilluminator (Syngene) to 
take images or cut bands for gel extraction. 
2.2.7.9 Gel extraction 
After agarose gel electrophoresis, the required products and fragments were excised 
using a clean scalpel and DNA was extracted from the gel pieces using the QIAEX II 
Gel Extraction kit according to the manufacturer’s instructions (Qiagen). DNA was 
eluted by resuspending the resulting beads pellet in 15 µl dH2O and incubating the 
suspension for 5 min at 50°C. The beads were pelleted by centrifugation for 1 min at 
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13,000 x g and the supernatant was collected. Subsequently the beads pellet was 
resuspended again in 15 µl dH2O and the suspension was incubated for 5 min at 50°C. 
The supernatant was collected and the eluates were combined.  
2.2.7.10 Ligation 
To estimate the DNA concentrations of insert and linear vectors, gel extraction eluates 
were analysed by agarose gel electrophoresis. In the ligation reaction a molar 
insert:vector ratio of approximately 1:1 was used. Ligation mixtures contained 400 U 
T4 DNA ligase (New England Biolabs), 1 x ligase buffer and dH2O in a total volume of 
10 µl. The mixtures were incubated for 1 hour at room temperature.  
2.2.7.11 Sequencing 
Sequencing reactions on plasmid DNA were performed by Cambridge Bioscience or 
Lark Technologies. Primers were provided by the companies.  
2.2.8 Other methods 
2.2.8.1 Luciferase reporter assay 
Cells were seeded on 96-well plates at a density of 5 x 103 to 1 x 104 cells per well and 
co-transfected the next day with the two luciferase constructs pTK-Ren and 
pNF-κB-fosp. After 24 hours cells were infected with Ad-Apoptin or treated with the 
respective drugs. Treatment of cells with 10 ng/ml recombinant TNFα for 16 hours 
served as positive control for NF-κB activation. Luciferase activity was determined at 
the indicated time points using the Dual-Glo Luciferase Assay System according to the 
manufacturer’s instructions (Promega). Firefly and Renilla luciferase activities were 
measured sequentially in a Veritas Luminometer (Turner Biosystems). Untransfected 
cells served as a negative control, Renilla luciferase activity was used to correct for 
transfection efficiency and activation of NF-κB was normalised to the transfected, 
untreated control wells. 
2.2.8.2 MTT assay 
Cell viability after drug treatment was determined using the MTT assay. This assay 
relies on the reduction of tetrazolium salts (MTT) into insoluble formazan salts by 
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respiratory enzymes in metabolically active cells. This reaction results in a colour 
change proportional to the number of living cells exposed to MTT. 
To measure viability at different time points after treatment cells on 96-well plates 
were incubated for 2 to 4 hours with 20 µl MTT solution at 37°C and 5% CO2 before 
150 µl of MTT solubilisation solution was added. After further incubation at 37°C and 
5% CO2 for at least 16 hours the absorbance of each well was measured at 595 nm in 
a LT-4000 microplate reader (Labtech). All values were normalised to the respective 
untreated controls. 
2.2.9 Statistical analysis 
All data was analysed using Microsoft Excel and GraphPad Prism 6 software.  
Bars or data points throughout this study represent mean values of independent 
results while error bars indicate the corresponding standard error of the mean (SEM). 
The number of independent repeats, defined as separate experiments performed at 
different times, is specified by “n = x” in the figure descriptions. For experiments 
involving measurement of replicate data such as MTT assays performed in triplicate, 
replicate values were combined into an average value and considered as one 
independently obtained result. 
Prior to testing for statistical significance to determine P values the normal distribution 
of the obtained data was confirmed using Microsoft Excel. Depending on the 
experimental design several statistical methods were used and analysis were 
performed on independent samples as indicated by “n = x”. The difference between 
two groups was tested using an unpaired, two-tailed Student’s t test. To test for 
significant differences between more than two means of one variable the one-way 
analysis of variance (ANOVA) was used. When measuring several independent factors 
between several groups, such as different drug treatments of different cell lines, 
statistical significance was determined by two-way ANOVA. Following one- or two-way 
ANOVA the Bonferroni method was employed to correct for multiple comparisons and 
extract P values for differences between specific means. 
 










Apoptin, or VP3, is a small viral protein that has become of interest in cancer research 
due to its ability to induce tumour cell-specific apoptosis. It was originally isolated from 
chicken anaemia virus (CAV) which represents an important avian pathogen causing a 
severe and mostly fatal disease in young chicken (Noteborn and Koch 1995). Since its 
isolation in 1979 CAV has remained the only member of the Gyrovirus genus within the 
Circoviridae family (Yuasa et al. 1979). In recent years several novel Gyroviruses have 
been identified that share significant sequence homology with CAV, including Human 
Gyrovirus (Sauvage et al. 2011), Avian Gyrovirus 2 (Rijsewijk et al. 2011), Gyrovirus 3 
(Phan et al. 2012) and other yet uncharacterised viral species (Phan et al. 2013). The 
first human Gyrovirus HGyV, isolated from skin swabs of healthy volunteers, was 
shown to encode a VP3 protein resembling the organisation of CAV-Apoptin (Sauvage 
et al. 2011). Potentially, this protein might exhibit a similar or even enhanced cytotoxic 
effect in human tumour cells compared to CAV-Apoptin and could therefore represent 
a novel tool to study mechanisms of Apoptin-induced cell death. 
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3.2 Results 
3.2.1 Generation of Human Gyrovirus Apoptin 
To functionally compare the HGyV-derived VP3 protein (HGyV-Apoptin) to CAV-Apoptin 
it was generated based on the previously reported sequence data (Sauvage et al. 
2011). HGyV-Apoptin comprises 124 amino acids, compared to the 121 amino acids of 
CAV-Apoptin. Despite low overall sequence homology, HGyV-Apoptin contains similar 
conserved domains, including the nuclear localisation and nuclear export sequences, 
an LRS and potential phosphorylation sites (Figure 3-1). 
 
Figure	  3-­‐1:	  Sequence	  Comparison	  of	  CAV-­‐Apoptin	  and	  HGyV-­‐Apoptin	  Alignment	   of	   CAV-­‐Apoptin	   (UniProt	   P54094)	   and	   HGyV-­‐Apoptin	   (UniProt	  F6IB05)	   protein	   sequences	   indicating	   conserved	   functional	   domains	   (LRS:	  leucine-­‐rich	   stretch,	  NLS:	   nuclear	   localisation	   sequence,	  NES:	   nuclear	   export	  sequence).	  
A synthetic HGyV-Apoptin gene fused to GFP or FLAG was developed by Dr. Joop 
Gäken2 as described previously (Bullenkamp et al. 2012). The expression of 
HGyV-GFP-Apoptin (HGyV-GFP-AP) from the generated plasmid in HCT116 colorectal 
cancer cells was tested at 2 days after transfection by Western blot analysis. In 
agreement with the amino acid sequence with predicted molecular weights of 40.1 kDa 
for CAV-GFP-Apoptin and 40.5 kDa for HGyV-GFP-Apoptin, HGyV-GFP-Apoptin was 
detected at a slightly higher molecular weight than observed for CAV-GFP-Apoptin 
(Figure 3-2). Of note, an antibody specifically directed against phosphorylated Thr-108 
of CAV-Apoptin did not show any cross-reactivity with HGyV-Apoptin (data not shown).  
                                            
2 Department of Haemato-Oncology, King’s College London 
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Figure	  3-­‐2:	  Expression	  of	  HGyV-­‐GFP-­‐Apoptin	  in	  HCT116	  Cells	  Western	  blot	  analysis	  (12%	  SDS	  gel)	  showing	  the	  expression	  of	  GFP-­‐Apoptin	  in	   HCT116	   cells	   at	   2	  days	   post-­‐transfection	   with	   the	   indicated	   plasmids.	  Arrows	  indicate	  molecular	  weights	  of	  the	  pre-­‐stained	  protein	  ladder.	  	  
3.2.2 Subcellular localisation of HGyV-Apoptin in cancer and 
normal cells 
One of the major tumour cell-specific characteristics of CAV-Apoptin is its translocation 
to the nucleus of transformed cells, which is at least partially required for cell death 
induction. The expression pattern of HGyV-Apoptin in HCT116 cells was analysed by 
fluorescence microscopy after transfection with CAV-GFP-AP and HGyV-GFP-AP. Similar 
to CAV-GFP-Apoptin, HGyV-GFP-Apoptin exhibited a fine granular distribution in the 
nucleus of HCT116 cells at 2 days post-transfection (Figure 3-3).  
In contrast, nucleofection of Apoptin-expressing plasmids into normal 1BR3 fibroblasts 
resulted in a predominantly cytoplasmic localisation of both CAV-GFP-Apoptin and 
HGyV-GFP-Apoptin similar to GFP alone, indicating a comparable differential subcellular 
expression pattern of the two types of Apoptin in tumour and normal cells (Figure 3-4).  
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Figure	  3-­‐3:	  Nuclear	  Translocation	  of	  GFP-­‐Apoptin	  in	  HCT116	  Cells	  HCT116	  cells	  were	  transfected	  with	  the	  indicated	  plasmids	  and	  fixed	  at	  2	  days	  post-­‐transfection	   for	   fluorescence	   microscopy.	   Nuclei	   were	   detected	   by	  counterstaining	  with	  DAPI	  (original	  magnification	  60x,	  bar	  =	  20	  µm).	  
 
Figure	  3-­‐4:	  Localisation	  of	  Apoptin	  in	  the	  Cytoplasm	  of	  Normal	  Cells	  1BR3	   normal	   fibroblasts	   were	   transfected	   with	   the	   indicated	   plasmids	   by	  nucleofection	   and	   fixed	   at	   2	  days	   post-­‐transfection	   for	   fluorescence	  microscopy.	   Nuclei	   were	   detected	   by	   counterstaining	   with	   DAPI	   (original	  magnification	  60x,	  bar	  =	  20	  µm).	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Fusion to GFP has been suggested to enhance the ability of Apoptin to translocate to 
the nucleus even in non-transformed cells (Rohn et al. 2005). We therefore used 
FLAG-tagged Apoptin for comparison to exclude an effect of the GFP-tag for the 
observed tumour cell-specific accumulation of Apoptin in the nucleus. Indirect 
immunofluorescence staining of Saos-2 osteosarcoma cells transfected with Apoptin 
plasmids after 5 days revealed a similar expression pattern of FLAG-Apoptin and 
GFP-Apoptin for both CAV- and HGyV-derived Apoptin (Figure 3-5). 
The expression of both CAV-Apoptin and HGyV-Apoptin was associated with induction 
of an apoptotic nuclear morphology in transfected cells as detected by counterstaining 
with DAPI (Figure 3-6). This was more pronounced in cells expressing Apoptin fused to 
GFP than FLAG-tagged Apoptin, the former showing an apoptotic nuclear morphology 
in more than 60% of cells compared to approximately 40% in FLAG-expressing cells.  
 
Figure	  3-­‐5:	  Expression	  Pattern	  of	  GFP-­‐	  and	  FLAG-­‐Apoptin	  in	  Saos-­‐2	  Cells	  Saos-­‐2	   cells	   were	   transfected	   by	   nucleofection	   with	   the	   indicated	   plasmids	  and	   fixed	   at	   5	  days	   post-­‐nucleofection	   for	   fluorescence	   microscopy.	   Cells	  transfected	  with	  FLAG-­‐Apoptin	  were	  stained	  with	  a	  primary	  mouse	  anti-­‐FLAG	  and	  secondary	  FITC-­‐conjugated	  anti-­‐mouse	  antibody.	  Nuclei	  were	  detected	  by	  counterstaining	  with	  DAPI	  (original	  magnification	  60x,	  bar	  =	  20	  µm).	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Figure	  3-­‐6:	  Apoptotic	  Morphology	  Induced	  by	  Apoptin	  in	  Saos-­‐2	  Cells	  Saos-­‐2	   cells	   transfected	   with	   the	   indicated	   plasmids	   for	   5	   days	   were	   fixed,	  stained	  with	  a	  primary	  mouse	  anti-­‐FLAG	  and	  secondary	  FITC-­‐conjugated	  anti-­‐mouse	   antibody	   (for	   CAV-­‐FLAG-­‐AP	   and	   HGyV-­‐FLAG-­‐AP)	   and	   counterstained	  with	  DAPI	  for	  the	  detection	  of	  nuclear	  morphology.	  Cell	  death	  was	  quantified	  as	   the	   percentage	   of	   GFP-­‐	   or	   FLAG-­‐positive	   cells	   showing	   condensed	   or	  fragmented	  nuclei.	  Error	  bars	  indicate	  SEM	  (n	  =	  2).	  
3.2.3 Induction of apoptosis in Saos-2 cells 
To compare the cytotoxic function of HGyV-Apoptin and CAV-Apoptin Saos-2 cells were 
transfected with CAV-GFP-AP, HGyV-GFP-AP or eGFP-C1 by nucleofection. After 5 days 
cells were collected, stained with Annexin V and propidium iodide (PI) and analysed by 
flow cytometry (FACS) for the detection of apoptotic cells. FACS dot plots, indicating 
Annexin V and PI positive cell populations, showed both apoptotic (Annexin V single-
positive) and (secondary) necrotic (double-positive) cells following transfection of 
CAV-GFP-AP and HGyV-GFP-AP similar to control treatment with 10 µg/ml cisplatin 
(Figure 3-7a). In contrast, expression of GFP alone only induced negligible positive 
staining for either Annexin V or PI compared to untransfected cells.  
Due to the relatively low transfection efficiency, which varied between experiments, 
apoptosis was quantified as the percentage of Annexin V positive cells within the 
transfected, GFP positive cell population. This approach may underestimate the actual 
percentage of apoptotic cells because cells at later stages of apoptosis can lose GFP 
expression and would therefore be excluded from the analysis. After 5 days between 
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40 and 50% of cells expressing GFP-Apoptin were detected as apoptotic, whereas only 
5% of cells transfected with control eGFP-C1 stained positive for Annexin V 
(Figure 3-7b). The level of cell death induced by HGyV-GFP-AP was similar to that 
following expression of CAV-GFP-AP.  
    
 
Figure	  3-­‐7:	  Induction	  of	  Apoptosis	  in	  Saos-­‐2	  Cells	  by	  Apoptin	  Saos-­‐2	   cells	   were	   transfected	   by	   nucleofection	   with	   CAV-­‐GFP-­‐AP,	  HGyV-­‐GFP-­‐AP	  or	  the	  corresponding	  eGFP-­‐C1	  control	  plasmid	  or	  treated	  with	  10	  µg/ml	   cisplatin.	   Apoptosis	   was	   detected	   at	   5	  days	   post-­‐transfection	   by	  FACS	  analysis	  after	  Annexin	  V/PI	  staining.	  (a)	  Representative	  FACS	  dot	  plots	  indicating	   percentages	   of	   Annexin	  V	   and	   PI	   positive	   cell	   populations	   after	  gating	  on	  GFP	  positive	  cells	  are	  shown.	  (b)	  Quantification	  of	  cell	  death	  as	  the	  percentage	   of	   Annexin	  V-­‐labelled	   cells	   within	   the	   GFP	   positive	   population.	  Error	   bars	   indicate	   SEM	   (n	  =	  3);	   statistical	   significance	   compared	   to	   cells	  transfected	  with	  GFP	  was	  determined	  by	  one-­‐way	  ANOVA	  (***	  P	  <	  0.001).	  
(a) 
(b) 
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3.2.4 Generation of lentiviral vectors for HGyV-Apoptin 
CAV-Apoptin has been proposed as an effective tumour-specific cytotoxic agent in cell 
lines derived from haematological malignancies such as multiple myeloma (Jiang et al. 
2010). In contrast to adherent cancer cell lines, plasmid transfection of suspension 
cells is generally inefficient and they require other vectors such as retro- or lentiviruses 
to achieve expression of exogenous genes.  
We therefore generated a lentiviral HGyV-GFP-Apoptin vector (Lenti-HGyV-GFP-AP) by 
insertion of the HGyV-GFP-Apoptin gene into the same lentiviral backbone as used for 
Lenti-CAV-GFP-AP3. Lentiviral particles expressing HGyV-GFP-Apoptin were then 
produced in HEK293T cells as described in section 2.2.3.4. The expression of 
HGyV-GFP-Apoptin was tested by Western blot analysis following infection of the 
parentally matched MM1.R and MM1.S multiple myeloma cell lines with the indicated 
lentiviruses at an MOI of 5  (Figure 3-8). Infection with Lenti-HGyV-GFP-AP resulted in 
expression of HGyV-GFP-Apoptin at similar levels as observed for Lenti-CAV-GFP-AP 
and at the expected slightly higher molecular weight than CAV-GFP-Apoptin.  
 
Figure	  3-­‐8:	  Expression	  of	  Lenti-­‐GFP-­‐Apoptin	  in	  Multiple	  Myeloma	  Cells	  MM1.R	   and	   MM1.S	   cells	   were	   infected	   with	   Lenti-­‐CAV-­‐GFP-­‐AP	   (CAV),	  Lenti-­‐HGyV-­‐GFP-­‐AP	  (HGyV)	  or	  Lenti-­‐GFP	  (GFP)	  at	  an	  MOI	  of	  5	  in	  the	  presence	  of	  5	  µg/ml	  polybrene.	  The	  expression	  of	  GFP-­‐Apoptin	  at	  5	  days	  post-­‐infection	  was	   detected	   by	   Western	   blot	   analysis	   (15%	   SDS	   gel).	   Arrows	   indicate	  molecular	  weights	  of	  the	  pre-­‐stained	  protein	  ladder.	  	  
                                            
3 generated in collaboration with Dr. Joop Gäken, Department of Haemato-Oncology, King’s 
College London 
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3.2.5 `Cytotoxicity of HGyV-Apoptin in multiple myeloma cells 
The sensitivity of multiple myeloma cells to HGyV-Apoptin was investigated by PI 
staining of MM1.R and MM1.S cells infected with Lenti-HGyV-GFP-AP and 
Lenti-CAV-GFP-AP or control Lenti-GFP at an MOI of 5. Subsequent FACS analysis 
revealed significant induction of cell death, measured as PI positive cells within the 
GFP-expressing population, in cells expressing GFP-Apoptin compared to Lenti-GFP 
(Figure 3-9). CAV-GFP-Apoptin seemed to be more potent in inducing cell death than 
HGyV-GFP-Apoptin but this difference was not significant across several experiments. 
The levels of cell death observed after 7 days were similar in both cell lines while 
MM1.R cells were slightly more sensitive to Apoptin expression at 5 days post-infection 
than MM1.S cells. 
 
Figure	  3-­‐9:	   Cell	   Death	   Induction	   in	   Multiple	   Myeloma	   Cells	   by	  
Lenti-­‐Apoptin	  MM1.R	   and	   MM1.S	   cells	   were	   infected	   with	   Lenti-­‐CAV-­‐GFP-­‐AP	   (CAV),	  Lenti-­‐HGyV-­‐GFP-­‐AP	  (HGyV)	  or	  Lenti-­‐GFP	  (GFP)	  at	  an	  MOI	  of	  5	  in	  the	  presence	  of	  5	  µg/ml	  polybrene.	  Cell	  death	  was	  detected	  by	  PI	  staining	  after	  5	  and	  7	  days	  and	   quantified	   as	   percentage	   of	   PI	   labelled	   cells	   within	   the	   GFP	   positive	  population.	  Error	  bars	   indicate	  SEM	  (n	  =	  3);	  statistical	  significance	  compared	  to	   cells	   infected	   with	   Lenti-­‐GFP	   was	   determined	   by	   two-­‐way	   ANOVA	  (*	  P	  <	  0.05,	  **	  P	  <	  0.01,	  ***	  P	  <	  0.001,	  ns	  P	  >	  0.05). 
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3.2.6 Effect of HGyV-Apoptin in normal cells 
The sensitivity of normal cells to HGyV-Apoptin was tested in peripheral blood 
mononuclear cells (PBMCs) obtained from healthy patients. In preliminary experiments 
unstimulated PBMCs that were freshly isolated or thawed from liquid nitrogen did not 
survive the experimental conditions (data not shown). PBMCs were therefore 
stimulated prior to infection on culture plates by anti-CD3 antibodies to maintain their 
survival. In MM1.R cells infection with Lenti-CAV-GFP-AP or Lenti-HGyV-GFP-AP 
induced a shift towards a PI positive fraction compared to Lenti-GFP, whereas PI 
histograms of PBMCs did not show any difference between GFP- or Apoptin-infected 
cells at either 5 or 7 days post-infection (Figure 3-10a).  
Normalisation of the percentage of PI positive cells to untreated controls showed that 
PBMCs were not affected by Apoptin expression, which induced similar levels of cell 
death as GFP alone, while they were sensitive to treatment with 10 µg/ml cisplatin 
(Figure 3-10b). In contrast, approximately 80% of MM1.R cells infected with 
Lenti-GFP-Apoptin stained positive for PI compared to 50% for Lenti-GFP.  
Similarly, analysis of cell viability using the MTT assay confirmed a marked reduction of 
cell viability in MM1.R cells but not in PBMCs following infection with Lenti-GFP-Apoptin 
at 5 days post-infection (Figure 3-11).  
 
(a) 
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Figure	  3-­‐10:	  PI	  Staining	  of	  MM1.R	  Cells	  and	  PBMCs	  Expressing	  Apoptin	  MM1.R	   cells	   and	  PBMCs	   activated	   by	   0.1	  µg/ml	   anti-­‐CD3	  were	   infected	  with	  the	   indicated	   lentiviruses	   at	   an	   MOI	   of	   50	   in	   the	   presence	   of	   5	  µg/ml	  polybrene	   or	   treated	   with	   10	  µg/ml	   cisplatin	   as	   a	   control.	   Cell	   death	   was	  detected	   by	   PI	   staining	   after	   5	   and	   7	  days.	   (a)	   Histograms	   indicating	   PI	  positive	   cell	   populations	   of	   infected	   cells.	   (b)	  Quantification	   of	   cell	   death	   as	  the	   percentage	   of	   PI	   positive	   cells	   normalised	   to	   respective	   untreated	   cells	  after	  5	  days.	  
 
Figure	  3-­‐11:	  MTT	  Analysis	  of	  MM1.R	  Cells	  and	  PBMCs	  Expressing	  Apoptin	  MM1.R	   cells	   and	  PBMCs	   activated	   by	   0.1	  µg/ml	   anti-­‐CD3	  were	   infected	  with	  the	   indicated	   lentiviruses	   at	   an	   MOI	   of	   50	   in	   the	   presence	   of	   5	  µg/ml	  polybrene	   or	   treated	   with	   10	  µg/ml	   cisplatin	   as	   a	   positive	   control.	   Cell	  viability	  was	  analysed	  after	  5	  days	  by	  the	  MTT	  assay	  of	  triplicate	  wells. Bars	  represent	  mean	   cell	   survival	   normalised	   to	   the	   respective	   untreated	   control	  cells	  (n	  =	  1).	  	  
(b) 
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3.3 Discussion and Conclusions 
The discovery of an Apoptin homologue in a human virus opened up a number of new 
possibilities. HGyV-Apoptin might display a more enhanced cytotoxic effect in human 
cells than its avian counterpart and would therefore represent an improved novel tool 
for cancer therapy. The purpose of this study was to identify the function of the novel 
HGyV-Apoptin and compare its activity to CAV-Apoptin, especially with regard to its 
tumour-specific expression pattern and cytotoxic effect in human cell lines. 
As expected from their sequence HGyV-Apoptin was detected at a slightly larger 
molecular weight of approximately 42 kDa than CAV-Apoptin (41 kDa) by Western blot 
analysis (Figure 3-2). The tumour cell-specific expression pattern of CAV-Apoptin, 
characterised by translocation to the nucleus, was also demonstrated for 
HGyV-Apoptin, which localised to the nucleus of HCT116 colorectal cancer or Saos-2 
osteosarcoma cells but was predominantly cytoplasmic in non-transformed 1BR3 
fibroblasts (Figure 3-3, Figure 3-4, Figure 3-5).  
Importantly, nuclear expression of GFP- and FLAG-tagged HGyV-Apoptin in Saos-2 cells 
was associated with morphological changes indicating apoptosis in transfected cells, 
which was confirmed by FACS analysis specifically detecting cells undergoing apoptosis 
(Figure 3-6). The cytotoxic effect of HGyV-GFP-Apoptin was not only restricted to 
adherent cancer cell lines but was also observed in multiple myeloma cell lines 
(Figure 3-9). In contrast to multiple myeloma cells, normal PBMCs were insensitive to 
the apoptosis-inducing effect of HGyV-Apoptin, suggesting tumour cell-specific 
induction of cell death (Figure 3-10, Figure 3-11). 
Taken together, these results suggest that HGyV-Apoptin has very similar properties as 
previously described for CAV-Apoptin and exerts a comparable cytotoxic effect in 
human cancer cells. Further studies using other non-transformed cells will be 
necessary to confirm the tumour specificity of HGyV-Apoptin; however the data 
obtained from normal fibroblasts as well as healthy PBMCs indicate that HGyV-Apoptin 
preferentially kills cancer cells in a similar way to CAV-Apoptin. Overall, HGyV-Apoptin 
represents a novel tool for future studies investigating the mechanisms of Apoptin-
induced cell death and might help the future development of effective novel anti-
cancer agents. 
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It remains to be determined whether HGyV-Apoptin activation requires tumour cell-
specific phosphorylation. Similar to CAV-Apoptin it contains a number of serine and 
threonine residues representing potential phosphorylation sites for cellular kinases as 
predicted from its sequence (Figure 3-12, Appendix I). These include Thr-111 which, 
like Thr-108 of CAV-Apoptin, matches the consensus motif for phosphorylation by PKC 
(S/TXK/R or S/TXXK/R) (Kennelly and Krebs 1991) and is adjacent to a putative NES 
within the respective protein (Figure 3-1). The phosphorylation of HGyV-Apoptin in 
human cancer cells as well as mapping of specific phosphorylated residues within its 
sequence could be further investigated using in vitro kinase assays or orthophosphate 
labelling in future studies as previously performed for CAV-Apoptin (Rohn et al. 2002). 
Functional characterisation of this novel viral protein might also contribute to future 
investigations of its role in HGyV biology. So far no link between HGyV and any human 
disease has been reported but the cytotoxic effect of HGyV-Apoptin suggests a 
possible function in pathological processes. It also remains to be determined whether 
several other recently identified Gyrovirus strains contain VP3 proteins with similar 
characteristics. 
    
Figure	  3-­‐12:	  Phosphorylation	  Site	  Prediction	  Assay	  of	  Apoptin	  	  Netphos	   online	   phosphorylation	   site	   prediction	   assay	   of	   (a)	   CAV-­‐Apoptin	  (UniProt	   P54094)	   and	   (b)	   HGyV-­‐Apoptin	   (UniProt	   F6IB05)	   sequences	  (http://www.cbs.dtu.dk/services/NetPhos/).	   Full	   results	   are	   shown	   in	  Appendix	  II.	  
(a) 
(b) 





Results II  
Interaction of Apoptin and PKCβI 
 
4.1 Introduction 
Apoptin induces cell death in many different types of cancer cell lines while leaving 
normal cells unharmed (Zhuang et al. 1995a; Danen-Van Oorschot et al. 1997; Guelen 
et al. 2004). While the precise mechanism of Apoptin’s tumour specificity remains 
unknown, two major differences have been observed that influence its differential 
cytotoxic function in transformed cells (Figure 1-3). Apoptin accumulates in the nucleus 
of cancer cells, which is regulated through the activity of nuclear localisation and 
nuclear export signals as described in section 1.3.2.2 (Danen-Van Oorschot et al. 2003; 
Heilman et al. 2006). Importantly, in tumour cells Apoptin is phosphorylated on 
Thr-108 which promotes its nuclear translocation and pro-apoptotic function, 
suggesting the presence of tumour-specific cellular kinases that determine the 
apoptotic response to Apoptin expression (Rohn et al. 2002). Identification of such 
Apoptin kinases therefore improves our understanding of Apoptin function and also 
suggests general tumour-specific processes, which could prove useful for the future 
developments of targeted therapeutic agents.  
A previous study identified an interaction between Apoptin and PKCβ in MM1.R multiple 
myeloma cells, resulting in PKC-mediated phosphorylation of Apoptin (Jiang et al. 
2010). The sensitivity of a pair of parentally matched multiple myeloma cell lines to 
Apoptin correlated with the respective expression levels of PKCβ while shRNA-mediated 
downregulation or pharmacological inhibition of PKCβ resulted in decreased Apoptin 
phosphorylation. Based on these findings, the role of PKCβ for the regulation of 
Apoptin function was further investigated in multiple myeloma and other types of 
cancer cell lines as described in the following section. 
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4.2 Results 
4.2.1 Function of Apoptin in multiple myeloma cells 
The initial work presented here aimed at confirming the interaction of Apoptin and 
PKCβ in multiple myeloma cells and attempted to expand the role of PKCβ for Apoptin 
regulation to a broader panel of multiple myeloma cells. 
4.2.1.1 Interaction between Apoptin and PKCβI in MM1.R cells 
The binding of Apoptin to PKCβI was investigated in MM1.R cells infected with 
Lenti-CAV-GFP-AP, Lenti-HGyV-GFP-AP or Lenti-GFP at an MOI of 4. At 3 days post-
infection PKCβI was immunoprecipitated from total cell extracts. Subsequent Western 
blot analysis detected a co-immunoprecipitation (Co-IP) of PKCβI and CAV-GFP-Apoptin 
and weakly of HGyV-GFP-Apoptin but not GFP alone, suggesting an interaction of 
GFP-Apoptin and PKCβI in MM1.R cells (Figure 4-1). 
 
Figure	  4-­‐1:	  Co-­‐IP	  of	  GFP-­‐Apoptin	  and	  PKCβI	  in	  MM1.R	  Cells	  MM1.R	  cells	  were	  infected	  with	  Lenti-­‐GFP,	  Lenti-­‐CAV-­‐GFP-­‐AP	  (CAV)	  or	  Lenti-­‐HGyV-­‐GFP-­‐AP	   (HGyV)	   at	   an	  MOI	   of	   4	   in	   the	   presence	   of	   5	  µg/ml	   polybrene.	  Total	  cell	  lysates	  prepared	  in	  RIPA	  buffer	  and	  immunocomplexes	  pulled	  down	  with	  anti-­‐PKCβI	  antibody	  at	  3	  days	  post-­‐infection	  were	  subjected	  to	  Western	  blot	   analysis	   (10%	   SDS	   gel).	   Arrows	   indicate	  molecular	   weights	   of	   the	   pre-­‐stained	  protein	  ladder.	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4.2.1.2 PKCβ  expression and Apoptin sensitivity in multiple myeloma 
cells 
To further investigate the link between PKCβ and Apoptin in multiple myeloma a panel 
of multiple myeloma cell lines was tested regarding their PKCβ expression status and 
sensitivity to Apoptin. In contrast to MM1.R cells all other cell lines investigated here 
expressed markedly lower levels of PKCβII and lacked detectable expression of PKCβI 
(Figure 4-2).  
 
Figure	  4-­‐2:	  PKCβ 	  Expression	  in	  Multiple	  Myeloma	  Cell	  Lines	  Western	  blot	  analysis	   (10%	  SDS	  gel)	   to	  determine	  PKCβ	  expression	   levels	   in	  the	   indicated	  multiple	  myeloma	   cell	   lines	   grown	   for	   5	  days.	   Arrows	   indicate	  molecular	  weights	  of	  the	  pre-­‐stained	  protein	  ladder.	  
We next investigated the sensitivity of the indicated multiple myeloma cell lines to in 
Apoptin by infection with Lenti-GFP or Lenti-CAV-GFP-AP at an MOI of 2. PI staining 
and FACS analysis after 3 and 7 days showed no correlation between PKCβ expression 
levels and efficiency of cell death in response to Apoptin expression (Figure 4-3). In 
MM1.R cells, but also in RPMI8226 cells expressing lower levels of PKCβ, infection with 
Lenti-GFP-Apoptin triggered cell death in approximately 80% of infected cells after 
7 days, while it did not significantly affect the survival of U266 or KMS-12-BM cells 
compared to expression of GFP alone.  




Figure	  4-­‐3:	  Apoptin	  Sensitivity	  of	  Multiple	  Myeloma	  Cell	  Lines	  The	  indicated	  cell	  lines	  were	  infected	  with	  Lenti-­‐GFP	  or	  Lenti-­‐CAV-­‐GFP-­‐AP	  at	  an	  MOI	  of	  2	  in	  the	  presence	  of	  5	  µg/ml	  polybrene.	  Cell	  death	  was	  detected	  by	  PI	   staining	   and	   FACS	   analysis	   after	   3	  	   (a)	   and	   7	  (b)	   days,	   quantified	   as	   PI	  positive	   cells	   in	   the	   GFP	   positive	   cell	   population.	   Error	   bars	   indicate	   SEM	  (n	  =	  3;	   n	  =	  1	   for	   KMS-­‐12-­‐BM);	   statistical	   significance	   compared	   to	   Lenti-­‐GFP	  was	  determined	  by	  two-­‐way	  ANOVA	  (*	  P	  <	  0.05,	  **	  P	  <	  0.01,	  ns	  P	  >	  0.05).	  
4.2.2 Interaction of Apoptin and PKCβI in colon cancer cells 
The above results do not indicate general correlation between PKCβ expression levels 
and sensitivity to Apoptin-induced cell death in multiple myeloma cells. This led us to 
investigate other cancer cell types to study PKCβI in the context of Apoptin activation. 
Previous work in our laboratory showed that the colorectal cancer cell line HCT116 
expresses elevated levels of PKCβI and is highly sensitive to Apoptin-induced cell death 
when compared to normal colon mucosa cell lines. In the following section the 
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4.2.2.1 Co-immunoprecipitation of Apoptin and PKCβI in HCT116 cells 
To test whether Apoptin binds to PKCβI in colon cancer cells, HCT116 cells were 
infected with Lenti-CAV-GFP-AP or Lenti-GFP at an MOI of 2 and collected after 4 days 
for immunoprecipitation with anti-PKCβI antibodies. Western blot analysis showed that 
CAV-GFP-Apoptin was pulled down in complexes with PKCβI, indicating binding of 
Apoptin to PKCβI in HCT116 cells (Figure 4-4). The detected band was, however, quite 
faint which might be due to a small interacting fraction of the two proteins, a transient 
interaction or insufficient pull-down of PKCβI.  
 
Figure	  4-­‐4:	  Co-­‐IP	  of	  GFP-­‐Apoptin	  and	  PKCβI	  in	  HCT116	  Cells	  HCT116	  cells	  were	  infected	  with	  Lenti-­‐GFP	  (GFP)	  or	  Lenti-­‐CAV-­‐GFP-­‐AP	  (Apo)	  at	   an	   MOI	   of	   2	   in	   the	   presence	   of	   5	  µg/ml	   polybrene.	   Total	   cell	   lysates	  prepared	  in	  RIPA	  buffer	  and	  immunocomplexes	  pulled	  down	  with	  anti-­‐PKCβI	  antibody	   at	   4	  days	   post-­‐infection	   were	   subjected	   to	   Western	   blot	   analysis	  (12%	  SDS	  gel).	  Arrows	  indicate	  molecular	  weights	  of	  the	  pre-­‐stained	  protein	  ladder.	  
In some cases co-immunoprecipitation of two proteins of interest is not possible when 
pulling down endogenous proteins. HCT116 cells were therefore co-transfected with 
plasmids to express CAV- or HGyV-FLAG-Apoptin as well as HA-PKCβI and collected 
after 2 days for immunoprecipitation with anti-FLAG or anti-HA antibodies. Western 
blot analysis of the pulled down complexes showed a clear co-immunoprecipitation of 
HA-PKCβI with both CAV- and HGyV-FLAG-Apoptin and vice versa (Figure 4-5). Despite 
similar expression levels shown in total cell lysates, the interaction between 
HGyV-Apoptin and PKCβI seemed to be markedly weaker than that of CAV-Apoptin. 




Figure	  4-­‐5:	  Co-­‐IP	  of	  FLAG-­‐Apoptin	  and	  HA-­‐PKCβI	  in	  HCT116	  Cells	  HCT116	   cells	  were	   co-­‐transfected	  with	  CAV-­‐FLAG-­‐AP	  or	  HGyV-­‐FLAG-­‐AP	  and	  HA-­‐PKCβI.	   Immunocomplexes	  pulled	  down	  with	  either	  anti-­‐HA	  or	  anti-­‐FLAG	  antibodies	  (a)	  and	  total	  cell	  lysates	  prepared	  in	  RIPA	  buffer	  (b)	  at	  2	  days	  post-­‐transfection	  were	   subjected	   to	  Western	  blot	   analysis	   (12%	  SDS	  gel).	  Arrows	  indicate	  molecular	  weights	  of	  the	  pre-­‐stained	  protein	  ladder.	  
4.2.2.2 Detection of the interaction between Apoptin and PKCβI using 
the Proximity Ligation Assay 
The above results indicate binding of Apoptin to PKCβI in HCT116 cells; however, 
overexpression of PKCβI was required for successful co-immunoprecipitation which 
might not entirely reflect the endogenous conditions. We therefore investigated other 
strategies for the detection of protein-protein interactions. As a relatively novel 
technology the in situ proximity ligation assay (PLA) allows for the visualisation of 
(a) 
(b) 
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specific protein complexes in fixed cells. It does not require overexpression of the 
potential binding partners and provides more detailed information regarding the 
subcellular localisation and quantification of positive signals. As described in section 
2.2.6.2 and illustrated in Figure 4-6, the PLA is based on the binding of two primary 
antibodies derived from different species to the target proteins which are subsequently 
detected by secondary antibodies linked to short DNA strands,  also referred to as 
proximity probes. If the target proteins are present within the same complex or 
co-localise and are therefore in close proximity these DNA strands can be ligated by 
connector oligonucleotides to form a circular DNA template which is then amplified in a 
rolling circle amplification step incorporating fluorescently labelled nucleotides. The 
resulting product can be detected as distinct spots on a fluorescence microscope that 
indicate an interaction of the proteins of interest.  
 
Figure	  4-­‐6:	  Concept	  of	  the	  Proximity	  Ligation	  Assay	  Illustration	  of	  the	  PLA	  reaction	  (adapted	  from	  Soderberg	  et	  al.	  (2008)).	  
As a positive control for all assays HCT116 cells were transfected with CAV-FLAG-AP or 
pcDNA3 for 48 hours before PLA analysis using anti-FLAG and anti-P-Apoptin 
antibodies. Images obtained on a fluorescence microscope showed a large number of 
clear bright red dots representing positive signals, in the nucleus of cells transfected 
with CAV-FLAG-AP but only few in pcDNA3 control transfected cells (Figure 4-7a).  
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Automated quantification of positive signals in at least 100 cells per treatment revealed 
an average number of approximately 25 signals in Apoptin-transfected cells compared 
to less than 10 in control cells (Figure 4-7b). The relatively low average number of 
signals in this positive control compared to fluorescent images is most likely due to the 
fact that the analysis also includes untransfected cells, not allowing selective analysis 
of cells expressing FLAG-Apoptin only. 
 
 
Figure	  4-­‐7:	  Detection	  of	  Protein	  Interactions	  using	  the	  PLA	  
(a)	   Representative	   immunofluorescence	   images	   of	   PLA	   staining	   in	   HCT116	  cells	   at	   2	  days	   post-­‐transfection	   with	   CAV-­‐FLAG-­‐AP	   or	   pcDNA3	   using	  anti-­‐FLAG	   and	   anti-­‐P-­‐Apoptin	   antibodies;	   nuclei	   were	   counterstained	   with	  DAPI	  (original	  magnification	  60x,	  bar	  =	  10	  µm).	  (b)	  Quantification	  of	  positive	  PLA	  signals	  using	  Blobfinder	  software.	  Bars	  represent	  the	  average	  number	  of	  signals	  per	  cell	  calculated	  from	  at	  least	  100	  analysed	  cells;	  error	  bars	  indicate	  SEM	   (n	  =	  3).	   Statistical	   significance	   was	   determined	   using	   the	   unpaired,	  two-­‐tailed	  Student’s	  t	  test	  (***	  P	  <	  0.001).	  
(a) 
(b) 
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To confirm the interaction of Apoptin and endogenous PKCβI HCT116 cells were 
transfected with CAV-FLAG-AP, HGyV-FLAG-AP or pcDNA3 as a control and analysed by 
PLA using anti-FLAG and anti-PKCβI antibodies at 2 days post-transfection. Apoptin-
transfected cells showed an average number of 16 or 14 signals per cell for 
CAV-FLAG-Apoptin or HGyV-FLAG-Apoptin, respectively, significantly more than present 
in control cells transfected with pcDNA3 (Figure 4-8a). The number of signals per cell 
ranged from 0 foci, probably representing untransfected cells, to more than 90 
(Figure 4-8b). These positive signals following expression of Apoptin were mainly 
localised in the nucleus of transfected cells, indicating nuclear co-localisation of PKCβI 
and Apoptin (Figure 4-8c). 
The quantitative analyses above also included untransfected cells, resulting in low but 
significantly higher average numbers of positive signals in Apoptin-treated cells 
compared to control cells. To specifically analyse cells expressing Apoptin or the 
respective control, HCT116 cells were transfected with CAV-GFP-AP, HGyV-GFP-AP or 
eGFP-C1. PLA analysis using anti-GFP and anti-PKCβI antibodies at 24 and 48 hours 
post-transfection detected positive signals in cells transfected with GFP-Apoptin but not 
in cells expressing GFP only (Figure 4-9a). Excluding untransfected cells that lacked 
GFP expression, an average number of 20 to 30 signals was detected in cells 
transfected with CAV-GFP-AP or HGyV-GFP-AP, compared to only 2 signals on average 
in GFP-transfected cells (Figure 4-9b). The majority of dots was localised in the nucleus 
of Apoptin-expressing cells, corresponding to the expected localisation of Apoptin 
expression. 
Taken together these results indicate that - as previously detected in multiple myeloma 
cell lines - Apoptin interacts with endogenous PKCβI in colon cancer cells and that the 
interaction occurs primarily in the nucleus. 
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Figure	  4-­‐8:	  PLA	  of	  FLAG-­‐Apoptin	  and	  PKCβI	  in	  HCT116	  Cells	  HCT116	  cells	  were	  transfected	  with	  CAV-­‐FLAG-­‐AP,	  HGyV-­‐FLAG-­‐AP	  or	  pcDNA3	  and	   analysed	   by	   PLA	   at	   2	  days	   post-­‐transfection	   using	   anti-­‐FLAG	   and	  anti-­‐PKCβI	   antibodies.	   (a)	   Quantification	   of	   PLA	   signals	   using	   Blobfinder	  software.	   Bars	   represent	   the	   average	   number	   of	   signals	   per	   cell	   calculated	  from	   at	   least	   100	   cells	   (excluding	   cells	   with	   1	   or	   less	   signals);	   error	   bars	  indicate	   SEM	   (n	  =	  3).	   Statistical	   significance	   was	   determined	   by	   one-­‐way	  ANOVA	  (*	  P	  <	  0.05,	  **	  P	  <	  0.01).	  (b)	  Distribution	  of	  number	  of	  signals	  per	  cell,	  indicating	   maximum,	   minimum	   and	   median	   values.	   (c)	   Representative	  immunofluorescence	   images	  of	  PLA	  staining	   showing	  nuclei	   (DAPI)	   and	  PLA	  signals	  (original	  magnification	  60x,	  bar	  =	  10	  µm).	  
(c) 
(b) (a) 




Figure	  4-­‐9:	  PLA	  of	  GFP-­‐Apoptin	  and	  PKCβI	  in	  HCT116	  Cells	  HCT116	  cells	  were	  transfected	  with	  CAV-­‐GFP-­‐AP	  (CAV),	  HGyV-­‐GFP-­‐AP	  (HGyV)	  or	   eGFP-­‐C1	   and	   analysed	   by	   PLA	   at	   1	   and	   2	  days	   post-­‐transfection	   using	  anti-­‐GFP	  and	  anti-­‐PKCβI	   antibodies.	   (a)	  Representative	   immunofluorescence	  images	  of	  PLA	  staining	  showing	  nuclei	  (DAPI),	  PLA	  signals	  and	  GFP	  (original	  magnification	   60x,	   bar	  =	  10	  µm).	   (b)	   Quantification	   of	   PLA	   signals	   using	  Blobfinder	   software.	   Bars	   represent	   the	   average	   number	   of	   signals	   per	   cell	  calculated	   from	   at	   least	   100	   GFP-­‐expressing	   cells,	   indicating	   nuclear	   or	  cytoplasmic	  localisation	  of	  foci	  (n	  =	  1).	  	  	  
(a) 
(b) 
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4.2.2.3 Interaction of N-terminally truncated Apoptin with PKCβI 
To test which region of Apoptin is required for its binding to PKCβI an N-terminally 
truncated GFP-Apoptin mutant was used lacking amino acids 1 to 73, which includes 
the LRS and a putative NES (Figure 1-2). HCT116 cells were co-transfected with 
HA-PKCβI and the indicated GFP-Apoptin plasmids and collected after 2 days for 
immunoprecipitation using anti-HA and anti-GFP antibodies. The results obtained from 
Western blot analyses of the pulled down protein complexes were, however, 
inconclusive (Figure 4-10). A faint band corresponding to HA-PKCβI was detected in 
complexes immunoprecipitated with anti-GFP antibodies from cells co-transfected with 
any of the GFP-Apoptin plasmids. However, it was also visible in cells expressing GFP 
only, which suggests this to be unspecific binding.  
The binding of full length (amino acids 1 to 121) or N-terminally truncated (amino 
acids 74 to 121) Apoptin to PKCβI was further investigated by PLA analysis in HCT116 
cells transfected with the respective GFP-Apoptin plasmids or eGFP-C1. PLA staining at 
2 days post-transfection using anti-GFP and anti-PKCβI antibodies showed positive 
signals in cells transfected with full length GFP-Apoptin as well as, to a lesser extent, 
cells expressing truncated Apoptin or GFP alone (Figure 4-11a). Notably, a truncated 
Apoptin mutant, in which Thr-108 was replaced with an unphosphorylatable alanine 
residue (74-121 T108A), was localised both to the nucleus and the cytoplasm of 
HCT116 cells, highlighting the importance of Thr-108 phosphorylation for nuclear 
accumulation of Apoptin.  
While positive signals could be detected using any of the GFP-Apoptin plasmids, only 
cells transfected with full length Apoptin contained significantly more signals than cells 
expressing GFP alone (Figure 4-11b). By contrast, cells expressing the N-terminally 
truncated forms of Apoptin 74-121 or 74-121 T108A showed only a small increase in 
the average number of signals compared to GFP alone. These data suggest that the 
Apoptin domain required for its interaction and co-localisation with PKCβI may be 
located within the N-terminal region of the protein.  




Figure	  4-­‐10:	   Co-­‐IP	   of	   GFP-­‐Apoptin	   Mutants	   and	   HA-­‐PKCβI	   in	   HCT116	  
Cells	  HCT116	  cells	  were	  co-­‐transfected	  with	  eGFP-­‐C1	  or	  the	  indicated	  GFP-­‐Apoptin	  plasmids	   (1-­‐121,	   74-­‐121,	   74-­‐121	   T108A)	   and	   HA-­‐PKCβI.	   Immunocomplexes	  pulled	   down	   with	   anti-­‐HA	   or	   anti-­‐GFP	   antibodies	   (a)	   and	   total	   cell	   lysates	  prepared	   in	   RIPA	   buffer	   (b)	   at	   2	  days	   post-­‐transfection	   were	   subjected	   to	  Western	   blot	   analysis	   (10%	   SDS	   gel).	   Arrows	   indicate	  molecular	  weights	   of	  the	  pre-­‐stained	  protein	  ladder.	  
(a) 
(b) 




Figure	  4-­‐11:	  PLA	  of	  GFP-­‐Apoptin	  Mutants	  and	  PKCβI	  in	  HCT116	  Cells	  HCT116	   cells	   were	   transfected	   with	   eGFP-­‐C1	   or	   the	   indicated	   GFP-­‐Apoptin	  plasmids	  (1-­‐121,	  74-­‐121,	  74-­‐121	  T108A)	  and	  analysed	  by	  PLA	  using	  anti-­‐GFP	  and	   anti-­‐PKCβI	   antibodies	   at	   2	  days	   post-­‐transfection.	   (a)	   Representative	  immunofluorescence	   images	   of	   PLA	   staining	   showing	   nuclei	   (DAPI),	   PLA	  signals	  and	  GFP	  (original	  magnification	  60x,	  bar	  =	  10	  µm).	  (b)	  Quantification	  of	  PLA	  signals	  using	  Blobfinder	  software.	  Bars	  represent	  the	  average	  number	  of	  signals	  per	  cell	  calculated	  from	  at	  least	  100	  GFP-­‐expressing	  cells;	  error	  bars	  indicate	   SEM	   (n	  =	  3).	   Statistical	   significance	   was	   determined	   by	   one-­‐way	  ANOVA	  (*	  P	  <	  0.05,	  ns	  P	  >	  0.05).	  	  
(a) 
(b) 
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4.2.3 Characterisation of Ad-Apoptin 
In order to achieve high transduction efficiency in various cell types an adenoviral 
vector to express untagged Apoptin (Ad-Apoptin) was previously generated in our 
laboratory using the AdEasy system (Taebunpakul et al. 2012). Initially, the cytotoxic 
effect of Ad-Apoptin was investigated in several cancer cell lines, including HCT116 
colorectal cancer cells, MM1.R multiple myeloma cells, Saos-2 osteosarcoma cells and 
HeLa cervical cancer cells. Infection with Ad-Apoptin at an MOI of 40 decreased cell 
viability of all cell lines compared to infection with Ad-GFP (Figure 4-12). 
 
Figure	  4-­‐12:	  Cell	  Viability	  of	  Cancer	  Cells	  after	  Infection	  with	  Ad-­‐Apoptin	  HCT116	   (a),	   Saos-­‐2	   (b),	   MM1.R	   (c)	   and	   HeLa	   (d)	   cells	   were	   infected	   with	  Ad-­‐GFP	  or	  Ad-­‐Apoptin	  at	  an	  MOI	  of	  40	  or	  treated	  with	  10	  µg/ml	  cisplatin.	  Cell	  viability	   was	   assessed	   at	   the	   indicated	   time	   points	   by	   MTT	   analysis.	   Bars	  represent	   mean	   cell	   survival	   from	   triplicate	   wells	   normalised	   to	   untreated	  controls	  (n	  =	  1).	  
This was associated with morphological changes indicating cell death such as shrinking 
and detachment of cells as shown by light microscopy of HCT116 and Saos-2 cells at 
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Figure	  4-­‐13:	  Morphology	  of	  Cancer	  Cells	  after	  Infection	  with	  Ad-­‐Apoptin	  HCT116	  and	  Saos-­‐2	  cells	  were	  infected	  with	  Ad-­‐GFP	  or	  Ad-­‐Apoptin	  at	  an	  MOI	  of	  40	  and	  analysed	  for	  morphological	  changes	  after	  1	  day	  by	  light	  microscopy	  (original	  magnification	  10x,	  bar	  =	  50	  µm).	  
To confirm that the expression of Apoptin from this adenoviral vector induces 
apoptosis, HCT116 and HeLa cells were infected with Ad-GFP or Ad-Apoptin at different 
MOIs and analysed by Annexin V/PI staining and flow cytometry after 24 hours. The 
obtained FACS dot plots showed a clear shift towards an Annexin V positive population 
induced by infection with Ad-Apoptin compared to control or Ad-GFP infected cells 
(Figure 4-14a). Approximately 40% of HCT116 cells and 50% of HeLa cells were killed 
by Ad-Apoptin at an MOI of 10 compared to 10% following infection with Ad-GFP, 
which was enhanced at a higher MOI (Figure 4-14b).  
 
(a) 
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Figure	  4-­‐14:	   Induction	   of	   Apoptosis	   in	   Cancer	   Cells	   after	   Infection	  with	  
Ad-­‐Apoptin	  HCT116	   and	   HeLa	   cells	   were	   infected	   with	   Ad-­‐GFP	   or	   Ad-­‐Apoptin	   at	   the	  indicated	  MOIs.	  Cells	  were	  collected	  after	  24	  hours	  for	  cell	  death	  detection	  by	  Annexin	  V/PI	   staining	   and	   FACS	   analysis.	   (a)	   FACS	   dot	   plots	   indicating	  Annexin	  V	  and	  PI	  positive	  cell	  populations.	  (b)	  Bars	  indicate	  the	  percentage	  of	  dead	  cells	  defined	  as	  either	  Annexin	  V	  or	  PI	  positive	  (n	  =	  1).	  
4.2.4 Activity of Apoptin in colon cancer and normal cell lines 
Further studies regarding the functional link between PKCβ and tumour-specific 
Apoptin-induced cell death were conducted using HCT116 cells, in which an interaction 
of Apoptin and PKCβI was demonstrated as described above. In the following section 
the function and activation of Apoptin were compared between HCT116 cancer cells 
and two normal colon mucosa (NCM) cell lines which differ in their respective 
expression levels of PKCβ. Both NCM356 and NCM460 cells were shown to contain 
similar levels of PKCβII as HCT116 cells whereas the expression levels of PKCβI were 
markedly lower in NCM356 cells and nearly undetectable in NCM460 cells 
(Figure 4-15). Compared to HCT116 cells these normal colon mucosa cell lines were 
also characterised by a significantly slower growth rate (Figure 4-16, Table 4-1). 
 
(b) 




Figure	  4-­‐15:	  Expression	  of	  PKCβ 	  in	  Colon	  Cancer	  and	  Normal	  Cells	  
(a)	  Western	  blot	  analysis	  (10%	  SDS	  gel)	  to	  determine	  PKCβ	  expression	  levels	  in	   HCT116,	   NCM356	   and	   NCM460	   cells	   grown	   for	   2	  days.	   Arrows	   indicate	  molecular	   weights	   of	   the	   pre-­‐stained	   protein	   ladder.	   (b)	   PKCβI	   expression	  levels	  relative	  to	  Tubulin	  or	  Actin	  were	  quantified	  using	  ImageJ	  software	  and	  normalised	   to	   HCT116	   cells.	   Error	   bars	   indicate	   SEM	   (n	  =	  3);	   statistical	  significance	  was	  determined	  by	  one-­‐way	  ANOVA	  (***	  P	  <	  0.001).	  
 
Figure	  4-­‐16:	  Growth	  Curves	  of	  Colon	  Cancer	  and	  Normal	  Cells	  Growth	   curves	   of	   HCT116,	   NCM356	   and	   NCM460	   cells	   were	   prepared	   by	  counting	  cells	  every	  24	  hours	  for	  5	  consecutive	  days.	  Error	  bars	  indicate	  SEM	  (n	  =	  2).	  	  	  	  	  
(a) (b) 
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Cell Line Doubling Time 
NCM460 25.57 hours 
NCM356 38.75 hours 
NCM460 35.18 hours 
	  
Table	  4-­‐1:	  Growth	  Rates	  of	  Colon	  Cancer	  and	  Normal	  Cells	  
4.2.4.1 Localisation of Apoptin in colon cancer and normal cells 
Cancer cells are characterised by accumulation of Apoptin in the nucleus while it is 
predominantly localised to the cytoplasm of normal cells. To compare the expression 
pattern of Apoptin HCT116, NCM356 and NCM460 cells were transfected with 
CAV-FLAG-AP or HGyV-FLAG-AP for indirect immunofluorescence staining using 
anti-FLAG antibodies after 24 hours. As shown by fluorescence microscopy 
FLAG-Apoptin accumulated in the nucleus of HCT116 cells but was expressed in the 
cytoplasm of both normal cell lines (Figure 4-17a).  
   
(a) 




Figure	  4-­‐17:	  Localisation	  of	  Apoptin	  in	  Colon	  Cancer	  and	  Normal	  Cells	  HCT116,	  NCM356	  and	  NCM460	  cells	  were	   transfected	  with	  CAV-­‐FLAG-­‐AP	  or	  HGyV-­‐FLAG-­‐AP,	   fixed	   after	   24	  hours	   and	   stained	   with	   a	   primary	   mouse	  anti-­‐FLAG	  and	   secondary	  FITC-­‐conjugated	   anti-­‐mouse	   antibody.	  Nuclei	  were	  detected	   by	   counterstaining	   with	   DAPI.	   (a)	   Representative	  immunofluorescence	   images	   (original	   magnification	   60x,	   bar	  =	  10	  µm).	   (b)	  Representative	   confocal	   images	   (original	   magnification	   100x,	   bar	  =	  20	  µm).	  
(c)	  Quantification	  of	  Apoptin	  localisation	  in	  the	  nucleus	  or	  the	  cytoplasm.	  Bars	  represent	   the	   percentage	   of	   cells	   showing	   nuclear	   accumulation	   of	   Apoptin,	  scoring	   at	   least	   50	   transfected	   cells	   per	   sample.	   Error	   bars	   indicate	   SEM	  (n	  =	  3);	  statistical	  significance	  was	  determined	  by	  two-­‐way	  ANOVA	  (*	  P	  <	  0.05,	  **	  P	  <	  0.01,	  ***	  P	  <	  0.001,	  ns	  P	  >	  0.05).	  
(b) 
(c)	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The two-dimensional images obtained on a fluorescence microscope do not clearly 
show whether Apoptin localises to both the nucleus and the cytoplasm or only to the 
cytoplasm of normal cells. Samples were therefore analysed by confocal microscopy to 
acquire three-dimensional images, which confirmed a cytoplasmic expression pattern 
of Apoptin in NCM356 and NCM460 cells (Figure 4-17b). Quantification of Apoptin 
localisation in at least 50 transfected cells per sample showed that Apoptin was almost 
exclusively present in the nucleus of HCT116 cells while the majority of normal cells 
showed Apoptin expression in the cytoplasm as well as partially the nucleus 
(Figure 4-17c). 
4.2.4.2 Phosphorylation of Apoptin in colon cancer and normal cells 
In tumour cells but not in normal cells Apoptin is phosphorylated on Thr-108, which is 
important for its nuclear accumulation and induction of cell death. To investigate the 
respective phosphorylation status of Apoptin HCT116, NCM356 and NCM460 cells were 
infected with Lenti-CAV-FLAG-AP at an MOI of 5. Western blot analysis at 2 days post-
infection revealed markedly higher total expression levels of FLAG-Apoptin in cancer 
cells than in normal cells (Figure 4-18a,b). This might be due to a lower infection 
efficiency of normal cells, indicated by GFP expression levels after infection with 
Lenti-GFP, but also degradation of Apoptin in normal cells as described by others 
(Zhang et al. 2003).  
The phosphorylation of Apoptin on Thr-108 was investigated using a phospho-specific 
antibody, showing markedly less phosphorylated Apoptin (P-Apoptin) in normal cells 
(Figure 4-18a). The ratio of P-Apoptin to total FLAG-Apoptin, calculated from the 
intensity of the respective bands, in NCM356 and NCM460 cells was less than 50% of 
that detected in HCT116 cancer cells, indicating significantly lower Apoptin 
phosphorylation (Figure 4-18c).  
 
(a)	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Figure	  4-­‐18:	   Phosphorylation	   Status	   of	   Apoptin	   in	   Colon	   Cancer	   and	  
Normal	  Cells	  HCT116,	  NCM356	   and	  NCM460	   cells	  were	   infected	  with	   Lenti-­‐GFP	   (GFP)	   or	  Lenti-­‐CAV-­‐FLAG-­‐AP	   (Apo)	   at	   an	   MOI	   of	   5	   in	   the	   presence	   of	   5	  µg/ml	  polybrene.	   (a)	   Western	   blot	   analysis	   (12%	   SDS	   gel)	   of	   total	   cell	   lysates	  collected	   after	   2	  days.	   Arrows	   indicate	  molecular	  weights	   of	   the	   pre-­‐stained	  protein	   ladder;	   blots	   were	   cut	   and	   combined	   at	   the	   indicated	   lines.	   (b/c)	  ImageJ	   quantification	   of	   Apoptin	   expression	   (b)	   and	   phosphorylation	   (c)	  levels	  normalised	  to	  HCT116	  cells.	  Error	  bars	  indicate	  SEM	  (n	  =	  4);	  statistical	  significance	   was	   determined	   by	   one-­‐way	   ANOVA	   (*	  P	  <	  0.05,	   ***	  P	  <	  0.001,	  ns	  P	  >	  0.05).	  
4.2.4.3 Cytotoxic effect of Apoptin in colon cancer and normal cells 
The cytotoxic effect of Apoptin in colon cancer and normal cells was investigated by 
Annexin V/PI staining of HCT116, NCM356 and NCM460 cells following infection with 
Ad-GFP or Ad-Apoptin at an MOI of 10 for 48 hours. The infection efficiency, indicated 
by the percentage of GFP positive cells after infection with Ad-GFP, was comparable 
between the three cell lines at around 60% (Figure 4-19a).  
Cell death in response to infection with Ad-Apoptin, detected as a shift to an Annexin V 
positive cell population in FACS dot plots, could only be observed in HCT116 cells but 
not in NCM356 or NCM460 cells. Apoptin expression in HCT116 cells resulted in 
approximately 20 to 30% Annexin-V positive cells compared to 5% after infection with 
Ad-GFP (Figure 4-19b). In contrast, the levels of cell death detected in normal cell lines 
did not differ between cells infected with Ad-Apoptin and Ad-GFP. It should be noted 
that due to the lack of a GFP-tag it was not possible to selectively gate on Apoptin-
expressing cells in this analysis, which might explain the relatively low levels of cell 
death in HCT116 cells following Apoptin expression. 
(b)	   (c)	  




Figure	  4-­‐19:	  Cytotoxic	  Effect	  of	  Apoptin	  in	  Colon	  Cancer	  and	  Normal	  Cells	  HCT116,	   NCM356	   and	   NCM460	   cells	   were	   infected	   with	   Ad-­‐GFP	   or	  Ad-­‐Apoptin	   at	   an	  MOI	   of	   10	   and	   collected	   at	   48	  hours	   post-­‐infection	   for	   cell	  death	   detection	   by	   Annexin	  V/PI	   staining	   and	   FACS	   analysis.	   (a)	   Infection	  efficiency	   shown	   as	   the	   percentage	   of	   GFP	   positive	   cells	   following	   infection	  with	   Ad-­‐GFP.	   (b)	   Cell	   death	   quantification	   shown	   as	   the	   percentage	   of	  Annexin	  V	   positive	   cells.	   Error	   bars	   indicate	   SEM	   (n	  =	  4);	   statistical	  significance	  was	  determined	  by	  two-­‐way	  ANOVA	  (***	  P	  <	  0.001).	  
4.2.5 Effect of PKC modulation on Apoptin function in colon cells 
The link between PKCβI and Apoptin function was further investigated by transient 
knockdown or overexpression studies of PKCβI in colon cell lines. 
4.2.5.1 Effect of PKCβI knockdown on Apoptin function in HCT116 cells 
HCT116 cells were transiently transfected with PKCβI-specific siRNA and infected 
24 hours later with Lenti-GFP or Lenti-CAV-GFP-AP at an MOI of 5 to test whether 
(a) 
(b) 
  Chapter 4: Results II 
 131 
Apoptin phosphorylation depends on the presence of PKCβI. The levels of total and 
phosphorylated Apoptin as well as PKCβI at 2 days post-infection were investigated by 
Western blot analysis (Figure 4-20a). Transfection of PKCβI siRNA almost completely 
abolished PKCβI expression compared to control-transfected cells (Figure 4-20b). 
PKCβI knockdown was associated with a significantly decreased phosphorylation of 
Apoptin to approximately 50% compared to control cells or cells transfected with 
GAPDH control siRNA (Figure 4-20c) as well as reduced levels of Apoptin expression 
(Figure 4-20a).  
The effect of PKCβI knockdown on the apoptotic activity of Apoptin was subsequently 
investigated in HCT116 cells after transfection with PKCβI or GAPDH control siRNA and 
infection 8 hours later with Ad-GFP or Ad-Apoptin at an MOI of 20. The successful 
knockdown of PKCβI was detected by Western blot analysis at 48 hours after 
transfection of the indicated siRNAs, showing that transfection with PKCβI siRNA 
completely reduced PKCβI expression levels compared to control cells (Figure 4-21a).  
At 40 hours post-infection with Ad-GFP or Ad-Apoptin cells were stained with 
Annexin V/PI and analysed by flow cytometry. The FACS dot profiles showed a clear 
occurrence of Annexin V positive cells (bottom right) following infection with 
Ad-Apoptin in both control and PKCβI knockdown cells (Figure 4-21b). Transfection of 
GAPDH and PKCβI siRNA by itself had a toxic effect, as indicated by an increased 
percentage of Annexin V/PI double positive cells (top right), and these cells seemed to 
display a higher sensitivity to Apoptin expression. 
Normalisation of the percentage of living cells after infection with Ad-GFP or 
Ad-Apoptin to the respective untreated cells revealed significant cell death induction by 
Ad-Apoptin compared to Ad-GFP (Figure 4-21c). As indicated on the FACS dot plots, 
cells transfected with siRNA were more sensitive to Apoptin expression, showing 
approximately 50% dead cells compared to 20% in untransfected control cells. 
However, there was no significant difference in Apoptin sensitivity between cells 
transfected with GAPDH or PKCβI siRNA, indicating that depletion of PKCβI alone does 
not impair the cytotoxic function of Apoptin. 
 




Figure	  4-­‐20:	  Effect	  of	  PKCβI	  Knockdown	  on	  Apoptin	  Phosphorylation	   in	  
HCT116	  Cells	  HCT116	   cells	   were	   transfected	   with	   GAPDH	   or	   PKCβI	   siRNA	   and	   infected	  24	  hours	   later	   with	   Lenti-­‐GFP	   or	   Lenti-­‐CAV-­‐GFP-­‐AP	   at	   an	   MOI	   of	   5	   in	   the	  presence	   of	   5	  µg/ml	   polybrene.	   (a)	  Western	   blot	   analysis	   (10%	   SDS	   gel)	   of	  total	  cell	  lysates	  collected	  at	  2	  days	  post-­‐infection.	  Arrows	  indicate	  molecular	  weights	   of	   the	   pre-­‐stained	   protein	   ladder.	   (b/c)	   ImageJ	   quantification	   of	  PKCβI	   expression	   levels	   normalised	   to	   Tubulin	   (b)	   and	   P-­‐Apoptin	   to	   total	  GFP-­‐Apoptin	  ratios	  (c).	  Error	  bars	  indicate	  SEM	  (n	  =	  3);	  statistical	  significance	  was	  determined	  by	  one-­‐way	  ANOVA	  (*	  P	  <	  0.05,	  **	  P	  <	  0.01,	  ***	  P	  <	  0.001).	  
(b) (c) 
(a) 




Figure	  4-­‐21:	   Effect	   of	   PKCβI	   Knockdown	   on	   Apoptin	   Cytotoxicity	   in	  
HCT116	  Cells	  HCT116	   cells	   were	   transfected	   with	   GAPDH	   or	   PKCβI	   siRNA	   and	   infected	  8	  hours	   later	   with	   Ad-­‐GFP	   or	   Ad-­‐Apoptin	   at	   an	   MOI	   of	   20	   or	   treated	   with	  10	  µg/ml	   cisplatin.	   Cell	   death	   was	   detected	   at	   40	  hours	   post-­‐infection	   by	  Annexin	  V/PI	  staining	  and	  FACS	  analysis.	  (a)	  Western	  blot	  analysis	  (12%	  SDS	  gel)	   to	   determine	   PKCβI	   expression	   levels	   at	   48	   hours	   post-­‐transfection	  Arrows	   indicate	   molecular	   weights	   of	   the	   pre-­‐stained	   protein	   ladder.	   (b)	  Representative	   FACS	   dot	   plots	   indicating	   Annexin	  V	   and	   PI	   positive	  populations.	  (c)	  Quantification	  of	  cell	  death	  as	  percentage	  of	  live	  cells	  (double	  negative	  population)	  normalised	  to	  untreated	  control	  cells.	  Error	  bars	  indicate	  SEM	  (n	  =	  3);	   statistical	   significance	   comparing	  PKCβI	   and	  GAPDH	  siRNA	  was	  determined	  by	  two-­‐way	  ANOVA	  (ns	  P	  >	  0.05).	  
(c) 
(a) (b) 
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4.2.5.2 Effect of PKCβI overexpression on Apoptin function in normal 
colon cells 
Conversely, HA-PKCβI was ectopically expressed in normal colon mucosa cells to 
determine whether higher levels of PKCβI would sensitise normal cells to Apoptin. Co-
transfection of HA-PKCβI with CAV-GFP-AP in NCM460 cells did not increase Apoptin 
phosphorylation compared to cells transfected with CAV-GFP-AP alone (Figure 4-22).  
The effect of PKCβI overexpression on the subcellular localisation of FLAG-Apoptin in 
normal cells was investigated in NCM356 and NCM460 cells transfected with 
CAV-FLAG-AP alone or in combination with HA-PKCβI. Apoptin was detected using an 
anti-FLAG antibody at 24 hours post-transfection. Fluorescence microscopy showed 
that the localisation of Apoptin to the cytoplasm of either cell line was not markedly 
affected by overexpression of HA-PKCβI (Figure 4-23a). Scoring of cells revealed only 
an approximately 10% increase in the percentage of cells expressing Apoptin in the 
nucleus following overexpression of HA-PKCβI in either cell line (Figure 4-23b). 
To test whether increased levels of PKCβI could sensitise cells to Apoptin expression, 
HCT116 and NCM460 were transfected with HA-PKCβI followed by infection with 
Ad-GFP or Ad-Apoptin at an MOI of 20. Annexin V/PI staining and FACS analysis at 
48 hours post-infection showed that transfection of either pcDNA3 or HA-PKCβI 
resulted in increased basal levels of cell death in uninfected cells (Figure 4-24). In 
HCT116 cells infection with Ad-Apoptin induced approximately 30% cell death 
compared to untreated cells, which was slightly increased following transfection of 
HA-PKCβI compared to pcDNA3 whereas NCM460 remained resistant to treatment with 
Apoptin even following overexpression of HA-PKCβI.  




Figure	  4-­‐22:	  Effect	  of	  PKCβI	  Overexpression	  on	  Apoptin	  Phosphorylation	  
in	  NCM460	  Cells	  
(a)	   NCM460	   cells	   were	   co-­‐transfected	   with	   CAV-­‐GFP-­‐AP	   or	   eGFP-­‐C1	   and	  HA-­‐PKCβI	  and	  collected	  after	  2	  days	  for	  Western	  blot	  analysis	  (12%	  SDS	  gel).	  Arrows	   indicate	   molecular	   weights	   of	   the	   pre-­‐stained	   protein	   ladder.	   (b)	  ImageJ	   quantification	   of	   P-­‐Apoptin	   to	   total	   GFP-­‐Apoptin	   ratios.	   Error	   bars	  indicate	   SEM	   (n	  =	  3);	   statistical	   significance	   was	   determined	   using	   the	  unpaired	  two-­‐tailed	  Student’s	  t	  test	  (ns	  P	  >	  0.05).	  
(b) 
(a)




Figure	  4-­‐23:	   Effect	   of	   PKCβI	   Overexpression	   on	  Apoptin	   Localisation	   in	  
NCM356	  and	  NCM460	  Cells	  NCM356	   and	   NCM460	   cells	   were	   co-­‐transfected	   with	   CAV-­‐FLAG-­‐AP	   and	  HA-­‐PKCβI	   and	   fixed	   after	   24	  hours	   for	   indirect	   immunofluorescence	   using	   a	  primary	   mouse	   anti-­‐FLAG	   and	   a	   secondary	   FITC-­‐conjugated	   anti-­‐mouse	  antibody.	   Nuclei	   were	   detected	   by	   counterstaining	   with	   DAPI.	  	  
(a)	   Representative	   immunofluorescence	   images	   (original	   magnification	   60x,	  bar	  =	  10	  µm).	   (b)	   Quantification	   of	   Apoptin	   localisation	   exclusively	   in	   the	  nucleus	  or	   in	   the	   cytoplasm	  of	   transfected	   cells.	  At	   least	  50	   transfected	   cells	  were	  scored	  in	  each	  sample	  (n	  =	  1).	  
(b) 
(a) 
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Figure	  4-­‐24:	   Effect	   of	   PKCβI	   Overexpression	   on	   Apoptin	   Sensitivity	   of	  
HCT116	  and	  NCM460	  Cells	  HCT116	   and	  NCM460	   cells	  were	   transfected	  with	  pcDNA3	  or	  HA-­‐PKCβI	   and	  infected	  after	  24	  hours	  with	  Ad-­‐GFP	  or	  Ad-­‐Apoptin	  at	  an	  MOI	  of	  10.	  Cell	  death	  was	   detected	   at	   48	  hours	   post-­‐infection	   by	   Annexin	  V/PI	   staining	   and	   FACS	  analysis.	   Bars	   represent	  Annexin	  V	  positive	   cells	   in	   the	   total	   cell	   population;	  error	  bars	  indicate	  SEM	  (n	  =	  2).	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4.3 Discussion and Conclusions 
The tumour-specific phosphorylation of Apoptin suggests the presence or activity of a 
cellular kinase in tumour cells but not in normal cells that mediates Apoptin activation. 
Recently, the PKC signalling pathway was implicated in Apoptin regulation in a pair of 
multiple myeloma cell lines in which Apoptin sensitivity and phosphorylation correlated 
with expression levels of PKCβ  (Jiang et al. 2010). Subsequent in vitro and in vivo 
kinase studies confirmed that Apoptin was phosphorylated by PKCβ, mediated through 
an interaction of Apoptin with PKCβ and their co-translocation to the nucleus of cancer 
cells.  
Based on these observations the overall aim of this study was to further investigate the 
role of PKCβ for Apoptin-induced cell death in cancer cells. Initial experiments aimed to 
confirm key findings of the study presented by Jiang et al. in order to establish the 
importance of PKCβ in multiple myeloma cells. Co-immunoprecipitation studies 
confirmed an interaction of CAV-GFP-Apoptin as well as, to a lesser extent, 
HGyV-GFP-Apoptin with PKCβI in MM1.R multiple myeloma cells (Figure 4-1). 
Further investigations of a panel of multiple myeloma cell lines showed that in contrast 
to MM1.R cells all other cell lines tested did not overexpress PKCβI and expressed 
markedly lower levels of PKCβII (Figure 4-2). Despite their relative lack of PKCβI 
RPMI8226 cells remained as sensitive to Apoptin expression as MM1.R cells while lower 
levels of cell death were detected in U266 and KMS-12-BM cells following infection with 
Lenti-CAV-GFP-AP (Figure 4-3).  
Overall, these data indicate that the sensitivity of multiple myeloma cells to Apoptin 
does not correlate with PKCβI expression levels but might involve other cellular 
kinases. In another study Apoptin was shown to be phosphorylated by Cdk2 following 
its activation by the PI3K/Akt pathway upon Apoptin expression (Maddika et al. 2008; 
Maddika et al. 2009). Potentially, other yet unidentified kinases can also mediate 
Apoptin phosphorylation on Thr-108, or alternatively the adjacent Thr-107 or Thr-106 
residues, which can compensate for lack of Thr-108 phosphorylation, possibly in a cell 
type-dependent manner (Rohn et al. 2005; Lanz et al. 2012a).  
Overexpression of PKCβ has been described in several other cancer types than multiple 
myeloma including colon cancer, gastric cancer and haematological malignancies 
where it might represent a target for the tumour-specific activation of Apoptin (Murray 
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et al. 1999; Gokmen-Polar et al. 2001; Jiang et al. 2004; Holler et al. 2009). As a 
model for further investigations of the role of PKCβ for Apoptin activation in tumour 
cells the colorectal cancer cell line HCT116 was chosen based on previous work in the 
laboratory demonstrating high PKCβI expression levels and Apoptin sensitivity. 
In co-immunoprecipitation studies both CAV-FLAG-Apoptin and HGyV-FLAG-Apoptin 
were found to bind to HA-PKCβI that was ectopically expressed in HCT116 cells 
(Figure 4-5). The interaction and co-localisation of CAV-Apoptin and HGyV-Apoptin 
with endogenous PKCβI was subsequently confirmed using PLA analyses (Figure 4-8, 
Figure 4-9). Positive PLA signals were predominantly localised in the nucleus of 
transfected cells corresponding to the expression pattern of Apoptin and indicating 
nuclear translocation of PKCβI following Apoptin expression which was previously 
implied in immunofluorescence studies (Jiang et al. 2010). The significance of this 
nuclear localisation for PKCβI remains unclear, but might cause changes to PKCβI 
substrate accessibility or activity. Similarly, Apoptin has been shown to trigger nuclear 
accumulation of the related kinase Akt, switching its activity from pro-survival to 
promoting apoptosis (Maddika et al. 2007).  
These data, obtained using two different methods, suggest that Apoptin co-localises 
and interacts with PKCβI not only in multiple myeloma cells but also in other cancer 
cell lines overexpressing PKCβI. Moreover, the novel Apoptin homologue from HGyV 
showed a comparable ability to bind PKCβI as CAV-Apoptin, suggesting a similar 
regulatory mechanism for the two types of Apoptin. However, the partially inconclusive 
results from Co-IP studies indicate that the interaction between Apoptin and PKCβI is 
rather weak and potentially only transient which might be further investigated in the 
future using alternative methods such as FRET, surface plasmon resonance or label 
transfer technologies. 
A number of proteins have been described in other studies as Apoptin binding partners 
in different cellular systems, affecting the function, localisation or stability of Apoptin 
(Table 1-1). Using truncated Apoptin proteins, domains required for the respective 
interactions were identified in these studies. While Apoptin binding to PI3K and APC-C1 
was mediated by residues located within the C-terminal half of Apoptin (Teodoro et al. 
2004; Maddika et al. 2008) the N-terminal region, which contains the LRS, was 
required for its interaction with PML, DEDAF, Hippi or Hsc-70 (Cheng et al. 2003; 
Danen-van Oorschot et al. 2004; Janssen et al. 2007; Chen et al. 2011a).  
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To identify regions of Apoptin that are responsible for its binding to PKCβI an 
N-terminally truncated Apoptin mutant lacking amino acids 1 to 73 was tested for its 
interaction with PKCβI. Whereas no conclusive results were obtained from 
co-immunoprecipitation studies, data from PLAs clearly indicated a requirement for the 
N-terminal region of Apoptin to interact with PKCβI (Figure 4-11). Moreover, the 
distribution pattern of an N-terminally truncated phosphorylation-deficient Apoptin 
mutant, which localised to the cytoplasm of HCT116 cells, highlighted the importance 
of phosphorylation for nuclear accumulation of Apoptin. Future studies using a larger 
panel of deletion mutants of Apoptin as well as PKCβI will be necessary to narrow 
down the precise protein regions mediating their interaction. 
In contrast to HCT116 cells, two cell lines derived from normal colon mucosa were 
found to express markedly lower levels of PKCβI, providing an interesting model to 
study the function of Apoptin regarding its regulation by PKCβI (Figure 4-15). Initially, 
the tumour cell-specific characteristics of Apoptin, including its nuclear accumulation 
and phosphorylation in cancer cells, were investigated in this colon cell line model.  
Apoptosis in response to Apoptin was only detectable in HCT116 cells while its 
expression did not significantly affect the viability of normal colon mucosa cell lines 
compared to untreated or Ad-GFP infected cells (Figure 4-19). Fluorescence and 
confocal microscopy demonstrated that the majority of normal colon mucosa cells 
expressed Apoptin in the cytoplasm and partially in the nucleus whereas Apoptin was 
almost exclusively localised to the nucleus of HCT116 cells (Figure 4-17). In normal 
colon mucosa cells Apoptin phosphorylation was reduced by more than 50% when 
compared to HCT116 cells which might be due to the relative lack of PKCβI in those 
cells (Figure 4-18). Moreover, they were characterised by markedly lower levels of 
Apoptin compared to cancer cells, even when taking the lower infection efficiency of 
normal colon mucosa cells into account. In several studies the cytotoxic function of 
Apoptin in cancer cells was shown to depend not only on phosphorylation on Thr-108 
and nuclear accumulation but also on intracellular protein levels (Guelen et al. 2004; 
Wadia et al. 2004). The lower expression levels of Apoptin in normal colon mucosa 
cells might therefore, together with impaired phosphorylation and nuclear 
translocation, contribute to the resistance of normal cells to Apoptin expression. 
Overall these results indicate a correlation between the function of Apoptin and PKCβI 
expression levels. To test whether Apoptin activation depends on the presence of 
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PKCβI knockdown and overexpression studies were conducted in HCT116 and normal 
colon mucosa cells, respectively. In Knockdown of PKCβI prior to Apoptin expression in 
HCT116 cells resulted in markedly reduced phosphorylation of Apoptin (Figure 4-20). 
While this indicates that Apoptin phosphorylation is dependent on PKCβI, the 
sensitivity of HCT116 cells to Apoptin-induced cell death was not affected by PKCβI 
knockdown (Figure 4-21). This might be due to the remaining phosphorylated Apoptin 
species being sufficient to induce apoptosis in cancer cells or other kinases 
compensating for the lack of PKCβI. In contrast to the work by Jiang et al., who used 
shRNAs to knock down both PKCβ splice variants in multiple myeloma cells, PKCβI-
specific siRNAs were used in this study to investigate the function of PKCβI in Apoptin 
regulation. At the time of Apoptin expression there might be residual PKCβI, or 
alternatively PKCβII, that mediate phosphorylation of Apoptin. 
Neither the phosphorylation of Apoptin nor its expression pattern were affected by 
overexpression of PKCβI in normal cell lines (Figure 4-22, Figure 4-23). Consequently, 
ectopic expression of PKCβI did not sensitise NCM460 cells to infection with Ad-Apoptin 
(Figure 4-24). These results indicate that mere overexpression of PKCβI is not 
sufficient to activate Apoptin in normal cells but that other processes specifically 
occurring in tumour cells are necessary trigger the cytotoxic effect of Apoptin.  
Taken together the data presented in this chapter support an important role for PKCβI 
for Apoptin activation in cancer cell lines that express high levels of the kinase such as 
MM1.R or HCT116 cells. PKCβI was confirmed as an Apoptin binding partner and this 
interaction seems to require the N-terminal region of Apoptin. The phosphorylation of 
Apoptin in HCT116 cells at least partially depends on the presence of PKCβI but might 
involve other, yet unidentified kinases in other cancer cell lines.  
	  






Apoptin-induced Activation of  
Protein Kinase C 
 
5.1 Introduction 
As described in Chapter 4, Apoptin interacts with PKCβI in HCT116 colorectal cancer 
cells and the differential activation of Apoptin in HCT116 cells and normal colon 
mucosa cells correlates with the respective expression levels of PKCβI. Taken together 
these data suggest an important role of PKCβI for Apoptin regulation in this model. It 
remains unclear, however, whether PKCβ is activated by Apoptin, which will be 
addressed in the following section. 
FRET-based biosensors represent novel tools to study kinase activation in live or fixed 
cells (Zhang and Allen 2007). In general, the phosphorylation of a kinase-specific 
substrate sequence is translated into a conformational change of the reporter, altering 
FRET between a pair of two suitable fluorescent proteins, which only occurs when they 
are in close proximity. Several methods have been established to detect FRET, 
including intensity-based methods, such as ratiometric FRET, or FLIM, which maps the 
fluorescence lifetime of a fluorophore, that is shortened due to FRET, across a cell. In 
this project fluorescence lifetimes were measured using a time-correlated single-
photon counting (TCSPC) FLIM system that is illustrated in Figure 5-1 (Festy et al. 
2007).  
  Chapter 5: Results III 
 143 
 
Figure	  5-­‐1:	  Schematic	  TCSPC	  Setup	  for	  FLIM/FRET	  A	  pulsed	   laser	  excites	  the	  sample	  at	  a	  set	  wavelength	  (black	  arrows)	  and	  the	  fluorescence	   is	   detected	   using	   a	   non-­‐descanned	   detector	   (grey	   arrows).	   All	  electronic	   signals	   are	   fed	   into	   a	   TCSPC	   card	   in	   a	   PC	   (dotted	   lines).	   The	   time	  delay	   between	   the	   laser	   excitation	   pulse	   and	   the	   arrival	   of	   the	   fluorescence	  photon	   is	   measured	   many	   times	   to	   build	   up	   a	   histogram	   of	   photon	   arrival	  times	   in	   each	   pixel	   of	   the	   image,	   representing	   the	   fluorescence	   decay.	  Fluorescence	  lifetimes	  are	  then	  extracted	  by	  fitting	  exponential	  decay	  models	  and	  visualised	  on	  a	  colour-­‐coded	  FLIM	  map	  (adapted	  from	  Festy	  et	  al.	  (2007).	  
The original PKC activity reporter CKAR developed by Violin et al. comprises CFP and 
YFP as a FRET pair linked by a PKC substrate sequence and an FHA2 phospho-
threonine binding domain from the rad53p yeast protein (Violin et al. 2003). 
Phosphorylation of the substrate and subsequent binding of the FHA2 domain triggers 
a conformational change which results in reduced FRET between CFP and YFP that was 
measured as an increase in the emission ratio of CFP to YFP (Figure 5-2). While CFP 
and YFP represent a widely used fluorophore pair for ratiometric FRET measurements, 
CFP may exhibit multi-exponential decay kinetics, complicating the quantitative 
analysis of interacting FRET populations by FLIM (Peter et al. 2005). Alternatively, GFP 
and RFP provide a novel FRET pair for FLIM assays with several advantages over 
CFP/YFP such as low emission crosstalk and mono-exponential decay kinetics of the 
donor fluorophore GFP. The original CKAR plasmid was therefore modified by 
replacement of CFP and YFP with GFP and RFP, respectively, making it more suitable 
for FLIM assays used in this study (Figure 5-2)4. 
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Figure	  5-­‐2:	  Structure	  of	  CKAR	  and	  Concept	  of	  FRET	  Imaging	  
(a)	   CKAR	   is	   comprised	   of	   two	   fluorophores	   linked	   by	   a	   PKC	   substrate	  sequence	   and	   the	   FHA2	   phospho-­‐threonine-­‐binding	   domain	   of	   Rad53p.	   The	  original	  CKAR	  employed	  the	  FRET	  pair	  CFP/YFP	  which	  was	  modified	  prior	  to	  this	   study	   to	   GFP/RFP.	   Upon	   phosphorylation	   of	   the	   substrate	   sequence	   by	  PKC	  a	  conformational	  change	  occurs	  due	  to	  binding	  of	  the	  FHA2	  domain	  to	  the	  phosphorylated	   residue.	   This	   results	   in	   reduced	   FRET	   since	   the	   distance	  between	   the	   two	   fluorophores	   increases.	   (b)	  The	   reduction	   of	   FRET	   can	   be	  detected	   as	   either	   an	   increase	   of	   fluorescence	   lifetime τ	   of	   the	   donor	  fluorophore	  or	  an	  increased	  ratio	  of	  donor	  to	  acceptor	  fluorescence	  intensity	  (adapted	  from	  Violin	  et	  al.	  (2003).	  
The following section describes how the TCSPC FLIM setup was established for the 
measurement of PKC activity using this modified CKAR variant. The activation status of 
PKC was investigated following induction by known pharmacological modulators or 
expression of Apoptin in HCT116 and normal colon mucosa cells. 
(b) 
(a) 
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5.2 Results 
5.2.1 Setup of CKAR/FLIM assay 
FLIM to measure PKC activation using CKAR was carried out in collaboration with 
Dr. Frederic Festy5. This involved the use of a home-built two-photon laser-scanning 
microscope that was under constant development and improvement. The experimental 
setup regarding cell preparation, imaging and data analysis used for all FLIM assays 
throughout this study is illustrated in Figure 5-3, while the imaging modalities used to 
obtain GFP lifetimes are described in more detail in section 2.2.6.3. 
 
Figure	  5-­‐3:	  Experimental	  Setup	  for	  CKAR	  Imaging	  Flow	  chart	  illustrating	  the	  general	  experimental	  setup	  for	  CKAR	  FLIM	  assays.	  Cells	   were	   seeded	   on	   sterile	   coverslips,	   transfected	   with	   GFP/RFP	   CKAR	   or	  GFP-­‐only	  control	  plasmids	  and	  treated	  24	  hours	  later	  as	  indicated.	  Treatment	  with	  TPA	  or	  Gö6976	  served	  as	  a	  control	  for	  the	  activation	  or	  inhibition	  of	  PKC.	  Cells	  were	   prepared	   for	   imaging	   and	   image	   series	   of	   at	   least	   15	   single	   cells	  were	  obtained	  on	  a	  two-­‐photon	   laser-­‐scanning	  microscope.	  The	  fluorescence	  lifetimes	  of	  single	  cells	  were	  calculated	  by	  fitting	  bi-­‐exponential	   fluorescence	  decay	  models	  to	  the	  images	  using	  TRI2	  software.	  Output	  files	  were	  analysed	  to	  produce	   a	   distribution	   of	   GFP	   lifetime	   across	   the	   cell	   and	   calculation	   of	  average	  donor	  lifetime	  in	  single	  cells.	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To test the ability of this system to detect FRET-induced changes of GFP lifetimes 
HCT116 cells were transfected with GFP/RFP CKAR or GFP-tagged PKCα plasmids and 
fixed the next day in preparation for FLIM. Fluorescence images of HCT116 cells taken 
in culture after transfection with CKAR showed both GFP and RFP fluorescence, 
confirming expression of the modified reporter (Figure 5-4). 
 
Figure	  5-­‐4:	  Expression	  of	  CKAR	  in	  HCT116	  Cells	  The	   expression	   of	   GFP	   and	   RFP	   in	   HCT116	   cells	   transfected	   with	  GFP/RFP	  CKAR	   is	   shown	   by	   fluorescence	   microscopy	   of	   cells	   in	   culture	  (original	  magnification	  10x,	  bar	  =	  50	  µm).	  
The fluorescence lifetime τ of the donor fluorophore GFP in transfected cells was 
subsequently determined by FLIM imaging and extraction of GFP lifetimes of single 
cells, assuming a bi-exponential decay of GFP fluorescence. A representative FLIM 
image of a CKAR-expressing HCT116 cell, indicating the distribution of the GFP lifetime 
as colour-coded pixels across the cell is shown in Figure 5-5a. Based on the structure 
of CKAR GFP lifetimes directly correspond to the activity of PKC in the respective 
location within the cell. The average lifetime of the cell of interest was calculated from 
a histogram showing the distribution of all lifetimes across the image (Figure 5-5b).  
For each sample at least 20 GFP positive cells were analysed accordingly to obtain an 
overall average GFP lifetime of the respective sample (Figure 5-5c). The average 
lifetime of cells expressing GFP-PKCα clustered around a mean value of 2.14 ns, which 
is slightly below values reported in literature (Pepperkok et al. 1999). In contrast, the 
average lifetime obtained from cells expressing CKAR was 1.86 ns, indicating FRET 
between GFP and RFP which reduces GFP lifetimes compared to samples expressing 
the donor fluorophore GFP alone. It should be noted that cells displaying extreme 
fluorescence intensities or aberrant morphologies, which might affect the measurement 
of GFP lifetimes, were excluded from the analysis. 




Figure	  5-­‐5:	  CKAR	  Imaging	  in	  HCT116	  Cells	  HCT116	   cells	   seeded	   on	   coverslips	  were	   transfected	  with	  GFP/RFP	  CKAR	  or	  GFP-­‐PKCα	   and	   fixed	   for	   FLIM	  analysis	   the	   following	  day.	   (a)	   Representative	  FLIM	   image	   of	   a	   CKAR-­‐expressing	  HCT116	   cell	   indicating	   the	  GFP	   lifetime	   τ	  (bar	  =	  10	  µm).	  (b)	  Histogram	  showing	  the	  distribution	  of	  GFP	  lifetimes	  across	  the	   cell	   shown	   in	   (a).	   The	   red	   line	   indicates	   the	   average	   value	   of	   τ	   for	   the	  whole	   cell.	   (c)	   Distribution	   of	   average	   GFP	   lifetimes	   in	   at	   least	   20	   cells	  expressing	   GFP-­‐PKCα	   or	   CKAR.	   The	   green	   line	   indicates	   the	   overall	   average	  GFP	  lifetime	  calculated	  from	  all	  cells	  in	  the	  respective	  sample.	  
5.2.2 Test measurement of PKC activity using CKAR 
TCSPC FLIM represents a complex system in which many parameters contribute to 
data output and analysis. Suitable controls are therefore required to ensure the proper 
functioning of the system. While the measurement of GFP lifetimes in cells expressing 
only the donor fluorophore GFP as described above served as a control for proper 
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affect the conformation of CKAR, resulting in altered FRET and GFP lifetimes. In a first 
step the ability of the phorbol ester TPA to activate PKC was confirmed in HCT116 cells 
expressing GFP-PKCα or RFP-PKCβII. Fluorescence imaging showed translocation of 
both conventional PKC isoforms to the plasma membrane after treatment with 200 nM 
TPA for 30 minutes, which represents an essential step for their activation (Figure 5-6).  
 
Figure	  5-­‐6:	   Membrane	   Translocation	   of	   PKC	   Isoforms	   after	   TPA	  
Treatment	  HCT116	   cells	   seeded	   on	   coverslips	   were	   transfected	   with	   GFP-­‐PKCα	   or	  RFP-­‐PKCβII	   and	   treated	   the	   following	   day	  with	   200	  nM	   TPA	   for	   30	  minutes	  before	   fixation	   and	   fluorescence	   microscopy	   (original	   magnification	   60x,	  bar	  =	  10	  µm).	  	  
For FLIM analysis HCT116 cells were transfected with CKAR and treated the next day 
with 200 nM TPA or 50 nM Gö6976 for different times between 10 and 120 minutes as 
indicated to activate or inhibit PKC, respectively. As shown on representative FLIM 
images TPA treatment for 30 minutes induced a shift towards higher GFP lifetimes, 
indicating PKC activation, whereas GFP lifetimes were reduced following treatment for 
30 minutes with the PKC inhibitor Gö6976 (Figure 5-7a).  
Averaging the lifetimes obtained from at least 15 cells per sample revealed an average 
GFP lifetime of 1.72 ns in untreated HCT116 cells, which was increased following 
treatment with TPA for 20 or 30 minutes and decreased after treatment with Gö6976 
for 30 or 120 minutes (Figure 5-7b). The detected changes in GFP lifetimes, indicating 
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alterations in PKC activity, were small but consistent and significant across several 
experiments (Figure 5-7c). These results indicate that FLIM of CKAR-expressing cells 
can be used to detect alterations in PKC activity following pharmacological modulation, 
providing suitable controls for further FLIM studies. 
5.2.3 PKC activity following Apoptin expression in HCT116 cells 
In preparation for FLIM-based measurements of PKC activity in response to Apoptin, 
the expression levels of Apoptin following infection with Ad-Apoptin at an MOI of 10 
were detected by Western blot analysis (Figure 5-8). Apoptin could be detected as 
early as 5 hours post-infection and its expression further increased until 16 hours post-
infection after which Apoptin levels were decreased. Phosphorylated Apoptin was only 
detected at 8 and 16 hours post-infection, suggesting activity of the Apoptin kinase 
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Figure	  5-­‐7:	   PKC	   Activity	   in	   HCT116	   Cells	   after	   Pharmacological	   PKC	  
Modulation	  HCT116	   cells	   seeded	   on	   coverslips	  were	   transfected	  with	  GFP/RFP	  CKAR	  or	  GFP-­‐PKCα	  and	  treated	  the	   following	  day	  with	  200	  nM	  TPA	  or	  50	  nM	  Gö6976	  for	   the	   indicated	   times	   before	   fixing	   for	   FLIM	   analysis.	   (a)	   Representative	  FLIM	   images	  of	   CKAR-­‐expressing	   cells	   left	   untreated	  or	   treated	  with	  TPA	  or	  Gö6976	   for	   30	  minutes	   (bar	  =	  10	  µm).	   Histograms	   show	   the	   distribution	   of	  GFP	   lifetimes	   across	   the	   respective	   cell;	   the	   red	   line	   indicates	   the	   average	  value	   for	   τ.	   (b)	   Average	  GFP	   lifetimes	  were	   calculated	   from	  at	   least	   15	   cells	  per	  sample,	  corresponding	  to	  PKC	  activity	  (n	  =	  1).	  (c)	  Bars	  represent	  average	  changes	   in	   GFP	   lifetimes	   following	   treatment	   with	   TPA	   for	   30	   minutes	   or	  Gö6976	  for	  120	  minutes,	  corresponding	  to	  changes	  in	  PKC	  activity.	  Error	  bars	  indicate	  SEM	  (n	  =	  5);	   statistical	  significance	  compared	   to	  untreated	  cells	  was	  determined	  by	  one-­‐way	  ANOVA	  (*	  P	  <	  0.05,	  ***	  P	  <	  0.001).	  	  
        
Figure	  5-­‐8:	  Expression	  of	  Ad-­‐Apoptin	  in	  HCT116	  Cells	  HCT116	  cells	  were	  infected	  with	  Ad-­‐Apoptin	  at	  an	  MOI	  of	  10	  and	  cell	   lysates	  were	   collected	   at	   the	   indicated	   time	   points.	   (a)	  Western	   blot	   analysis	   (15%	  SDS	   gel)	   to	   detect	   Apoptin	   expression	   and	   phosphorylation.	   Blots	   were	   cut	  and	  combined	  at	  the	  indicated	  line;	  arrows	  indicate	  molecular	  weights	  of	  the	  pre-­‐stained	   protein	   ladder.	   (b)	   Quantification	   of	   Apoptin	   expression	   at	   the	  indicated	   time	  points	   normalised	   to	  Actin	   using	   ImageJ	   software;	   error	   bars	  indicate	  SEM	  (n	  =	  3).	  
(c) 
(b) (a) 
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To investigate whether Apoptin alters cellular PKC activity, CKAR-transfected HCT116 
cells were infected with Ad-Apoptin at an MOI of 10 and fixed for FLIM using the same 
time points post-infection as for expression analysis. Control cells were treated with 
400 nM TPA for 30 minutes, 100 nM Gö6976 for 2 hours or 10 µg/ml cisplatin for 
24 hours. As shown on representative FLIM images the expression of Apoptin for 8 and 
in particular 16 hours triggered activation of PKC, indicated by a shift to higher GFP 
lifetimes in Apoptin-treated cells, similar to control treatment with TPA (Figure 5-9a).  
Calculation of average GFP lifetimes of at least 15 single cells revealed a clear increase 
or decrease following treatment with TPA or Gö6976, respectively (Figure 5-9b). 
Similarly, Apoptin expression triggered an initial reduction of PKC activity at 2 hours 
post-infection which then increased significantly until 16 hours post-infection after 
which it dropped back down to basal levels (Figure 5-9b,c). The detected change in 
GFP lifetime following Apoptin expression for 8 or 16 hours was similar to that detected 
in samples treated with TPA by approximately 0.06 ns on average (Figure 5-7c, 
Figure 5-9c). Overall these data demonstrate Apoptin-induced activation of PKC, 
correlating with the expression and phosphorylation levels of Apoptin as detected by 
Western blot analysis (Figure 5-8). 
       
(a)	  




Figure	  5-­‐9:	  PKC	  Activity	  in	  HCT116	  Cells	  after	  Apoptin	  Expression	  HCT116	  cells	  seeded	  on	  coverslips	  were	  transfected	  with	  GFP/RFP	  CKAR	  and	  infected	  the	  following	  day	  with	  Ad-­‐Apoptin	  at	  an	  MOI	  of	  10	  for	  the	  indicated	  times	   before	   fixing	   for	   FLIM	   analysis.	   Control	   samples	   were	   treated	  with	  400	  nM	   TPA	   for	  30	  minutes,	   100	  nM	   Gö6976	   for	  120	  min	   or	   10	  µg/ml	  cisplatin	   (Cis)	   for	  24	  hours.	   (a)	   Representative	   FLIM	   images	   of	   CKAR-­‐expressing	  cells	  after	  the	  indicated	  treatments	  (bar	  =	  10	  µm).	  (b)	  Average	  GFP	  lifetimes	  were	  calculated	   from	  at	   least	  15	  cells	  per	  sample,	  corresponding	   to	  PKC	   activity	   (n	  =	  1).	   (c)	   Bars	   represent	   average	   changes	   in	   GFP	   lifetimes	  following	  Apoptin	  expression,	  corresponding	  to	  changes	  in	  PKC	  activity.	  Error	  bars	   indicate	   SEM	   (n	  =	  5	   for	   8h	   /	   16h	   /	   24h;	   n	  =	  3	   for	   2h	   /	   5h);	   statistical	  significance	  compared	  to	  untreated	  cells	  was	  determined	  by	  one-­‐way	  ANOVA	  (**	  P	  <	  0.01,	  ***	  P	  <	  0.001).	  	  
(b) 
(c) 
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HCT116 cells harbour an activating mutation in codon 13 of the KRAS proto-oncogene 
and contain wild type p53 (Bunz et al. 1998; Brink et al. 2003). Several isogenic cell 
lines are available to study the function of oncogenes or tumour suppressor genes in 
this model, including p53 knockout cells (HCT116 p53-/-) and Hke-3 cells that only 
contain the wild type KRAS allele (Shirasawa et al. 1993). Comparison of PKCβI 
expression levels showed no clear difference between HCT116, HCT116 p53-/- and 
Hke-3 cells (Figure 5-10).  
 
Figure	  5-­‐10:	  PKC	  Expression	  Levels	  in	  Isogenic	  HCT116	  Cell	  Lines	  Western	  blot	  analysis	  (12%	  SDS	  gel)	  to	  determine	  PKCβI	  expression	  levels	  in	  HCT116	  wild	  type,	  HCT116	  p53-­‐/-­‐	  and	  Hke-­‐3	  cells	  grown	  for	  2	  days.	  Arrows	  indicate	  molecular	  weights	  of	  the	  pre-­‐stained	  protein	  ladder.	  	  
The role of p53 and mutated KRAS for Apoptin-induced PKC activation was 
investigated in the three cell lines by FLIM analysis following expression of Apoptin. 
HCT116 wild type, HCT116 p53-/- and Hke-3 cells were transfected with CKAR and 
infected with Ad-Apoptin at an MOI of 10 for 8 and 16 hours. FLIM and subsequent 
calculation of average GFP lifetimes from at least 15 CKAR-expressing cells showed a 
similar effect of Apoptin on PKC activity in all three isogenic cell lines (Figure 5-11). All 
cell lines were characterised by markedly higher GFP lifetimes following Apoptin 
expression for 16 hours compared to untreated cells similar to treatment with TPA. 
This suggests that Apoptin-induced PKC activation in HCT116 cells occurs 
independently of mutated KRAS or p53 status. 
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Figure	  5-­‐11:	   PKC	   Activity	   in	   Isogenic	   HCT116	   Cell	   Lines	   after	   Apoptin	  
Expression	  HCT116	   wild	   type	   (a),	   HCT116	   p53-­‐/-­‐	   (b)	   and	   Hke-­‐3	   (c)	   cells	   seeded	   on	  coverslips	   were	   transfected	   with	   GFP/RFP	  CKAR	   and	   infected	   the	   following	  day	  with	  Ad-­‐Apoptin	  at	  an	  MOI	  of	  10	  for	  8	  or	  16	  hours	  before	  fixing	  for	  FLIM	  analysis.	   Control	   cells	   were	   treated	   with	  400	   nM	   TPA	   for	  30	  minutes.	   The	  average	   GFP	   lifetime	   was	   calculated	   from	   at	   least	   15	   cells	   per	   sample,	  corresponding	  to	  PKC	  activity	  (n	  =	  1).	  	  
(c) 
(a) (b) 
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5.2.4 PKC activity following Apoptin expression in normal colon 
mucosa cells 
As shown in Chapter 4 the normal colon mucosa cell lines NCM356 and NCM460 are 
characterised by lower PKCβI levels as well as reduced Apoptin activation compared to 
HCT116 cancer cells. They therefore provided a suitable model to investigate whether 
Apoptin-induced activation of PKC also occurs in normal cell lines. Moreover they allow 
for testing the importance of PKCβI expression for the observed increase in PKC 
activity following Apoptin treatment. 
HCT116, NCM356 and NCM460 cells were transfected with CKAR and infected the 
following day with Ad-Apoptin at an MOI of 10 for 8 and 16 hours before fixation for 
FLIM analysis. After imaging of at least 10 CKAR-expressing cells per sample the GFP 
lifetimes of each cell were calculated and combined into average values. Normal 
NCM356 or NCM460 cells displayed slightly lower and less homogeneous basal levels of 
PKC activity than HCT116 cells (Figure 5-12a).  
As before expression of Apoptin in HCT116 cells triggered activation of PKC both at 8 
and 16 hours post-infection, indicated by a nearly 10 ns increase of the average GFP 
lifetime compared to untreated control cells (Figure 5-12b). In contrast, no induction of 
PKC activity was observed in either NCM356 or NCM460 cells at 8 hours post-infection 
while the average GFP lifetime was increased by approximately 5 ns after 16 hours in 
both cell lines (Figure 5-12c,d). Side-by-side comparison of average changes in GFP 
lifetime after treatment compared to the respective untreated cells from several 
experiments clearly showed significant PKC activation in response to Apoptin after 
8 hours only in HCT116 cells (Figure 5-12e). This was significantly enhanced after 
16 hours in HCT116 cells when compared to NCM356 or NCM460 cells.  
 
(b) (a) 
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Figure	  5-­‐12:	   PKC	   Activity	   in	   HCT116,	   NCM356	   and	   NCM460	   Cells	   after	  
Apoptin	  Expression	  HCT116,	   NCM356	   and	   NCM460	   cells	   seeded	   on	   coverslips	  were	   transfected	  with	   eGFP-­‐C1	   or	   GFP/RFP	  CKAR	   and	   infected	   the	   following	   day	   with	  Ad-­‐Apoptin	  at	  an	  MOI	  of	  10	  for	  8	  or	  16	  hours	  before	  fixing	  for	  FLIM	  analysis.	  Control	  cells	  were	  treated	  with	  400	  nM	  TPA	  for	  30	  minutes.	  (a)	  Distribution	  of	  average	  GFP	  lifetimes	  in	  cells	  expressing	  GFP	  or	  CKAR.	  At	   least	  10	  cells	  were	  analysed	  per	  sample.	  The	  green	  line	  indicates	  the	  average	  value	  of	  τ	  calculated	  for	   the	   respective	   sample.	   (b-­‐d)	   Average	   GFP	   lifetimes	   in	   HCT116	   (b),	  NCM356	   (c)	   or	  NCM460	   (d)	   cells	  were	   calculated	   from	   at	   least	   10	   cells	   per	  sample,	   corresponding	   to	   PKC	   activity	   (n	  =	  1).	   (e)	   Bars	   represent	   average	  changes	   in	   GFP	   lifetimes	   after	   treatment	   compared	   to	   untreated	   cells,	  corresponding	   to	   changes	   in	   PKC	   activity.	   Error	   bars	   indicate	   SEM	   (n	  =	  3);	  statistical	  significance	  compared	  to	  HCT116	  cells	  was	  determined	  by	  two-­‐way	  ANOVA	  (*	  P	  <	  0.05,	  **	  P	  <	  0.01,	  ns	  P	  >	  0.05).	  
(c) (d) 
(e) 
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The reduced activation of PKC in response to Apoptin expression in normal colon 
mucosa cells might be due to their lack of PKCβI expression compared to HCT116 cells. 
To test whether overexpression of PKCβI would restore PKC activation following 
treatment with Apoptin, NCM356 cells were co-transfected with plasmids expressing 
CKAR and PKCβI and compared to HCT116 and NCM356 cells transfected with CKAR 
alone. The overexpression of PKCβI was confirmed by Western blot analysis, showing 
similar PKCβI levels as wild type HCT116 cells (Figure 5-13).  
 
Figure	  5-­‐13:	  Overexpression	  of	  PKCβI	  in	  NCM356	  Cells	  Western	  blot	  analysis	  (12%	  SDS	  gel)	  to	  determine	  PKCβI	  expression	  levels	  in	  HCT116,	   NCM356	   or	   NCM356	   cells	   transfected	   with	   pBabe-­‐puro	   PKCβI	   at	  1	  day	  post-­‐transfection.	  Arrows	  indicate	  molecular	  weights	  of	  the	  pre-­‐stained	  protein	  ladder.	  	  
Transfected cells were infected with Ad-Apoptin for 16 hours before FLIM analysis to 
measure GFP lifetimes. The basal PKC activity in untreated cells did not differ between 
HCT116 or NCM356 wild type and PKCβI-overexpressing cells (Figure 5-14a). As shown 
previously, infection with Ad-Apoptin for 16 hours triggered a shift of average 
histograms from at least 15 cells per sample to higher GFP lifetimes in HCT116 cells, 
indicating PKC activation (Figure 5-14b). By contrast, GFP lifetimes were reduced in 
NCM356 wild type cells infected with Ad-Apoptin whereas NCM356 cells overexpressing 
PKCβI showed a similar shift as HCT116 cells (Figure 5-14c,d). PKC activity, indicated 
by the average GFP lifetime, was increased in HCT116 cells as well as NCM356 cells 
overexpressing PKCβI in response to Apoptin in contrast to a reduction of GFP lifetime 
in NCM356 cells (Figure 5-14e). 






Figure	  5-­‐14:	  PKC	  Activity	  in	  NCM356	  Cells	  Overexpressing	  PKCβI	  HCT116	   and	   NCM356	   cells	   seeded	   on	   coverslips	   were	   transfected	   with	  GFP-­‐PKCα	   or	   GFP/RFP	  CKAR	   alone	   or	   with	   pBabe-­‐puro	   PKCβI	   and	   infected	  the	  following	  day	  with	  Ad-­‐Apoptin	  at	  an	  MOI	  of	  10	  for	  16	  hours	  before	  fixing	  for	  FLIM	  analysis.	  (a)	  Distribution	  of	  average	  GFP	  lifetimes	  in	  cells	  expressing	  GFP-­‐PKCα	  or	  CKAR.	  The	  green	  line	  indicates	  the	  average	  value	  of	  τ	  calculated	  for	  the	  respective	  sample.	  (b-­‐d)	  Average	  histograms	  showing	  the	  distribution	  of	  GFP	  lifetimes	  across	  at	  least	  15	  cells	  per	  sample	  (b:	  HCT116,	  c:	  NCM356,	  d:	  NCM356	  +	  PKCβI).	  (e)	  Bars	  represent	  average	  changes	  of	  GFP	  lifetimes	  or	  PKC	  activity	  following	  infection	  with	  Ad-­‐Apoptin	  for	  16	  hours	  (n	  =	  1).	  	  
(a) 
(e) 
(b) (d) (c) 
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5.2.5 Effect of Apoptin on PKC activity in HCT116 Cells after 
PKCβI knockdown 
Based on its substrate sequence CKAR detects activation of all conventional and novel 
PKC isoforms with comparable sensitivities (Kajimoto et al. 2010). To investigate 
whether PKCβI is required for Apoptin-induced PKC activation, it was knocked down in 
CKAR-expressing cells 24 hours prior to infection with Ad-Apoptin for 8 hours and FLIM 
analysis to measure GFP lifetimes in at least 15 CKAR-expressing cells (Figure 5-15). 
 
Figure	  5-­‐15:	  Experimental	  Setup	  of	  PKCβI	  Knockdown	  FLIM	  Assay	  HCT116	   seeded	   on	   coverslips	   were	   transfected	   with	   CKAR	   and	   transfected	  after	   24	  hours	   with	   GAPDH	   or	   PKCβI	   siRNA.	   The	   following	   day	   cells	   were	  infected	  with	  Ad-­‐Apoptin	  at	  an	  MOI	  of	  10	  for	  8	  hours	  or	  treated	  with	  400	  nM	  TPA	  for	  30	  minutes	  before	  fixing	  for	  FLIM	  analysis.	  	  
 
Figure	  5-­‐16:	  PKCβI	  Knockdown	  in	  HCT116	  Cells	  Western	  blot	  analysis	  (10%	  SDS	  gel)	  to	  determine	  PKCβI	  expression	  levels	  in	  HCT116	   cells	   transfected	   with	   GAPDH	   or	   PKCβI	   siRNA	   and	   control	   cells.	  Arrows	  indicate	  molecular	  weights	  of	  the	  pre-­‐stained	  protein	  ladder.	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The successful knockdown of PKCβI was confirmed by Western blot analysis in samples 
collected at 24 hours post-transfection (Figure 5-16). Compared to control cells or 
GAPDH siRNA-transfected cells, PKCβI expression levels were undetectable following 
transfection of PKCβI siRNA. 
While the average PKC activity in untreated PKCβI knockdown cells was significantly 
reduced compared to control cells, the majority of cells displayed similar levels of PKC 
activation as shown by the distribution of GFP lifetimes across the cell population 
(Figure 5-17a). Only approximately 35% of the cells displayed a markedly reduced 
basal PKC activity below an arbitrary threshold set at a GFP lifetime of 1.81 ns. Cells 
with intact PKC activity similar to control cells might represent cells that were not 
successfully transfected with PKCβI siRNA or started re-expressing PKCβI at later 
stages after siRNA transfection. Alternatively activity of other PKC isoforms such as 
PKCβII might be responsible for the observed PKC activation status in the majority of 
cells. 
Comparison of PKC activity in response to Apoptin expression revealed lower levels of 
Apoptin-induced PKC activation in cells lacking PKCβI while the response to treatment 
with TPA was not affected by PKCβI knockdown (Figure 5-17b). The relative change of 
GFP lifetime, indicating PKC activation in response to Ad-Apoptin, was, however, 
comparable to control cells by approximately 0.04 ns due to the reduced basal levels of 
PKC activity in untreated PKCβI knockdown cells.  
Plotting the distribution of GFP lifetimes instead of average values revealed a clear 
difference between control and PKCβI knockdown cells. While the majority of PKCβI 
knockdown cells responded to Apoptin expression in a similar way as control cells, 
showing a general shift towards higher GFP lifetimes, approximately 20% of the cells 
were characterised by significantly lower lifetimes below 1.81 ns (Figure 5-17a). The 
latter might represent cells with lower PKCβI expression levels following siRNA 
transfection, which do not respond to Apoptin expression with increased PKC activity. 
Both GAPDH control samples and cells with intact PKC activity above 1.81 ns were 
characterised by an average increase of GFP lifetimes by approximately 0.02 to 0.04 ns 
in response to Apoptin expression. By contrast, the average GFP lifetime of all cells 
below the arbitrary threshold of τ = 1.81 ns did not change following infection with 
Ad-Apoptin, indicating lack of PKC activation. 




Figure	  5-­‐17:	  Apoptin-­‐induced	  PKC	  Activity	   in	  HCT116	  Cells	   after	   PKCβI	  
Knockdown	  HCT116	  cells	  seeded	  on	  coverslips	  were	  transfected	  with	  GFP/RFP	  CKAR	  and,	  after	  24	  hours,	  GAPDH	  or	  PKCβI	  siRNA.	  The	  following	  day	  cells	  were	  infected	  with	   Ad-­‐Apoptin	   at	   an	   MOI	   of	   10	   for	   8	   hours	   or	   treated	   with	   400	  nM	   TPA	  for	  30	  minutes	  before	  fixing	  for	  FLIM	  analysis.	  (a)	  Distribution	  of	  average	  GFP	  lifetimes	  in	  cells	  expressing	  CKAR.	  At	  least	  10	  cells	  were	  analysed	  per	  sample.	  The	   green	   line	   indicates	   the	   average	   value	   of	   τ	   calculated	   for	   the	   respective	  sample,	   the	   red	   line	   represents	   an	   arbitrary	   threshold	   set	   below	   the	   lowest	  value	   in	   untreated	   cells	   at	   τ	  =	  1.81	  ns.	   (b)	   Average	   GFP	   lifetimes	   were	  calculated	   from	   at	   least	   15	   cells	   per	   sample,	   corresponding	   to	   PKC	   activity	  (n	  =	  1).	  
(a) 
(b) 
  Chapter 5: Results III 
 162 
5.3 Discussion and Conclusions 
An association between PKCβ expression levels and Apoptin phosphorylation and 
activation in cancer cells has been shown previously. Moreover, recombinant PKCβII or 
PKCβI pulled down from cell lysates can phosphorylate MBP-Apoptin while PKC 
inhibition negatively affects Apoptin phosphorylation (Jiang et al. 2010). Nevertheless, 
it still remained to be determined whether Apoptin expression is associated with 
increased activity of PKC, consequently resulting in its PKC-mediated phosphorylation.  
In another study, Apoptin phosphorylation was shown to occur through Apoptin-
induced activation of the PI3K/Akt pathway and the downstream effector kinase Cdk2 
(Maddika et al. 2009). The activity of the respective kinases was measured using ELISA 
assays, detection of the active form of Akt phosphorylated on Ser-473 and in vitro 
kinase assays using recombinant proteins (Maddika et al. 2007; Maddika et al. 2008). 
While these represent common tools to measure kinase activities they might not 
entirely reflect the regulation of kinases in their biological context, which may be lost 
during cell lysis. 
Here, PKC activation was measured using a modified version of the FRET-based PKC 
kinase activity reporter CKAR (Violin et al. 2003). In general, biosensors such as CKAR 
are based on a conformational change induced by increased activity of a specific kinase 
or other enzyme, resulting in an alteration of FRET between two attached 
fluorophores. Enzymatic activity can therefore be detected as a change in FRET for 
which several imaging methods are available (Zhang and Allen 2007). 
In the original paper by Violin et al. as well as follow-up studies by the same group, 
changes in intramolecular FRET were detected as altered ratios of CFP (donor) to YFP 
(acceptor) emission intensity in live cells (Violin et al. 2003). Based on the structural 
design of CKAR an increased ratio of donor to acceptor emission, indicating reduced 
FRET, corresponds to activation of PKC. Using this approach increased PKC activity was 
detected in live cells treated with a phorbol ester, which was reversible upon addition 
of a pan-PKC inhibitor. While intensity-based imaging such as ratiometric FRET is a 
widely used method to detect changes in FRET, it has certain disadvantages such as 
spectral bleed-through and dependency on fluorophore concentrations or stoichiometry 
between donor and acceptor fluorophores. Alternatively, FRET can be detected as a 
decrease of the fluorescence lifetime of the donor fluorophore by FLIM (Becker 2012). 
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This requires a more elaborate setup of the microscope and is more time-consuming 
than other approaches; however data obtained from FLIM only depend on the 
molecular environment and enable the distinction of interacting and non-interacting 
donor fractions (Bastiaens and Squire 1999; Peter and Ameer-Beg 2004).  
To improve its applicability in FLIM studies, CKAR was modified prior to this study by 
replacing the fluorophores CFP and YFP with GFP and RFP respectively (Figure 5-2). 
Whereas the FRET pair CFP/YFP has been widely used for ratiometric FRET 
measurements, the combination of GFP and RFP offers multiple advantages for FLIM. 
The emission spectra of GFP and RFP are further separated than those of CFP and YFP, 
reducing spectral bleed-through (Figure 5-18). Moreover, GFP is characterised by high 
photostability and mono-exponential fluorescence decay kinetics compared to the 
multi-exponential decay observed for CFP, which facilitates measurements of 
fluorescence lifetimes (Peter et al. 2005). 
 
Figure	   5-­‐18:	   Emission	   and	   Excitation	   Spectra	   of	   Green	   Fluorescent	  
Proteins	  Emission	  and	  excitation	  spectra	  of	  the	  FRET	  pairs	  CFP/YFP	  (a)	  and	  GFP/RFP	  
(b)	  were	  created	  using	   the	  Fluorescence	  SpectraViewer	  online	   tool	  provided	  by	  Invitrogen.	  
(a) 
(b) 
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Initial experiments confirmed the suitability of CKAR, used in an experimental TCSPC 
FLIM two-photon microscope setup, to detect activation of PKC. Cells transfected with 
GFP/RFP CKAR displayed a markedly lower GFP lifetime than GFP-expressing cells, 
indicating FRET between GFP and RFP (Figure 5-5). Based on the structure of CKAR 
the average GFP lifetime in a cell directly reflects its PKC activation status because 
phosphorylation of CKAR results in reduced FRET and therefore increased donor 
lifetime. Compared to untreated CKAR-expressing cells GFP lifetimes were significantly 
increased following treatment with the phorbol ester TPA and, conversely, decreased 
when treated with the PKC inhibitor Gö6976 (Figure 5-7). These results suggest that 
CKAR is suitable for the detection of pharmacologically induced changes in PKC 
activity, providing a useful tool to study the role of PKC in Apoptin signalling. 
A strong activation of PKC could be observed following infection with Ad-Apoptin, 
correlating with the expression and phosphorylation levels of Apoptin (Figure 5-8, 
Figure 5-9). A drop of PKC activity to baseline levels at a later time point may relate to 
cells undergoing apoptosis as a similar reduction of PKC activity was observed in cells 
treated with the apoptosis-inducing drug cisplatin. Apoptin-induced activation of PKC 
occurred similarly in isogenic Hke-3 cells, containing only the wild type KRAS allele, and 
p53 knockout HCT116 cells (Figure 5-11). In contrast, two normal colon mucosa cell 
lines displayed significantly reduced and delayed induction of PKC activity following 
Apoptin expression compared to HCT116 cells (Figure 5-12) which correlated with the 
decreased levels of PKCβI and Apoptin activation in these cells described in Chapter 4. 
Taken together, these data showed for the first time that Apoptin induces marked 
activation of PKC in cancer cells but not, or to a much lower extent, in normal cells. 
The reduced activation of PKC observed in normal cells following Apoptin expression 
might be due to their lack in endogenous PKCβI compared to HCT116 cells. These 
results also support an important role for PKC for the tumour-specific regulation of 
Apoptin. 
CKAR has a similar specificity for all conventional and novel PKC isoforms (Kajimoto et 
al. 2010), therefore not allowing measurement of the isoform-specific activation of 
PKC. The contribution of PKCβI to Apoptin-induced PKC activation was investigated by 
overexpression and knockdown studies. Overexpression of PKCβI in normal NCM356 
cells resulted in restoration of PKC activation in response to Apoptin to similar levels as 
observed in HCT116 cells (Figure 5-14). Conversely, knockdown of PKCβI in HCT116 
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cells significantly reduced basal as well as Apoptin-induced levels of PKC activity but 
did not impair its activation in response to TPA treatment (Figure 5-17). This suggests 
that Apoptin requires PKCβI expression to induce PKC activation in cancer cells but 
further investigations will be necessary to confirm these results. 
Taken together, the data presented in this chapter propose that Apoptin expression in 
cancer cells triggers activation of PKC, which might specifically involve activity of the 
PKCβI isoform. This provides the missing link for a model in which the expression of 
Apoptin, previously shown to interact with PKCβI, results in activation of PKC and 
subsequently PKC-mediated phosphorylation of Apoptin to trigger nuclear translocation 
and activate its pro-apoptotic function (Figure 5-19). In addition to phosphorylating 
Apoptin, activated PKC might also trigger other yet unknown cellular signalling 
pathways ultimately resulting in apoptosis, which will be investigated in future studies. 
Moreover, prolonged activation of PKCβ might trigger its dephosphorylation and 
degradation (Hansra et al. 1999). Potentially this might promote apoptosis induction in 
Apoptin-treated cells due to a lack of pro-survival signals through PKCβ. 
 
Figure	  5-­‐19:	  Proposed	  Model	  of	  Apoptin	  and	  PKC	  Interaction	  In	   tumour	   cells	   Apoptin	   interacts	   with	   PKCβ,	   either	   directly	   or	   indirectly	  triggering	  activation	  of	  PKCβ.	  Active	  PKCβ	   in	   turn	  mediates	  phosphorylation	  of	  Apoptin,	  resulting	   in	  Apoptin	  accumulation	  in	  the	  nucleus	  and	  subsequent	  induction	   of	   apoptosis,	   which	   might	   involve	   activation	   of	   PKCδ.	   Moreover,	  active	   PKCβ	   might	   trigger	   other	   cellular	   signalling	   pathways	   (?)	   while	   its	  prolonged	  activation	  can	  result	  in	  its	  dephosphorylation	  and	  degradation.	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It remains to be determined how Apoptin triggers activation of PKC. Interestingly, an in 
vitro kinase assay conducted previously by Jiang et al. showed Apoptin phosphorylation 
following incubation with PKCβ alone, without any additional PKC activators such as 
TPA in the reaction (Jiang et al. 2010). This suggests that the presence of Apoptin 
alone is sufficient for PKC activation. A study published in 1994 proposed that PKCβII 
can be activated by conventional and non-conventional compounds which both trigger 
its allosteric activation and release of the pseudosubstrate from the active site (Orr and 
Newton 1994). This was suggested to involve exposure of Arg-19 of PKCβII to 
proteolysis which is shielded by a cluster of acidic residues under non-stimulated 
conditions. Apoptin is rich in basic amino acids which might bind to these acidic 
residues on PKCβ to expose Arg-19 and thereby trigger Apoptin-induced PKC 
activation. 
The TCSPC FLIM setup established during this work might also provide a useful tool for 
future FRET-based investigations such as live cell imaging of CKAR in cancer cells 
following Apoptin expression, protein interaction studies or specific detection of PKCδ 
activity using the recently developed δCKAR biosensor (Kajimoto et al. 2010). Cleavage 
of PKCδ to generate the catalytically active fragment was detected previously in MM1.R 
cells expressing Apoptin, indicating PKCδ activation (Jiang et al. 2010). PKCδ is 
generally considered a pro-apoptotic PKC isoform and its activation has been observed 
in response to many other apoptotic stimuli (Basu et al. 2001; Brodie and Blumberg 
2003). Further FLIM-based investigations of PKCδ activity in response to Apoptin 
expression as well as its downstream targets, including proteins involved in the DNA 
damage response and cell death, will therefore provide further insights into the 
signalling mechanisms downstream of Apoptin activation. 
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Apoptin-induced Signalling Pathways 
 
6.1 Introduction 
Several distinct signalling pathways have been implicated in the tumour cell-specific 
cytotoxic function of Apoptin and the precise mechanism of cell killing probably 
depends on the tumour type, the cellular background regarding specific genetic 
alterations and the mode of Apoptin delivery to the cell.  
It is generally agreed that Apoptin triggers apoptotic cell death in cancer cells, inducing 
characteristic changes of apoptosis such as DNA fragmentation and nuclear 
condensation. Expression of Apoptin was shown to ultimately result in caspase-3 
activation at least at late stages of cell death, which involves loss of the mitochondrial 
membrane potential and cytochrome c release but not death receptor signalling 
(Danen-van Oorschot et al. 2000; Maddika et al. 2005; Burek et al. 2006).  
Apoptin can trigger G2/M cell cycle arrest and subsequent apoptosis in p53-deficient 
tumour cells through inhibition of the APC/C (Teodoro et al. 2004). This might involve 
selective stabilisation of pro-apoptotic TAp73 isoforms in response to Apoptin, which 
share significant homology and functional overlap with p53 (Oren 1997), to induce cell 
cycle arrest and apoptosis (Klanrit et al. 2008; Taebunpakul et al. 2012).  
Other events proposed to be involved in Apoptin-induced signalling include mitotic 
catastrophe (Lanz et al. 2012b), modulation of sphingolipid-ceramide metabolism (Liu 
et al. 2006b) and activation of NF-κB (Tavassoli et al. 2005). Moreover, a recent study 
identified a link between the DNA damage response and nuclear translocation of 
Apoptin in cancer cells, suggesting that intact DNA damage signalling is required for 
Apoptin accumulation in the nucleus (Kucharski et al. 2011).  
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Here, two events potentially involved in cellular signalling downstream of Apoptin 
expression as well as the involvement of caspases in Apoptin-induced cell death were 
investigated. Moreover, the combinatory effect of Apoptin and the chemotherapeutic 
agents TRAIL and Bortezomib was investigated in HCT116 colorectal cancer and 
normal colon mucosa cells. 
6.2 Results 
6.2.1 Apoptin and DNA damage 
The nuclear expression pattern of Apoptin and its ability to bind free DNA double 
strand ends suggest a potential link between Apoptin and DNA damage. The induction 
of DNA damage in response to Apoptin expression was therefore investigated by 
detecting the phosphorylation of histone H2AX at Ser-139 (γH2AX) that co-localises 
with DNA double strand breaks (Sharma et al. 2012). HCT116 colorectal cancer cells 
were transfected with CAV-FLAG-AP, HGyV-FLAG-AP or pcDNA3 and fixed at 1 or 
2 days post-transfection for indirect immunofluorescence staining with anti-γH2AX and 
anti-FLAG antibodies. Control cells were irradiated with 6 Gy, which resulted in marked 
induction of DNA double strand breaks as indicated by the presence of γH2AX foci in 
irradiated cells (Figure 6-1a). Transfection of Apoptin induced DNA double strand 
breaks in approximately 60 to 70% of FLAG-Apoptin-expressing cells compared to 
approximately 40% in untransfected cells in the same sample (Figure 6-1b). The 
number of γH2AX foci following Apoptin expression was however, lower than in 
irradiated cells. The relatively high percentage of FLAG-negative cells displaying γH2AX 
foci might represent a consequence of transfection or alternatively indicate a high 
amount of constitutive DNA damage in HCT116 cancer cells due to their high 
proliferation rate and general genetic instability. 
6.2.2 Apoptin and NF-κB activation 
A previous study detected activation of NF-κB in response to transfection of 
CAV-Apoptin in H1299 cells using a luciferase reporter assay (Tavassoli et al. 2005). 
Moreover, several conventional and novel PKC isoforms, including PKCβ, have been 
implicated in NF-κB activation through activation of IκB kinases (IKK) resulting in 
increased IκB phosphorylation and nuclear translocation of NF-κB as well as 
IKK-independent pathways (Shinohara et al. 2005; Holden et al. 2008; Li et al. 2009). 




Figure	  6-­‐1:	  γH2AX	  Staining	  in	  HCT116	  Cells	  after	  Apoptin	  Expression	  HCT116	  cells	  were	  transfected	  with	  CAV-­‐FLAG-­‐AP,	  HGyV-­‐FLAG-­‐AP	  or	  pcDNA3	  for	   1	   or	   2	  days	   or	   irradiated	   at	   6	  Gy	   as	   a	   control.	   Cells	  were	   stained	  with	   a	  primary	   rabbit	   anti-­‐γH2AX	   and	   secondary	   FITC-­‐conjugated	   anti-­‐rabbit	  antibody	   as	   well	   as	   a	   primary	   mouse	   anti-­‐FLAG	   and	   secondary	   TRITC-­‐conjugated	   anti-­‐mouse	   antibody	   for	   FLAG-­‐transfected	   cells.	   Nuclei	   were	  detected	  by	  counterstaining	  with	  DAPI.	  (a)	  Representative	  images	  of	  fixed	  and	  stained	   cells	   (original	  magnification	   60x,	   bar	  =	  10	   µm).	   (b)	   Quantification	   of	  cells	   displaying	   γH2AX	   foci	   in	   the	   nucleus.	   At	   least	   50	   cells	  were	   scored	   per	  Apoptin	   sample,	   comparing	  untransfected	  and	  FLAG-­‐expressing	  cells	   in	  each	  sample.	  
(a) 
(b) 
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The activation of NF-κB in HCT116 cells in response to Apoptin was investigated using 
a combination of approaches. Western blot analysis of HCT116 cells infected with 
Ad-Apoptin at an MOI of 10 for 8 or 24 hours revealed a marked decrease of IκBα 
levels in Apoptin-treated cells compared to cells infected with Ad-GFP or untreated cells 
(Figure 6-2). Moreover, the phosphorylation of the NF-κB family member p65 on 
Ser-536, which can enhance its nuclear import and increase the transcriptional activity 
of NF-κB (Sakurai et al. 1999; Mattioli et al. 2004), was analysed. Comparison of 
phosphorylated to total p65 levels revealed reduced Ser-536 phosphorylation after 
treatment with Ad-Apoptin for 8 hours while similar phosphorylation levels were 
observed at 24 hours post-infection with Ad-GFP or Ad-Apoptin (Figure 6-2).  
 
Figure	  6-­‐2:	  IκBα 	  Degradation	  and	  p65	  Phosphorylation	  in	  HCT116	  Cells	  
after	  Apoptin	  Expression	  Western	  blot	  analysis	   (10%	  SDS	  gel)	   for	   the	  detection	  of	   IκBα,	   p65	  and	  p65	  phosphorylated	  on	  Ser-­‐536	  (P-­‐p65)	  in	  HCT116	  cells	  infected	  with	  Ad-­‐Apoptin	  or	  Ad-­‐GFP	  at	  an	  MOI	  of	  10	  for	  the	  indicated	  times.	  Arrows	  indicate	  molecular	  weights	  of	  the	  pre-­‐stained	  protein	  ladder.	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The reduced levels of IκBα observed following infection with Ad-Apoptin suggested an 
effect of Apoptin on the activation of NF-κB because IκB proteins keep NF-κB dimers 
sequestered in the cytoplasm and therefore inactive (Beg et al. 1992). The localisation 
of p65 was investigated by immunofluorescence staining in HCT116 cells following 
transfection with CAV-FLAG-AP for 24 or 48 hours or treated with 200 nM TPA for 
30 minutes (Figure 6-3). In untreated or pcDNA3-transfected cells, p65 was almost 
exclusively localised in the cytoplasm with little nuclear staining, whereas treatment 
with TPA triggered nuclear translocation of p65 in approximately 80% of treated cells. 
Similarly, around 40% of Apoptin-expressing cells showed clear nuclear staining of p65 
after 24 and 48 hours, indicating p65 translocation and potentially activation of NF-κB 
in response to Apoptin expression. 
To further test whether Apoptin triggers NF-κB activation, HCT116 cells were 
transfected with an NF-κB Firefly luciferase reporter construct as well as a Renilla 
luciferase plasmid as a transfection control and infected the next day with Ad-Apoptin 
at an MOI of 10. As a control for NF-κB activation transfected cells were treated with 
10 ng/ml TNFα. Measurement and normalisation of luciferase activities at the indicated 
time points showed a significant induction of NF-κB activity at 16 hours post-infection 
with Ad-Apoptin compared to untreated control cells (Figure 6-4a). In contrast, NF-κB 
activation was not significantly affected by infection with Ad-Apoptin for 8 or 24 hours. 
Compared to control treatment with TNFα the Apoptin-induced NF-κB activity was only 
marginal, approximately 1.5-fold over untreated cells. A similar effect of Apoptin 
expression on NF-κB activation was observed at 24 hours after co-transfection of the 
luciferase constructs with CAV-FLAG-AP compared to a pcDNA3 control vector 
(Figure 6-4b).  
Taken together, these data indicate a potential activation of NF-κB following Apoptin 
expression downstream of Apoptin-induced IκBα degradation, which was associated 
with nuclear translocation of p65 in HCT116 cells. 
 
 




Figure	  6-­‐3:	  Nuclear	  Translocation	  of	  p65	   in	  HCT116	  Cells	  after	  Apoptin	  
Expression	  HCT116	   cells	   were	   transfected	   with	   pcDNA3	   or	   CAV-­‐FLAG-­‐AP	   for	   24	   or	  48	  hours	  or	  treated	  with	  200	  nM	  TPA	  for	  30	  minutes.	  Cells	  were	  stained	  with	  a	   primary	   rabbit	   anti-­‐p65	   and	   secondary	   FITC-­‐conjugated	   anti-­‐rabbit	  antibody	   as	   well	   as	   a	   primary	   mouse	   anti-­‐FLAG	   and	   secondary	   TRITC-­‐conjugated	   anti-­‐mouse	   antibody	   for	   FLAG-­‐transfected	   cells.	   Nuclei	   were	  detected	  by	  counterstaining	  with	  DAPI.	  (a)	  Representative	  images	  of	  fixed	  and	  stained	   cells	   (original	  magnification	   60x,	   bar	  =	  10	   µm).	   (b)	   Quantification	   of	  cells	  displaying	  nuclear	  translocation	  of	  p65.	  At	  least	  50	  cells	  were	  scored	  per	  sample	  and	  only	  FLAG-­‐expressing	  cells	  were	  analysed	  in	  Apoptin	  samples.	  
(a) 
(b) 




Figure	  6-­‐4:	   NF-­‐κB	   Reporter	   Assay	   in	   HCT116	   Cells	   after	   Apoptin	  
Expression	  
(a)	   HCT116	   cells	   were	   transfected	   with	   the	   luciferase	   reporter	   constructs	  pTK-­‐Ren	  and	  pNF-­‐κB-­‐fosp.	  The	  next	  day	  cells	  were	  infected	  with	  Ad-­‐Apoptin	  at	   an	  MOI	   of	   10	   for	   the	   indicated	   times	   or	   treated	  with	   10	  ng/ml	   TNFα	   for	  16	  hours.	   Luciferase	   activity	   from	   triplicate	   wells	   was	   determined	   at	   the	  indicated	   times	   using	   the	   Dual-­‐Glo	   Luciferase	   Assay	   System.	   Untransfected	  cells	   served	   as	   a	   negative	   background	   control	   and	  Renilla	   luciferase	   activity	  was	   used	   to	   correct	   for	   transfection	   efficiency.	   Bars	   represent	   activation	   of	  NF-­‐κB	  compared	  to	  untreated	  cells;	  error	  bars	  indicate	  SEM	  (n	  =	  4).	  Statistical	  significance	  was	   determined	   by	   one-­‐way	   ANOVA	   (**	  P	  <	  0.01,	   ***	  P	  <	  0.001).	  
(b)	   HCT116	   cells	   were	   co-­‐transfected	   with	   pTK-­‐Ren	   and	   pNF-­‐κB-­‐fosp	   and	  CAV-­‐FLAG-­‐AP	  or	  pcDNA3	   for	  24	  hours	   to	  determine	  NF-­‐κB	  activity	  as	  above	  (n	  =	  1).	  
(a) 
(b) 
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6.2.3 Combination of Apoptin with other cytotoxic agents 
As discussed previously, Apoptin cytotoxicity depends on intracellular protein levels of 
Apoptin, requiring a certain threshold before efficient induction of cell death, which 
might represent an obstacle regarding its future application as a therapeutic agent 
(Guelen et al. 2004). Combination with low doses of other cytotoxic agents might 
improve the response of cancer cells to Apoptin without affecting the sensitivity of 
normal cells. 
The combinatory effect of Apoptin and the targeted anti-cancer agent tumour necrosis 
factor-related apoptosis-inducing ligand (TRAIL) was investigated in HCT116 cancer 
cells as well as NCM460 normal colon mucosa cells by MTT analysis at 48 hours after 
treatment. Infection with Ad-Apoptin at MOIs of 10 or 20 resulted in marked cell death 
in HCT116 cells compared to infection with Ad-GFP, killing more than 50% of cells 
(Figure 6-5a). Single treatment with recombinant IZ-TRAIL at concentrations of 10 and 
50 ng/ml reduced the viability of HCT116 cells in a dose-dependent manner by up to 
70%. In combination with Ad-Apoptin, the effect of TRAIL seemed to be rather 
additive than synergistic, increasing the cytotoxic effect of Apoptin treatment alone by 
approximately 10%. However, about 25% of cells remained viable following 
combination treatment with TRAIL and Ad-Apoptin. As expected, NCM460 cells were 
completely resistant to Apoptin expression and only showed marginal sensitivity to 
TRAIL (Figure 6-5b). Similarly to HCT116 cells, no synergistic effect of TRAIL and 
Apoptin was observed in NCM460 cells. Combination treatment with TRAIL and 
Ad-Apoptin reduced cell viability by less than 40% compared to more than 70% in 
HCT116 cells. 
Inhibition of proteasomal activity has previously been shown to stabilise Apoptin in 
normal cells but not in tumour cells, suggesting that the protein levels of Apoptin can 
be regulated through proteasomal degradation (Lanz et al. 2012b). The cytotoxic effect 
of Apoptin in combination with the clinically approved proteasome inhibitor Bortezomib 
was therefore investigated in HCT116 and NCM460 cells by MTT assay at 48 hours 
post-treatment. Infection with Ad-Apoptin at an MOI of 20 resulted in approximately 
60% of cell death in HCT116 cells as opposed to 30% in NCM460 cells (Figure 6-6). 
Treatment with Bortezomib alone at a low concentration of 0.5 ng/ml had a similar 
effect in both cell lines, killing 30% of treated cells, while HCT116 cells were highly 
sensitive to treatment with 2.5 ng/ml Bortezomib compared to NCM460 cells. In 
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HCT116 cells co-treatment with Bortezomib did not markedly enhance the induction of 
cell death by Apoptin. In contrast, the cytotoxic effect of 2.5 ng/ml Bortezomib was 
even partially reduced when cells were additionally infected with Ad-Apoptin 
(Figure 6-6a). Similarly, co-treatment with Bortezomib did not sensitise NCM460 cells 
to Apoptin-induced apoptosis, suggesting that proteasome inhibition is not sufficient to 
enhance the cytotoxic effect of Apoptin in normal cells (Figure 6-6b). 
 
 
Figure	  6-­‐5:	   Combination	   Treatment	   of	   HCT116	   and	   NCM460	   Cells	   with	  
Apoptin	  and	  TRAIL	  HCT116	  (a)	  and	  NCM460	  (b)	  cells	  were	  infected	  with	  Ad-­‐GFP	  or	  Ad-­‐Apoptin	  at	   the	   indicated	   MOIs	   and/or	   treated	   with	   10	  ng/ml	   or	   50	  ng/ml	   IZ-­‐TRAIL.	  Cell	  viability	  was	  assessed	  at	  48	  hours	  after	  treatment	  by	  MTT	  analysis.	  Bars	  represent	   average	   values	   from	   triplicate	   wells	   normalised	   to	   untreated	  control	  cells;	  error	  bars	  indicate	  SEM	  (n	  =	  2).	  
(a) 
(b) 




Figure	  6-­‐6:	   Combination	   Treatment	   of	   HCT116	   and	   NCM460	   Cells	   with	  
Apoptin	  and	  Bortezomib	  HCT116	  (a)	  and	  NCM460	  (b)	  cells	  were	  infected	  with	  Ad-­‐GFP	  or	  Ad-­‐Apoptin	  at	  the	  indicated	  MOIs	  and/or	  treated	  with	  0.5	  ng/ml	  or	  2.5	  ng/ml	  Bortezomib	  (Btz).	  Cell	  viability	  was	  assessed	  at	  48	  hours	  after	  treatment	  by	  MTT	  analysis.	  Bars	   represent	   average	   values	   from	   triplicate	  wells	   normalised	   to	   untreated	  control	  cells;	  error	  bars	  indicate	  SEM	  (n	  =	  2).	  
(a) 
(b) 
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6.2.4 Mechanism of Apoptin-induced cell death in HCT116 cells 
In several studies Apoptin-induced cell death was associated with caspase-3 activation, 
albeit mainly at late stages of apoptosis, while caspase inhibition could not entirely 
abolish apoptosis induction following Apoptin expression (Danen-van Oorschot et al. 
2000; Burek et al. 2006). Here, the type of cell death in HCT116 cells in response to 
infection with Ad-Apoptin was further investigated.  
Infection of HCT116 cells with Ad-Apoptin at an MOI of 20 induced cell death in 
approximately 30% of cells at 48 hours post-infection, as detected by Annexin V/PI 
staining of infected cells and subsequent FACS analysis. The obtained FACS dot profiles 
clearly showed Annexin V single positive cells that were not present in untreated or 
Ad-GFP-infected cells (Figure 6-7a). While the expression of Apoptin did not trigger 
G2/M cell cycle arrest, as reported for other cell types, a small sub-G1 population could 
be detected in cell cycle profiles of Ad-Apoptin-infected HCT116 cells, indicating 
apoptotic cells (Figure 6-7b,c).  
The activation of caspase-3 was investigated in HCT116 cells following infection with 
Ad-GFP or Ad-Apoptin at an MOI of 10 or treatment with 100 ng/ml TRAIL. Western 
blot analysis of cell lysates collected at the indicated time points showed clear cleavage 
of caspase-3, generating active p19, p17 and p12 fragments, in response to TRAIL 
treatment (Figure 6-8). In contrast, no cleaved caspase-3 fragments or reduction of 
full-length caspase-3 levels could be detected following infection with Ad-Apoptin for 
either 24 or 48 hours.  
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Figure	  6-­‐7:	   FACS	  Analysis	   of	   Cell	  Death	   Induction	   in	  HCT116	  Cells	   after	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Figure	  6-­‐8:	  Caspase-­‐3	  Levels	  in	  HCT116	  Cells	  after	  Apoptin	  Expression	  Western	  blot	  analysis	  (15%	  SDS	  gel)	  for	  the	  detection	  of	  cleaved	  caspase-­‐3	  in	  HCT116	  cells	   infected	  with	  Ad-­‐Apoptin	  or	  Ad-­‐GFP	  at	  an	  MOI	  of	  10	   for	  24	  or	  48	  hours	   or	   treated	   with	   100	  ng/ml	   TRAIL	   for	   24	  hours.	   Arrows	   indicate	  molecular	  weights	  of	  the	  pre-­‐stained	  protein	  ladder.	  
To further test whether Apoptin-induced cell death in HCT116 cells is caspase-
dependent or involves necroptotic processes, HCT116 cells were pre-treated with 
20 µM z-Vad-fmk (zVad) prior to infection with Ad-GFP or Ad-Apoptin at MOIs of 40 or 
20, respectively. Additionally, cells were incubated with the RIP1 kinase inhibitor 
necrostatin-1 (nec-1) alone or in combination with zVad. Nec-1 and zVad were 
replenished at 24 hours post-infection to ensure inhibition of caspases and RIP1 kinase 
throughout the duration of the experiment. Cell viability analysis at 48 hours post-
infection revealed no effect of caspase or RIP1 kinase inhibition on Apoptin-induced 
cell death whereas zVad inhibited cell death induced by treatment with 100 ng/ml 
TRAIL for 24 hours by approximately 50% (Figure 6-9).  
Taken together these data suggest that Apoptin triggers apoptosis in HCT116 cells but 
in a caspase-independent manner not involving activation of caspase-3. 
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Figure	  6-­‐9:	  MTT	  Assay	   of	  HCT116	  Cells	   after	   Infection	  with	  Ad-­‐Apoptin	  
combined	  with	  zVad/nec-­‐1	  HCT116	  cells	  were	  infected	  with	  Ad-­‐GFP	  or	  Ad-­‐Apoptin	  at	  an	  MOI	  of	  10	  alone	  or	  in	  combination	  with	  the	  caspase	  inhibitor	  z-­‐VAD-­‐fmk	  (zVad,	  20	  µM)	  and/or	  the	   RIP1	   kinase	   inhibitor	   necrostatin-­‐1	   (nec-­‐1,	   30	  µM).	   The	   inhibitors	   were	  added	  to	  cells	  again	  at	  24	  hours	  post-­‐infection	  and	  treatment	  with	  100	  ng/ml	  TRAIL	  served	  as	  a	  control	  for	  caspase-­‐dependent	  cell	  death.	  Cell	  survival	  was	  measured	  at	  48	  hours	  post-­‐infection	  by	  MTT	  analysis.	  Bars	  represent	  average	  values	   from	  triplicate	  wells	  normalised	   to	  untreated	  control	  cells;	  error	  bars	  indicate	  SEM	  (n	  =	  2).	  	  
6.3 Discussion and Conclusions 
One of the major tumour cell-specific characteristics of Apoptin is its translocation to 
the nucleus preceding the induction of apoptosis. In the nucleus, Apoptin is often 
concentrated into distinct foci that resemble damage foci. We therefore investigated 
the induction of DNA damage in HCT116 cells following transfection of Apoptin 
plasmids. Expression of Apoptin was associated with an increased percentage of nuclei 
displaying γH2AX foci compared to untreated cells, indicating the presence of DNA 
double strand breaks (Figure 6-1). This finding provides a basis for future investigation 
of the role of DNA damage-associated signalling in cancer cells treated with Apoptin. 
Activation of the DNA damage response can trigger multiple effector pathways 
including DNA damage repair, cell cycle arrest and apoptosis (Jackson and Bartek 
(2009). Several proteins, such as TAp73 isoforms and PKCδ, that have already been 
linked to Apoptin expression, can be induced following DNA damage to mediate cell 
cycle arrest or apoptosis (Gong et al. 1999; Basu et al. 2001; Ren et al. 2002; Urist et 
al. 2004). 
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In a recent study, the nuclear translocation of Apoptin in cancer cells was shown to 
depend on intact DNA damage response signalling while exogenous induction of DNA 
damage resulted in nuclear accumulation of Apoptin even in normal cells (Kucharski et 
al. 2011). Many cancers are characterised by constitutive DNA damage due to constant 
genotoxic stress or dysregulation of DNA repair mechanisms (Bartkova et al. 2005; 
Halazonetis et al. 2008) and the findings presented in that study provide a potential 
mechanism for the tumour cell-specific induction of apoptosis by Apoptin. In contrast 
to findings presented here, expression of Apoptin was shown to decrease the number 
of DNA damage foci induced in normal fibroblasts by treatment with the DNA 
damaging agent bleomycin (Kucharski et al. 2011). This experimental setup - 
exogenous induction of DNA damage in normal cells expressing Apoptin - might, 
however, not entirely reflect the endogenous conditions in cancer cells which might 
explain differences to results described here. 
In a previous study Apoptin expression in H1299 cells was associated with increased 
NF-κB activity measured in a luciferase reporter assay which was blocked by 
exogenous expression of IκBα, suggesting activation of the canonical NF-κB pathway 
in response to Apoptin (Tavassoli et al. 2005). While NF-κB has been well established 
as a mediator of cell survival and proliferation, recent studies also propose a 
pro-apoptotic role for NF-κB for example during p53- and Fas-mediated apoptosis or 
cell death in response to viral infections (Kasibhatla et al. 1998; Fujioka et al. 2004). 
Importantly, several PKC isoforms have been implicated in the regulation of NF-κB 
activity while PKC activation by phorbol esters such as TPA can result in transient 
NF-κB activation through a novel IKK complex (Lallena et al. 1999; Martin et al. 2001; 
Saijo et al. 2002; Garg et al. 2012). PKCβ in particular is a critical regulator of NF-κB 
activation during B cell receptor signalling, mediating IKK activation, IκBα degradation 
and subsequent release and nuclear translocation of NF-κB subunits (Shinohara et al. 
2005). Moreover, sustained activation of PKC following prolonged exposure of HCT116 
cells to phorbol esters resulted in downregulation of NF-κB signalling in colon epithelial 
cells (Park et al. 2007).   
As shown in Chapter 5 PKC is activated following Apoptin expression in HCT1116 cells. 
The activation of canonical NF-κB signalling as a potential target of PKC was therefore 
investigated using a combination of methods. Apoptin expression was associated with 
reduced levels of IκBα and increased transcriptional activity of NF-κB in a luciferase 
reporter assay. (Figure 6-2, Figure 6-4). Compared to treatment with TNFα Apoptin-
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induced NF-κB activation was only marginal by approximately 1.5-fold but coincided 
with the highest levels of PKC activity observed following Apoptin expression in the 
previous chapter (Figure 5-9c). Whereas p65 phosphorylation on Ser-536 was 
decreased after infection with Ad-Apoptin compared to untreated cells (Figure 6-2), 
which would negatively affect the function of p65, Apoptin-expressing cells showed an 
enhanced translocation of p65 into the nucleus (Figure 6-3). Similarly, pharmacological 
activation of PKC with TPA triggered nuclear translocation of p65, indicating a 
promoting role of PKC activity on p65 translocation. Taken together these data indicate 
that Apoptin seems to affect NF-κB signalling in HCT116 cell but that further studies 
will be necessary to establish a role for NF-κB in Apoptin-mediated cell death and to 
investigate the link between Apoptin-induced PKC activation and subsequent effects on 
NF-κB signalling.  
The clinical application of Apoptin might be limited by a need for high expression 
levels. In vitro and in vivo studies have shown promising enhancement of Apoptin-
induced cytotoxicity when Apoptin was combined with other anti-cancer agents such as 
etoposide, irradiation, TRAIL or mda-7 (Olijslagers et al. 2007; Cao et al. 2010; Schoop 
et al. 2010; Yuan et al. 2013). In our study, HCT116 cancer cells were killed more 
efficiently when treated with a combination of TRAIL and Ad-Apoptin while normal 
NCM460 cells remained resistant to both drugs alone or in combination (Figure 6-5). 
However, approximately 25% of HCT116 cells remained resistant to the combination of 
TRAIL and Apoptin and further studies will be necessary to improve the efficiency of 
cell death in cancer cells. 
In a recent study, treatment with proteasome inhibitors such as Bortezomib was shown 
to stabilise Apoptin in normal cells (Lanz et al. 2012b). This might increase the 
cytotoxic effect of Apoptin through protein stabilisation, however no data on the effect 
of Bortezomib on Apoptin cytotoxicity in normal cells were provided. In our study, 
co-treatment with Bortezomib did not synergistically enhance the cytotoxic effect of 
Ad-Apoptin in either HCT116 or NCM460 cells (Figure 6-6). Of note, the highest 
Bortezomib concentration used in this study - 2.5 ng/ml corresponding to 6.5 nM - was 
nearly 10-fold lower than doses used in the study by Lanz et al., which could explain 
the lack of synergism between Apoptin and Bortezomib on cell death induction in 
normal NCM460 cells.  
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Apoptin expression in cancer cells is believed to induce apoptosis mediated through the 
intrinsic pathway in a caspase-dependent manner. Several observations, however, 
indicate that mitochondrial permeabilisation and caspase activation only occur as a 
consequence of cell death and that cell killing also involves caspase-independent 
pathways (Danen-van Oorschot et al. 2000; Burek et al. 2006). Whereas FACS 
analyses of Apoptin-treated HCT116 cells showed Annexin V single positive cells and 
the presence of a sub-G1 population (Figure 6-7), clearly indicating apoptosis, cleavage 
of caspase-3 could not be detected in response to Apoptin expression (Figure 6-8). 
Moreover, pre-treatment with the pan-caspase inhibitor zVad alone or in combination 
with nec-1 was not sufficient to protect cells Apoptin-induced cell death (Figure 6-9).  
In conclusion the data presented here provide some evidence for future investigations 
of the DNA damage response and NF-κB signalling as well as associated signalling 
pathways in Apoptin-induced cell death. Furthermore, they highlight the need for 
closer investigation of cell death pathways triggered by Apoptin to identify the precise 
molecular players involved in the tumour cell-specific killing by Apoptin. 
 





Results V  
Sensitisation of HPV positive HNSCC Cells to 
TRAIL by Bortezomib 
 
7.1 Introduction 
TRAIL has been shown to selectively kill several types of malignant cells with little 
effect on normal cells (Falschlehner et al. 2009). In contrast to Apoptin, the 
mechanism of TRAIL-induced apoptosis is well described and recombinant TRAIL or 
monoclonal antibody agonists of TRAIL receptors are already in use in clinical trials 
(Herbst et al. 2010; Younes et al. 2010). Many cancer cells remain resistant to TRAIL, 
necessitating combination with other therapeutic agents to achieve efficient cell death 
(Hellwig and Rehm 2012). In several types of cancers co-treatment with proteasome 
inhibitors such as Bortezomib or MG132 has been shown to sensitise previously 
resistant cancer cells to TRAIL through several potential mechanisms (Johnson et al. 
2003; Sayers et al. 2003; Lashinger et al. 2005; Nikrad et al. 2005; Chen et al. 2008; 
Brooks et al. 2010; Seki et al. 2010; Jane et al. 2011; Naumann et al. 2011; 
Unterkircher et al. 2011; Yoshiba et al. 2011).  
So far little is known about the therapeutic potential of TRAIL alone or in combination 
with Bortezomib in cells derived from head and neck squamous cell carcinomas 
(HNSCC). Although the overall incidence of head and neck cancer is declining, the rate 
of a subset of oropharyngeal cancers associated with infection with high-risk human 
papillomavirus (HPV) serotypes has dramatically increased (Chaturvedi et al. 2011). 
The viral oncoproteins E6 and E7 trigger cellular transformation, mainly through 
inactivation of the p53 and retinoblastoma tumour suppressor proteins (Rampias et al. 
2009). HPV-related HNSCCs are biologically distinct from other head and neck cancers 
and are characterised by a better overall survival and response to chemo- or 
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radiotherapy (Dayyani et al. 2010). Nevertheless, conventional therapies are often 
accompanied by severe side effects and the development of more specific targeted 
agents or combination therapies employing reduced drug doses is important to 
improve patient care. 
7.2 Results 
7.2.1 Combination treatment of HPV-associated HNSCC cell lines 
with TRAIL and Bortezomib 
Despite their generally enhanced sensitivity to chemo- or radiotherapy compared to 
HPV negative (HPV-) HNSCC cell lines, HPV positive (HPV+) cell lines tested here were 
found to be resistant to TRAIL-induced apoptosis, even at high concentrations of 
TRAIL (Bullenkamp et al., manuscript in submission). This study aimed to investigate 
whether the clinically approved proteasome inhibitor Bortezomib was able to sensitise 
HPV+ HNSCC cells to TRAIL as well as to identify underlying mechanisms for enhanced 
TRAIL sensitivity following Bortezomib treatment. 
7.2.1.1 Synergistic cytotoxic effect of TRAIL and Bortezomib in HNSCC 
cell lines 
The differential sensitivity of the two representative HNSCC cell lines 089 (HPV-) and 
090 (HPV+) to TRAIL or Bortezomib was tested by analysing cell viability after 48 hours 
of treatment with increasing concentrations of the respective drug. Whereas HPV- 089 
cells died in a dose-dependent manner in response to TRAIL, the survival of HPV+ 090 
cells was not significantly affected even after treatment with 100 ng/ml TRAIL 
(Figure 7-1). By contrast, 089 and 090 cells displayed a similar sensitivity to treatment 
with Bortezomib with an IC50 value of approximately 2.5 ng/ml for both cell lines 
(Figure 7-2). 
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Figure	  7-­‐1:	  TRAIL	  Sensitivity	  of	  089	  and	  090	  HNSCC	  Cell	  Lines	  HPV-­‐	  089	  and	  HPV+	  090	  cells	  were	   treated	  with	   increasing	  concentrations	  of	  TRAIL	   ranging	   from	   0	   to	   100	  ng/ml.	   Cell	   viability	  was	   analysed	   at	   48	  hours	  after	   treatment	   by	   MTT	   assay	   of	   triplicate	   wells.	   Bars	   represent	   mean	   cell	  survival	  normalised	  to	  untreated	  controls;	  error	  bars	  indicate	  SEM	  (n	  =	  3).	  	  
 
Figure	  7-­‐2:	  Bortezomib	  Sensitivity	  of	  089	  and	  090	  HNSCC	  Cell	  Lines	  HPV-­‐	  089	  and	  HPV+	  090	  cells	  were	   treated	  with	   increasing	  concentrations	  of	  Bortezomib	   ranging	   from	   0	   to	   10	  ng/ml.	   Cell	   viability	   was	   analysed	   at	  48	  hours	   after	   treatment	   by	   MTT	   assay	   of	   triplicate	   wells.	   Data	   points	  represent	   mean	   cell	   survival	   normalised	   to	   untreated	   controls;	   error	   bars	  indicate	  SEM	  (n	  =	  3).	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The sensitising effect of Bortezomib on TRAIL-induced cell death in 089 and 090 cells 
was tested using 50 ng/ml TRAIL in combination with Bortezomib at several 
concentrations below the IC50 value. Co-treatment with 2.5 ng/ml Bortezomib 
sensitised HPV+ 090 cells to TRAIL-induced cell death while Bortezomib alone did not 
markedly impair cell viability (Figure 7-3a). In HPV- 089 cells the cytotoxic effect of 
TRAIL was significantly enhanced when combined with Bortezomib. 
To further investigate the synergy between TRAIL and Bortezomib 089 and 090 cells 
were treated with different concentration ratios of TRAIL and Bortezomib for 48 hours. 
Treatment with 0.625 or 1.25 ng/ml Bortezomib enhanced the cytotoxic effect of 
TRAIL used at 12.5, 25 or 50 ng/ml in HPV+ 090 cells (Figure 7-3c). At all ratios tested 
the effect of Bortezomib on TRAIL-induced cell death in 090 cells was synergistic as 
indicated by a combination index (CI) value below 1.0 (Table 7-1). In TRAIL-sensitive 
089 cells addition of Bortezomib further enhanced TRAIL cytotoxicity, displaying a 
synergistic effect at low TRAIL to Bortezomib ratios such as 25 ng/ml TRAIL combined 








Figure	  7-­‐3:	  Synergistic	  Cytotoxic	  Effect	  of	  TRAIL	  and	  Bortezomib	   in	  089	  
and	  090	  Cells	  HPV-­‐	  089	  and	  HPV+	  090	  cells	  were	  treated	  with	  the	   indicated	  concentrations	  of	   TRAIL	   and	   Bortezomib.	   Cell	   viability	   was	   analysed	   at	   48	   hours	   after	  treatment	  by	  MTT	  assay	  of	  triplicate	  wells	  and	  all	  values	  were	  normalised	  to	  untreated	   control	   cells.	   (a)	   Bars	   represent	   mean	   cell	   survival	   following	   the	  respective	  combination	  treatments;	  error	  bars	  indicate	  SEM	  (n	  =	  3).	  Statistical	  significance	   was	   determined	   by	   two-­‐way	   ANOVA	   (*	  P	  <	  0.05,	   ***	  P	  <	  0.001).	  
(b/c)	  Bars	  represent	  viability	  of	  089	  (b)	  and	  090	  (c)	  cells	  treated	  with	  TRAIL	  as	   indicated	   plus	   increasing	   concentrations	   of	   Bortezomib,	   data	   points	  represent	  samples	  treated	  with	  Bortezomib	  only.	  	  
(b) 
(c)	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TRAIL:Btz 40:1 20:1 10:1 
089 1.12 0.51 0.67 
090 0.24 0.51 0.28 
	  
Table	  7-­‐1:	  Synergy	  of	  TRAIL	  And	  Bortezomib	  in	  089	  and	  090	  Cells	  CI	   values	   calculated	   using	   CompuSyn	   software	   of	   089	   and	   090	   cells	   treated	  with	  the	  indicated	  concentration	  ratios	  of	  TRAIL	  to	  Bortezomib	  (Btz).	  
The sensitising effect of Bortezomib on TRAIL-induced cell death was subsequently 
confirmed in a larger panel of HPV+ and HPV- HNSCC cell lines. Combination treatment 
with 50 ng/ml TRAIL and 2.5 ng/ml Bortezomib for 48 hours resulted in significantly 
enhanced cell death in all cell lines tested compared to single treatments with either 
drug (Figure 7-4).  
 
Figure	  7-­‐4:	   Combination	   Treatment	   of	   HNSCC	   Cells	   with	   TRAIL	   and	  
Bortezomib	  Seven	  HPV-­‐	  or	  HPV+	  HNSCC	  cell	  lines	  were	  treated	  with	  TRAIL	  (50	  ng/ml)	  and	  Bortezomib	  (Btz,	  2.5	  ng/ml)	  alone	  or	  in	  combination	  for	  48	  hours	  before	  MTT	  analysis.	  Bars	  represent	  mean	  cell	  survival	  from	  triplicate	  wells	  normalised	  to	  untreated	  controls;	  error	  bars	  indicate	  SEM	  (n	  =	  3).	  Statistical	  significance	  was	  determined	  by	  two-­‐way	  ANOVA	  (***	  P	  <	  0.001).	  
  Chapter 7: Results V 
 190 
As for Bortezomib co-treatment with a subtoxic dose of the proteasome inhibitor 
MG132 sensitised HPV+ 090 cells to TRAIL (Figure 7-5). Taken together, these data 
indicate a generally synergistic effect of proteasome inhibition on TRAIL-induced cell 
death in HPV+ cancer cells. 
 
Figure	  7-­‐5:	  Combination	  Treatment	  of	  090	  Cells	  with	  TRAIL	  and	  MG132	  HPV+	  090	   cells	  were	   treated	  with	  TRAIL	   as	   indicated	   and	  0.1	  µM	  MG132	   for	  48	  hours.	  Bars	   represent	  mean	  cell	   survival	   from	   triplicate	  wells	  normalised	  to	  untreated	  controls;	  error	  bars	   indicate	  SEM	  (n	  =	  3).	  Statistical	  significance	  was	  determined	  by	  two-­‐way	  ANOVA	  (**	  P	  <	  0.01).	  
7.2.1.2 Induction of apoptosis by TRAIL and Bortezomib 
To determine whether TRAIL and Bortezomib induce apoptosis or other forms of cell 
death in HNSCC cells, HPV- 089 and HPV+ 090 cells were treated with 50 ng/ml TRAIL 
and/or 2.5 ng/ml Bortezomib and analysed by microscopy as well as Annexin V/PI 
staining for cell death detection by FACS analysis. 
Imaging of HPV- 089 cells showed detachment of cells following treatment with TRAIL 
after 16 hours, which was markedly enhanced after co-treatment with TRAIL and 
Bortezomib (Figure 7-6a). In contrast, TRAIL alone did not affect the morphology of 
HPV+ 090 cells but triggered detachment of cells in combination with Bortezomib, 
albeit at later time points than in 089 cells (Figure 7-6b). Compared to the combination 
treatment, Bortezomib alone only had a minor effect on cell morphology in both cell 
lines at late time points after treatment. 




Figure	  7-­‐6:	  Light	  Microscopy	  of	  089	  and	  090	  Cells	  after	  Treatment	  with	  
TRAIL	  and	  Bortezomib	  HPV-­‐	  089	  (a)	  and	  HPV+	  090	  (b)	  cells	  were	  treated	  with	  50	  ng/ml	  TRAIL	  and	  2.5	  ng/ml	  Bortezomib	  alone	  or	  in	  combination.	  Cell	  cultures	  were	  observed	  at	  the	   indicated	   times	   after	   treatment	   by	   light	   microscopy	   (original	  magnification	  10x,	  bar	  =	  50	  µm).	  
(a) 
(b)	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Cell death, as defined by positive staining for Annexin V and/or PI, was detected in 
both cell lines treated with TRAIL and Bortezomib, killing approximately 80% of cells at 
48 hours after treatment (Figure 7-7a). In contrast, treatment with TRAIL alone for 
48 hours reduced the viability of HPV- 089 cells by approximately 50% but did not have 
any measureable cytotoxic effect in HPV+ 090 cells. Bortezomib used as a single drug 
displayed only slight toxicity in both cell lines. 
While TRAIL and Bortezomib reduced cell viability to similar extents in both 089 and 
090 cells, the FACS dot plot profiles showed a very distinct pattern for each cell line. In 
HPV- 089 cells TRAIL alone or in combination with Bortezomib triggered classical 
apoptosis as characterised by an increase in the Annexin V single-positive cell 
population before the occurrence of secondary necrosis and a shift to a double-positive 
cell population (Figure 7-7b). In contrast, in HPV+ 090 cells the combination treatment 
induced a shift towards a PI single-positive population before staining with Annexin V 








Figure	  7-­‐7:	   Quantification	   of	   Cell	   Death	   in	   089	   and	   090	   Cells	   after	  
Treatment	  with	  TRAIL	  and	  Bortezomib	  HPV-­‐	  089	  and	  HPV+	  090	  cells	  were	  treated	  with	  50	  ng/ml	  TRAIL	  and	  2.5	  ng/ml	  Bortezomib	   (Btz)	   alone	   or	   in	   combination.	   Cells	   were	   collected	   at	   the	  indicated	   time	   points	   for	   Annexin	  V/PI	   staining	   and	   FACS	   analysis.	   (a)	  Bars	  represent	   the	   percentage	   of	   dead	   cells	   defined	   as	   either	   Annexin	  V	   or	   PI	  positive;	  error	  bars	   indicate	  SEM	  (n	  =	  3).	  Statistical	  significance	  compared	   to	  untreated	   cells	   was	   determined	   by	   two-­‐way	   ANOVA	   (**	  P	  <	  0.01,	  ***	  P	  <	  0.001).	   (b/c)	  Representative	   FACS	   dot	   plots	   of	   089	   (b)	   and	   090	   (c)	  cells	  indicating	  Annexin	  V	  and	  PI	  positive	  cell	  populations	  are	  shown.	  
(b) 
(c) 
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7.2.1.3 Role of caspases in TRAIL/Bortezomib-induced cell death 
To test whether the induction of cell death in HNSCC cells requires caspase activity, 
089 and 090 cells were treated with TRAIL and Bortezomib combined with the pan-
caspase inhibitor zVad and/or the RIP1 kinase nec-1 for 48 hours. Pre-treatment with 
20 µM zVad significantly reduced cell death by approximately 30% and 40% in 089 
and 090 cells respectively (Figure 7-8). Addition of 30 µM nec-1 further blocked cell 
death induction by about 20% in both cell lines, which might indicate partially 
necroptotic cell death induced by TRAIL and Bortezomib. The inability of zVad with or 
without nec-1 to completely restore cell viability following the combination treatment 
might be due to reduced proliferation of Bortezomib-treated cells instead of cell death, 
which would reduce the MTT signal due to decrease in the number of viable cells. 
 
Figure	  7-­‐8:	   Viability	   of	   089	   and	   090	   Cells	   after	   Treatment	   with	   TRAIL	  
and	  Bortezomib	  Combined	  with	  zVad/nec-­‐1	  HPV-­‐	  089	  and	  HPV+	  090	  cells	  were	  treated	  with	  50	  ng/ml	  TRAIL	  and	  2.5	  ng/ml	  Bortezomib	   alone	   or	   combined	  with	   the	   caspase	   inhibitor	   z-­‐VAD-­‐fmk	   (zVad,	  20	  µM)	   and/or	   the	   RIP1	   kinase	   inhibitor	   necrostatin-­‐1	   (nec-­‐1,	   30	  µM).	   Cell	  survival	  was	  measured	  48	  hours	   later	  by	  MTT	  analysis.	  Bars	  represent	  mean	  values	   from	   triplicate	   wells	   normalised	   to	   untreated	   controls;	   error	   bars	  indicate	   SEM	   (n	  =	  4).	   Statistical	   significance	   was	   determined	   by	   two-­‐way	  ANOVA	  (*	  P	  <	  0.05,	  **	  P	  <	  0.01,	  ***	  P	  <	  0.001).	  
These results were confirmed by Annexin V/PI staining after 24 hours of treatment of 
089 and 090 cells with TRAIL and Bortezomib. Combination treatment induced cell 
death in approximately 60 to 70% of cells, slightly less than compared to MTT assays 
at a later time point (Figure 7-9a). Addition of zVad alone or in combination with nec-1 
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had a similar effect on the inhibition of cell death as observed in MTT assays, reducing 
the percentage of dead cells by approximately 30% in both cell lines (Figure 7-9a). As 
expected, caspase inhibition in HPV- 089 cells almost completely abolished the 
Annexin V single-positive population and markedly decreased the double-positive 
population shown on the FACS dot plots (Figure 7-9b). Addition of zVad also 
diminished both the double-positive and the PI single-positive cell after treatment in 
HPV+ 090 cells. The significance of this caspase-dependent shift to a PI single-positive 
population in HPV+ cells remains to be determined. 
 
 
Figure	  7-­‐9:	   FACS	   Analysis	   of	   089	   and	   090	   Cells	   after	   Treatment	   with	  
TRAIL	  and	  Bortezomib	  Combined	  with	  zVad/nec-­‐1	  HPV-­‐	  089	  and	  HPV+	  090	  cells	  were	  treated	  with	  50	  ng/ml	  TRAIL	  and	  2.5	  ng/ml	  Bortezomib	  combined	  with	  20	  µM	  zVad	  and/or	  50	  µM	  nec-­‐1	  for	  24	  hours	  and	  stained	   with	   Annexin	  V	   and	   PI	   for	   FACS	   analysis.	   (a)	   Bars	   represent	   the	  percentage	  of	  dead	  cells	  defined	  as	  either	  Annexin	  V	  or	  PI	  positive;	  error	  bars	  indicate	   SEM	   (n	  =	  3).	   Statistical	   significance	   was	   determined	   by	   one-­‐way	  ANOVA	  (**	  P	  <	  0.01,	   ***	  P	  <	  0.001).	   (b)	  Representative	  FACS	  dot	  plots	  of	  089	  and	  090	  cells	  indicating	  Annexin	  V	  and	  PI	  positive	  cell	  populations	  are	  shown.	  	  	  
(a) 
(b) 
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The processing of caspase-3 and caspase-8 in 089 and 090 cells following treatment 
with TRAIL and/or Bortezomib was investigated by Western blot analysis at different 
time points. In 089 cells treatment with TRAIL alone or in combination with Bortezomib 
resulted in the cleavage of caspase-3 as well as a reduction of full-length caspase-8 
detected at 8 hours after treatment (Figure 7-10, upper panel). In contrast, caspase-3 
processing was only detected after 16 hours following co-treatment with TRAIL and 
Bortezomib in 090 cells with no detectable effect on pro-caspase-8 levels. These 
kinetics of caspase processing suggest that cell death induced by TRAIL and 
Bortezomib is a caspase-dependent process in both 089 and 090 cells. 
 
 
Figure	  7-­‐10:	  Western	  Blot	  Analysis	  of	  089	  and	  090	  Cells	  after	  Treatment	  
with	  TRAIL	  and	  Bortezomib	  Western	   blot	   analysis	   (15%	   SDS	   gels)	   for	   the	   detection	   of	   the	   indicated	  proteins	  in	  HPV-­‐	  089	  and	  HPV+	  090	  cells	  treated	  with	  TRAIL	  (T,	  50	  ng/ml)	  and	  Bortezomib	  (B,	  2.5	  ng/ml)	  alone	  or	   in	  combination	  (BT)	   for	  4,	  8	  or	  16	  hours.	  Arrows	   indicate	  molecular	  weights	  of	   the	  pre-­‐stained	  protein	   ladder.	  Dotted	  lines	  were	  included	  for	  easier	  comparison	  of	  individual	  samples.	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7.2.2 Mechanism of Bortezomib-mediated sensitisation to TRAIL 
Several mechanisms have been proposed to mediate Bortezomib-induced sensitisation 
to TRAIL-induced apoptosis, including inhibition of NF-κB signalling, enhanced 
activation of caspase-8, induction of p53 and p21, stabilisation of tBid or inhibition of 
XIAP (Lashinger et al. 2005; Brooks et al. 2010; Naumann et al. 2011; Unterkircher et 
al. 2011). 
7.2.2.1 Role of caspase-8 in cell death induced by TRAIL and Bortezomib 
Caspase-8 is the major initiator caspase recruited to the activated TRAIL receptor 
complex to trigger the apoptotic caspase cascade. Initial results suggested that 
pro-caspase-8 is cleaved in HPV- 089 cells in response to TRAIL alone or in 
combination with Bortezomib but is not visibly affected in HPV+ 090 cells at any of the 
time points investigated in this study (Figure 7-10).  
For further studies inducible caspase-8 knockdown cell lines as well as the respective 
scrambled control cells were generated as described in section 2.2.3.8, achieving a 
knockdown efficiency of 80 to 100% after doxycycline induction for 48 hours 
(Figure 7-11a). Processing of caspase-3 to generate the active p19 and p17 fragments 
in response to combination treatment with 50 ng/ml TRAIL and 2.5 ng/ml Bortezomib 
was markedly reduced in both cell lines following knockdown of caspase-8 
(Figure 7-11a).  
To analyse the effect of caspase-8 knockdown on cell survival control and knockdown 
cells were treated with 50 ng/ml TRAIL and increasing concentrations of Bortezomib 
between 0.5 and 2.5 ng/ml for 48 hours. 089 cells lacking caspase-8 were only 
partially rescued from apoptosis induced by TRAIL alone or in combination with 
Bortezomib (Figure 7-11b). Similarly, knockdown of caspase-8 significantly protected 
090 cells from cell death induced by TRAIL and Bortezomib, but only by approximately 
30% compared to control cells (Figure 7-11c). This might indicate involvement of other 
initiator caspases or caspase-independent mechanisms mediating cell death in 
response to treatment with TRAIL and Bortezomib or be due to remaining caspase-8 
following induction of shRNAs with doxycycline. 





Figure	  7-­‐11:	   Effect	   of	   Caspase-­‐8	  Knockdown	  on	  Response	   to	  TRAIL	   and	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7.2.2.2 Role of Bid in cell death induced by TRAIL and Bortezomib 
The BH3-only protein Bid provides a link between death receptor activation and 
permeabilisation of the outer mitochondrial membrane after its caspase-8-mediated 
cleavage to tBid, which can be stabilised through proteasome inhibition (Unterkircher 
et al. 2011). 
In HPV- 089 cells, but not in HPV+ 090 cells, treatment with TRAIL alone resulted in Bid 
cleavage, which was markedly enhanced following co-treatment with Bortezomib 
(Figure 7-12). However, only a faint band corresponding to tBid was detected in 090 
cells treated with TRAIL and Bortezomib, indicating that tBid is not required for the 
sensitising effect of Bortezomib. 
 
Figure	  7-­‐12:	  Stabilisation	  of	  tBid	  in	  089	  Cells	  by	  Bortezomib	  Truncation	   of	   Bid	   to	   tBid	  was	   analysed	   by	  Western	   blot	   analysis	   (15%	   SDS	  gel)	  in	  HPV-­‐	  089	  and	  HPV+	  090	  cells	  treated	  for	  8	  hours	  with	  50	  ng/ml	  TRAIL	  alone	   (T),	   2.5	  ng/ml	   Bortezomib	   (B)	   or	   a	   combination	   of	   both	   (BT).	   Arrows	  indicate	  molecular	  weights	  of	  the	  pre-­‐stained	  protein	  ladder.	  
Moreover, no significant difference in response to 50 ng/ml TRAIL combined with 
1 ng/ml Bortezomib was observed after stable knockdown of Bid in either 089 or 090 
cells compared to the respective controls (Figure 7-13). This suggests that Bortezomib-
induced sensitisation to TRAIL occurs independently of Bid. 
	  





Figure	  7-­‐13:	   Effect	   of	   Bid	   Knockdown	   on	   Response	   to	   TRAIL	   and	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7.2.2.3 Role of XIAP in cell death induced by TRAIL and Bortezomib 
The anti-apoptotic protein XIAP prevents caspase-3 activation by several mechanisms 
(Deveraux et al. 1997) and its overexpression in cancer cells has been linked to TRAIL 
resistance (Cummins et al. 2004). In TRAIL-sensitive HPV- 089 cells, but not in 
resistant HPV+ 090 cells, an early cleavage of XIAP, reducing full-length XIAP levels 
and generating a 29 kDa fragment, was detected after treatment with TRAIL alone or 
in combination with Bortezomib (Figure 7-10).  
Stable XIAP or LacZ knockdown cells were generated with a knockdown efficiency of 
80% or 70% for 089 and 090 cells, respectively (Figure 7-14a). These were treated 
with 50 ng/ml TRAIL in combination with different concentrations of Bortezomib for 
48 hours and cell viability was analysed by the MTT assay. XIAP knockdown completely 
reduced the survival of HPV- 089 cells in response to TRAIL to a similar level as 
obtained in combination with Bortezomib while their sensitivity to Bortezomib alone 
was unaffected (Figure 7-14b). TRAIL-resistant HPV+ 090 cells lacking XIAP were 
significantly more sensitive to treatment with TRAIL alone, showing a decrease of cell 
viability by approximately 30% compared to LacZ control cells (Figure 7-14c). In both 
089 and 090 cells knockdown of XIAP enhanced cell death following combination 
treatment with TRAIL and Bortezomib at lower concentrations tested.  
The effect of XIAP knockdown on caspase-3 activation in 089 and 090 cells was 
investigated by Western blot analysis of knockdown or control cells treated with 
50 ng/ml TRAIL and/or 2.5 ng/ml Bortezomib for 16 hours. Depletion of XIAP resulted 
in a markedly enhanced processing of caspase-3 to generate the fully processed p17 
fragment in both cell lines treated with TRAIL and Bortezomib (Figure 7-15). Whereas 
cleavage of full-length caspase-3 into the p19 and p12 fragments is mediated by 
upstream initiator caspases, processing of p19 to generate p17 by removal of the 
remaining pro-domain represents an autocatalytic step and therefore indicates activity 
of caspase-3 (Han et al. 1997). In line with that, we observed increased cleavage of 
the caspase-3 substrate PARP in XIAP knockdown cells showing increased levels of the 
p17 fragment following combination treatment with TRAIL and Bortezomib 
(Figure 7-15). By contrast, XIAP knockdown did not markedly affect caspase-3 
activation in response to TRAIL alone at this time point. 





Figure	  7-­‐14:	   Effect	   of	   XIAP	   Knockdown	   on	   Response	   to	   TRAIL	   and	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Figure	  7-­‐15:	   Effect	   of	   XIAP	   Knockdown	   on	   Caspase-­‐3	   Activation	   in	   089	  
and	  090	  Cells	  Stable	  HPV-­‐	   089	   and	  HPV+	   090	   XIAP	   and	   LacZ	   shRNA	   cells	  were	   treated	   for	  16	  hours	   with	   50	  ng/ml	   TRAIL	   alone	   (T),	   2.5	  ng/ml	   Bortezomib	   (B)	   or	   a	  combination	  of	  both	   (BT).	  Levels	  of	   the	   indicated	  proteins	  were	  analysed	  by	  Western	   blot	   analysis	   (15%	   SDS	   gel).	   Arrows	   indicate	  molecular	  weights	   of	  the	  pre-­‐stained	  protein	  ladder.	  
7.2.2.4 p53 induction and cell cycle arrest in HNSCC cells by Bortezomib 
The majority of HPV- head and neck tumours contain mutations in the TP53 tumour 
suppressor gene which are predominantly located within the DNA-binding domain and 
disrupt its ability to activate transcription of target genes (Poeta et al. 2007; Suh et al. 
2014). Mutant p53 accumulates in tumour cells due to defective degradation by the 
ubiquitin proteasome system compared to wild type p53 or other yet unidentified 
mechanisms (Lukashchuk and Vousden 2007). In contrast, HPV+ tumours retain wild 
type p53 which is inactivated through E6-dependent proteasomal degradation 
(Scheffner et al. 1990).  
In 090 cells as well as other HPV+ HNSCC cell lines tested Bortezomib alone or in 
combination with TRAIL mediated cellular stabilisation of wild type p53 due to reduced 
proteasomal degradation as well as induction of its target protein p21 after 16 hours of 
treatment (Figure 7-16). Increased levels of p53 in response to Bortezomib might 
result in transcription of other pro-apoptotic target genes to promote cell death in 
HPV+ cells as p53 in these cells is not mutated and therefore functionally intact. In 
contrast, HPV- 089 or 072 cells containing mutated p53 (White et al. 2007) showed no 
further increase in p53 protein levels or induction of p21 at any of the time points 
analysed (Figure 7-16, Figure 7-10).  




Figure	  7-­‐16:	  Induction	  of	  p53	  and	  p21	  in	  HPV+	  Cells	  by	  Bortezomib	  Expression	  levels	  of	  p53	  and	  p21	  was	  detected	  by	  Western	  blot	  analysis	  (12%	  SDS	  gel)	  in	  (a)	  HPV-­‐	  089	  and	  HPV+	  090	  cells	  after	  16	  hours	  of	  treatment	  with	  50	  ng/ml	  TRAIL	  alone	  (T),	  2.5	  ng/ml	  Bortezomib	  (B)	  or	   in	  combination	  (BT)	  as	   well	   as	   (b)	   2	   HPV-­‐	   and	   3	   HPV+	   HNSCC	   cell	   lines	   treated	   with	   2.5	  ng/ml	  Bortezomib	   (B)	   for	  16	  hours.	  Arrows	   indicate	  molecular	  weights	   of	   the	  pre-­‐stained	  protein	  ladder.	  
The cyclin-dependent kinase inhibitor p21 represents a major mediator of p53-induced 
cell cycle arrest in G0/G1 phase in response to DNA damaging agents and other 
cellular stresses (Waldman et al. 1995). The effect of Bortezomib on the cell cycle was 
therefore analysed by flow cytometry at 24 hours after treatment of HNSCC cells with 
TRAIL and/or Bortezomib. Bortezomib alone or in combination with TRAIL induced G2 
arrest of approximately 25 to 30% in both 089 and 090 cells while TRAIL alone did not 
affect cell cycle profiles (Figure 7-17a,b). Moreover, a small sub-G1 population was 
detected in 089 cells treated with TRAIL and Bortezomib, indicating induction of 
apoptosis. Similarly, other HNSCC cell lines showed a strong G2/M arrest which was 
more pronounced in HPV- cells compared to HPV+ cell lines (Figure 7-17c). Whether 
increased levels of p53 and arrest of cells in G2/M phase in response to Bortezomib 
treatment contribute to the increased sensitivity of HPV+ HNSCC cells to TRAIL remains 
to be determined. 
(b) 
(a) 
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Figure	  7-­‐17:	   Cell	   Cycle	   Analysis	   of	   HPV+	   and	   HPV-­‐	   HNSCC	   Cells	   after	  
Treatment	  with	  TRAIL	  and	  Bortezomib	  
(a/b)	  HPV-­‐	  089	  and	  HPV+	  090	  cells	  were	  treated	  with	  50	  ng/ml	  TRAIL	  and/or	  2.5	  ng/ml	   Bortezomib	   (Btz)	   for	   24	  hours	   before	   cell	   cycle	   analysis	   by	   PI	  staining	   and	   flow	   cytometry.	   (a)	   Representative	   PI	   histograms	   showing	  number	   of	   cells	   in	   G1	  phase	   (left	   peak),	   G2	  phase	   (right	   peak)	   as	   well	   as	  S	  phase	  and	  sub-­‐G1	  phase.	  (b)	  Quantification	  of	  cells	  in	  the	  indicated	  cell	  cycle	  phases	  after	   treatment;	  error	  bars	   indicate	  SEM	  (n	  =	  3).	  (c)	  7	  HPV-­‐	  or	  HPV+	  HNSCC	  cell	  lines	  were	  treated	  with	  2.5	  ng/ml	  Bortezomib	  for	  24	  hours	  before	  cell	   cycle	   analysis	   by	   flow	   cytometry.	   Bars	   represent	   increase	   of	   the	  percentage	  of	  cells	  in	  G2/M	  phase	  following	  treatment	  compared	  to	  untreated	  control	  cells;	  error	  bars	  indicate	  SEM	  (n	  =	  3).	  
(a) 
(b) (c) 
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7.2.2.5 Activation of NF-κB in HNSCC cells treated with TRAIL and 
Bortezomib 
Initial studies on the effect of Bortezomib in multiple myeloma suggested inhibition of 
NF-κB signalling through stabilisation of the inhibitory protein IκBα as the major 
mechanism of its anti-tumour function (Hideshima et al. 2002). However, other studies 
suggest that prolonged treatment with Bortezomib can, in contrast, induce IκBα 
degradation and thus activate NF-κB (Hideshima et al. 2009). 
Detection of IκBα levels by Western blot analysis showed degradation of IκBα in 089 
cells treated with 50 ng/ml TRAIL alone at all time points tested, indicating NF-κB 
activation (Figure 7-10). Co-treatment with 2.5 ng/ml Bortezomib partially reduced this 
TRAIL-induced degradation of IκBα but the levels of IκBα remained below those in 
untreated cells. In contrast, TRAIL alone did not affect the levels of IκBα in 090 cells 
while co-treatment with TRAIL and Bortezomib slightly reduced IκBα expression levels 
at 16 hours after treatment. 
The effect of TRAIL and Bortezomib on NF-κB activation in HPV- 089 and HPV+ 090 
cells was further analysed using a luciferase reporter assay at 16 hours after treatment 
with 50 ng/ml TRAIL and/or 2.5 ng/ml Bortezomib. In both cell lines the combination 
of TRAIL and Bortezomib triggered a strong activation of NF-κB of nearly 10-fold 
compared to untreated cells whereas marginally increased NF-κB activity in response 
to TRAIL alone was only observed in 089 cells (Figure 7-18). Treatment with 
Bortezomib alone slightly enhanced NF-κB activity in 089 cells but did not affect its 
activation in 090 cells.  
Moreover, cells treated with 50 ng/ml TRAIL alone or in combination with 2.5 ng/ml 
Bortezomib for 16 hours were analysed by fluorescence microscopy to investigate the 
localisation of p65, a subunit of the NF-κB transcription complex and a component of 
canonical NF-κB signalling. Immunofluorescence analysis revealed translocation of p65 
to the nucleus, which represents an essential step for its activation, in both 089 and 
090 cells in response to TRAIL and Bortezomib (Figure 7-19).  
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Overall, these data indicate activation of NF-κB signalling in HNSCC cells in response to 
the combination treatment with TRAIL and Bortezomib while Bortezomib alone did not 
significantly affect NF-κB activation in either cell line. Whether this involves canonical 
or non-canonical NF-κB pathways as well as the functional consequences of NF-κB 
activation remain to be determined. 
 
Figure	  7-­‐18:	  NF-­‐κB	  Reporter	  Assay	  of	  089	  and	  090	  Cells	  after	  Treatment	  
with	  TRAIL	  and	  Bortezomib	  HPV-­‐	  089	  and	  HPV+	  090	  cells	  were	  co-­‐transfected	  with	  the	  luciferase	  reporter	  constructs	   pTK-­‐Ren	   and	   pNF-­‐κB-­‐fosp	   and	   treated	   24	  hours	   later	   with	  50	  ng/ml	  TRAIL,	  2.5	  ng/ml	  Bortezomib	  (Btz)	  or	  both.	  Luciferase	  activity	  was	  determined	   after	   16	  hours	   using	   the	   Dual-­‐Glo	   Luciferase	   Assay	   System.	  Untransfected	   cells	   served	   as	   a	   negative	   background	   control	   and	   Renilla	  luciferase	   activity	   was	   used	   to	   correct	   for	   transfection	   efficiency.	   Bars	  represent	  NF-­‐κB	  activation	  normalised	  to	  untreated	  cells	  from	  triplicate	  wells;	  error	  bars	  indicate	  SEM	  (n	  =	  3).	  Statistical	  significance	  compared	  to	  untreated	  cells	  was	  determined	  by	  one-­‐way	  ANOVA	  (*	  P	  <	  0.05,	  ns	  P	  >	  0.05).	  




Figure	  7-­‐19:	   Nuclear	   Translocation	   of	   p65	   in	   089	   and	   090	   Cells	   after	  
Treatment	  with	  TRAIL	  and	  Bortezomib	  HPV-­‐	   089	   (a)	   and	   HPV+	   090	   (b)	   cells	   were	   treated	   with	   50	  ng/ml	   TRAIL,	  2.5	  ng/ml	  Bortezomib	  or	  both	  for	  16	  hours.	  Cells	  were	  stained	  with	  a	  primary	  rabbit	   anti-­‐p65	   and	   secondary	   FITC-­‐conjugated	   anti-­‐rabbit	   antibody.	   Nuclei	  were	   detected	   by	   counterstaining	   with	   DAPI	   (original	   magnification	   60x,	  bar	  =	  10	  µm).	  
(a) 
(b) 
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7.3 Discussion and Conclusions 
HPV+ head and neck cancers are characterised by an improved response to 
conventional treatment with radio- or chemotherapy; however, it remains important to 
develop novel targeted therapeutic agents in order to minimise treatment-associated 
toxicity. Despite promising results using TRAIL in other cancer types its effectiveness in 
HPV+ or HPV- head and neck cancer has not been described so far. While the HPV- cell 
lines tested here responded to TRAIL in a dose-dependent manner, all HPV+ cells were 
found to be resistant to TRAIL-induced cell death (Figure 7-1, Figure 7-4). This 
suggests that, from a clinical perspective, TRAIL alone should not be considered as an 
effective treatment option for the management of head and neck cancer patients. 
Many proteins involved in TRAIL-induced apoptosis are regulated by ubiquitination and 
subsequent proteasomal degradation. In several other TRAIL-resistant cancer cell lines 
inhibition of proteasomal function was shown to sensitise cells to TRAIL. In agreement 
with these data combination treatment with low doses of TRAIL and the proteasome 
inhibitor Bortezomib resulted in the efficient synergistic killing of HPV+ HNSCC cell lines 
while Bortezomib alone at these low concentrations only displayed little cytotoxicity 
(Figure 7-3, Figure 7-4, Table 7-1).  
In combination with TRAIL, Bortezomib induced enhanced apoptosis in HPV- 089 cells, 
accompanied by increased processing of caspase-8 and caspase-3 (Figure 7-7, 
Figure 7-10), while the precise mechanism of cell death in HPV+ 090 cells remains 
unclear. Induction of cell death involved caspase-3 processing and was blocked by 
pre-treatment with the pan-caspase inhibitor z-Vad-fmk (Figure 7-8, Figure 7-10), but 
clear apoptosis could not be detected by flow cytometry after Annexin V/PI staining 
(Figure 7-7, Figure 7-9). Further studies on other HPV-associated cell lines could clarify 
whether this is a general feature of HPV+ cells. 
Subsequently, several previously described potential mechanisms of Bortezomib-
mediated sensitisation to TRAIL were investigated in these representative HPV+ and 
HPV- cell lines.  
Active caspase-8 fragments were recently found to be regulated through ubiquitination 
and degradation and stabilised by proteasome inhibition (Gonzalvez et al. 2012). 
Whereas processed caspase-8 could not be detected in this study, probably due to 
technical issues with inadequate antibodies, pro-caspase-8 levels were found to be 
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decreased in HPV- 089 cells treated with TRAIL and/or Bortezomib but not in HPV+ 090 
cells (Figure 7-10). However, depletion of caspase-8 significantly protected both 089 
and 090 cells from cell death induced by the combination treatment (Figure 7-11). This 
indicates a role of caspase-8 in the response of both HPV+ and HPV- HNSCC cells to 
TRAIL and Bortezomib. The residual levels of cell death observed in caspase-8 
knockdown cells might indicate involvement of other initiator caspases such as 
caspase-10 or induction of non-apoptotic pathways. 
In glioblastoma cells stabilisation of tBid after treatment with Bortezomib enhanced 
TRAIL-induced apoptosis by activating the intrinsic pathway of apoptosis (Unterkircher 
et al. 2011). Here, depletion of Bid did not affect the sensitivity of either cell line to 
TRAIL alone or in combination with Bortezomib, suggesting that the mitochondrial 
amplification loop may not be involved (Figure 7-13).  
Downregulation or inhibition of XIAP by Bortezomib, which prevents the activation of 
caspase-3 and caspase-9, has been proposed to sensitise cells to TRAIL in different 
cancer models (Thayaparasingham et al. 2009; Gillissen et al. 2013). In this study, 
XIAP depletion enhanced the sensitivity of both HPV- 089 and HPV+ 090 cells to TRAIL 
alone, indicating that XIAP might at least partially account for the initial resistance of 
HPV+ to TRAIL (Figure 7-14, Figure 7-15). Moreover, both HPV+ and HPV- cells lacking 
XIAP were significantly more sensitive to the combined treatment with TRAIL and 
Bortezomib. This is in agreement with a study on HPV+ cervical cancer cells in which 
XIAP downregulation increased apoptosis in response to TRAIL in particular when 
combined with the proteasome inhibitor MG132 (Hougardy et al. 2006). 
Restoration of functional p53 through proteasome inhibition using Bortezomib or 
downregulation of E6 was shown to trigger cell cycle arrest and apoptosis in 
HPV-associated head and neck cancer cells (Li and Johnson 2013). Moreover, 
treatment with MG132 enhanced TRAIL-induced apoptosis in HPV+ cervical cancer cells 
through p53-mediated upregulation of the death receptors DR4 and DR5 after 
proteasome inhibition (Wu et al. 1999; Hougardy et al. 2006).  
Similarly, restoration of p53 and induction of its target protein p21 was observed in the 
HPV+ HNSCC cell lines tested here in response to Bortezomib (Figure 7-16). Moreover, 
Bortezomib alone or in combination with TRAIL triggered G2/M arrest in both HPV+ and 
HPV- HNSCC cells (Figure 7-17). A recent study suggests increased sensitivity of cell 
cycle-arrested cells to TRAIL; however the precise underlying mechanism was not 
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identified (Ehrhardt et al. 2013). Bortezomib-induced cell cycle arrest might therefore 
contribute to the enhanced TRAIL sensitivity of HPV+ and HPV- HNSCC cells following 
the combination treatment. However, the importance and requirement of p53 induction 
as well as cell cycle arrest for TRAIL sensitisation in HPV+ cells remain to be 
determined. 
The enhanced sensitivity of either HNSCC cell line to TRAIL after treatment with 
Bortezomib was not associated with downregulation of NF-κB signalling. By contrast, a 
strong activation of NF-κB was observed in response to the combination treatment in 
both HPV- and HPV+ HNSCC cells as shown by NF-κB transcriptional activity and 
nuclear translocation of p65 (Figure 7-18, Figure 7-19). Whether this promotes or 
rather inhibits the induction of apoptosis was not further investigated as part of this 
work. 
At this stage, the precise mechanism of Bortezomib-mediated sensitisation to TRAIL in 
HPV+ head and neck cancer cells has not yet been established. The data presented 
here suggest activation of caspase-3 and p53 induction as well as caspase-8 and XIAP 
as important mediators or regulators of apoptosis induced by TRAIL and Bortezomib. 
Further studies are necessary to investigate the role of Bortezomib-mediated p53 
activation in TRAIL-induced apoptosis of HPV+ cells. Moreover, the link between HPV 
infection and expression of E6 or E7 to TRAIL resistance remains unclear. This could 
be further investigated by screening of head and neck tumour samples for changes in 
gene expression or protein profiles associated with HPV positivity. 
Overall, this work proposes the combination of TRAIL and Bortezomib as a promising 
novel therapeutic approach for the future management of head and neck cancer. 





Discussion and Conclusion 
 
Cancer remains a major cause of morbidity and mortality in the Western world and a 
wide range of treatment strategies are available for the management of cancer 
patients. Conventional approaches such as radiotherapy or chemotherapy are, 
however, unspecific and inevitably result in unwanted side effects, highlighting the 
need for more specific and effective therapies. Most cancer cells are characterised by a 
number of phenotypic changes designated the “Hallmarks of Cancer” including 
uncontrolled proliferation or evasion of apoptosis (Hanahan and Weinberg 2000, 
2011). Potentially these characteristics, rather than the specific underlying causes of 
malignancy, might be sensed and exploited by targeted therapeutic agents to kill 
cancer cells. Several cellular or viral proteins such as TRAIL or Apoptin have been 
shown to selectively induce cell death in tumour cells with minimal impact on normal 
cells (Grimm and Noteborn 2010). Understanding their mechanism of action and 
tumour specificity will help to develop these agents into effective future therapies. 
Apoptin, the apoptosis-inducing protein from chicken anaemia virus (CAV), has been 
shown in many studies to preferentially kill tumour cells irrespective of the cancer type 
while not harming non-transformed cells (Zhuang et al. 1995a; Danen-Van Oorschot et 
al. 1997; Guelen et al. 2004). Whereas the precise mechanism of cell death induction 
by Apoptin remains unknown two major differences have been observed affecting its 
differential function. Apoptin is phosphorylated by a cellular kinase on threonine-108 
and subsequently translocates to the nucleus, which occurs only in tumour cells but 
not in normal cells and promotes apoptosis (Rohn et al. 2002; Danen-Van Oorschot et 
al. 2003). PKCβ, a conventional isozyme of the protein kinase C family, was recently 
identified as an Apoptin kinase in multiple myeloma cells, providing a link between a 
cancer-related signalling pathway and Apoptin regulation (Jiang et al. 2010). 
Based on these observations in multiple myeloma cells, the overall aim of this study 
was to further investigate the interaction and functional link between Apoptin and PKC, 
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in particular PKCβ, in a suitable cellular model of cancer and normal cells to gain 
further understanding of the tumour cell-specific regulation of Apoptin by PKC-
mediated phosphorylation. PKC signalling has predominantly been associated with 
survival or proliferation and represents an important target for the development of 
anti-cancer agents. 
8.1 Characterisation of the novel HGyV-Apoptin 
The VP3 protein derived from a novel Gyrovirus discovered in human skin samples was 
shown to share significant sequence homology with CAV-Apoptin (Sauvage et al. 
2011). Initially, the function of this HGyV-Apoptin was investigated using a 
combination of methods, which revealed similar characteristics as previously observed 
for CAV-Apoptin, including a distinct subcellular expression pattern in normal and 
transformed human cells and tumour-selective induction of apoptosis. Taken together 
the results suggest that HGyV-Apoptin shares a comparable tumour cell-specific 
cytotoxic potential as CAV-Apoptin. Further investigation of its function and regulation 
through phosphorylation by cellular kinases such as PKC might improve our 
understanding of Apoptin function in order to develop it into a targeted anti-cancer 
therapy. Moreover, characterisation of HGyV-Apoptin and potentially similar proteins 
from a range of other recently discovered Gyroviruses will help to unravel potential 
involvement of these viruses in yet unspecified pathological processes. 
8.2 Interaction of Apoptin and PKCβI in cancer cells 
Based on previously published findings that proposed PKCβ as an Apoptin kinase in 
multiple myeloma (Jiang et al. 2010) we investigated the interaction of Apoptin and 
PKCβI in HCT116 cells, a colorectal cancer cell line displaying comparatively high 
Apoptin sensitivity and PKCβI expression levels compared to normal colon mucosa cell 
lines. Initial co-immunoprecipitation studies in HCT116 and MM1.R cells did not provide 
convincing evidence for binding of Apoptin to PKCβI as previously suggested. Unless 
PKCβI was overexpressed together with Apoptin the detected bands were rather faint, 
which might indicate a weak or transient interaction rather than direct binding. More 
detailed interaction assays such as surface plasmon resonance analysis or label 
transfer will be required to identify and confirm the precise nature of the interaction 
between Apoptin and PKCβI. 
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In contrast to pull-down studies, proximity ligation assays clearly showed 
co-localisation of Apoptin with PKCβI within the same complexes in the nucleus of 
cancer cells. Results obtained from proximity ligation assays using truncated proteins 
suggest that domains located within the N-terminal region (amino acids 1 to 74) of 
Apoptin are responsible for its interaction with PKCβI. However, further studies 
employing a range of Apoptin or PKCβI mutants lacking important domains or 
phosphorylation sites will be necessary to precisely map sequences required for their 
interaction. Interestingly, the novel HGyV-Apoptin showed a similar ability to 
co-localise with PKCβI as CAV-Apoptin, suggesting regulation of its function by PKCβI-
mediated phosphorylation. 
Similar to PKCβI, Apoptin was shown to induce nuclear translocation of the related 
kinase Akt in prostate cancer cells, altering its activity to promote apoptosis instead of 
survival. Nuclear localisation of PKCβI in response to Apoptin, as evident from 
proximity ligation assays, might cause similar changes to its accessibility for substrates 
or its activity.  
8.3 PKCβI expression and Apoptin function in normal 
and cancer cells 
In contrast to the study by Jiang et al., who identified a correlation of PKCβI 
expression and Apoptin sensitivity in a pair of parentally matched multiple myeloma 
cells (Jiang et al. 2010), the sensitivity of a larger panel of multiple myeloma cells to 
Apoptin investigated here does not depend on the presence of PKCβI. Instead Apoptin 
phosphorylation might involve other cellular kinases such as PKCβII or Cdk2 depending 
on the cell line of interest.  
The specific role of PKCβI for Apoptin-induced cell death was further investigated by 
comparing the function of Apoptin in HCT116 colorectal cancer cells to two cell lines 
derived from normal colon mucosa. The higher expression levels of PKCβI in HCT116 
cells correlated with enhanced activation of Apoptin, demonstrated by increased 
expression and phosphorylation levels of Apoptin, accumulation in the nucleus as well 
as induction of apoptosis in HCT116 cells while normal colon mucosa cells remained 
resistant to Apoptin expression. While this suggests differential regulation of Apoptin 
function depending on PKCβI expression levels in malignant and normal cells, the link 
between PKCβI and cell death induction following Apoptin expression still remains 
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unclear. Knockdown of PKCβI in HCT116 cells reduced Apoptin phosphorylation levels 
but did not impair the pro-apoptotic effect of Apoptin which might be due to a number 
of factors as discussed in Chapter 4.  
8.4 Apoptin-induced PKC activation in cancer cells 
While previously published data and results presented in this study indicate a role of 
PKCβ for Apoptin regulation it remains unclear whether Apoptin itself has any effect on 
the activation of PKC isoforms, in particular PKCβI.  
Using CKAR, a genetically encoded FRET-based biosensor for PKC activity (Violin et al. 
2003), we showed a transient increase in PKC activation following Apoptin expression 
in HCT116 cells, correlating with the expression and phosphorylation levels of Apoptin. 
At later stages of Apoptin expression, coinciding with the onset of cell death, PKC 
activity was found to be reduced which might be due to apoptotic processes or a 
desensitisation mechanism following long-term activation of PKC (Hansra et al. 1999). 
Expression of Apoptin in MM1.R or HCT116 cells was associated with reduced levels of 
PKCβI supporting the idea that PKC is constitutively activated in the presence of 
Apoptin which then results in PKC degradation to terminate signal transduction. 
Compared to HCT116 cells the activation of PKC was significantly reduced and delayed 
in two normal colon mucosa cell lines following Apoptin expression. This suggests that 
PKC is specifically activated in cancer cells but not in normal cells, which potentially 
affects the activation of Apoptin as well as other cellular signalling pathways towards 
cell death induction.  
CKAR is an unspecific reporter of PKC activity and does not discriminate between 
different classical and novel PKC isoforms (Kajimoto et al. 2010). The results presented 
here do therefore not allow for a definite conclusion whether Apoptin specifically 
triggers activation of PKCβI. However, there is some evidence suggesting that PKCβI is 
the major isoform activated following Apoptin expression, including the lack of PKC 
activation in normal cells with low PKCβI expression levels as well as overexpression 
and knockdown studies. 
A potential involvement of other PKC isoforms, including PKCβII or PKCδ, can, 
however, not be excluded and should be investigated further in future studies. 
Knockdown of PKCβI in HCT116 cells only partially reduced Apoptin phosphorylation 
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and did not negatively affect Apoptin-induced cell death, indicating that other kinases 
such as PKCβII might be involved in the regulation of Apoptin in the absence of PKCβI. 
PKCδ in particular represents a pro-apoptotic PKC isoform and is activated in response 
to apoptotic stimuli such as genotoxic stress (Basu et al. 2001). Future investigations 
should clarify whether cleavage of PKCδ in Apoptin-expressing MM1.R cells to generate 
the catalytically active fragment represents merely a consequence of Apoptin-induced 
caspase activation or whether PKCδ is actively involved in Apoptin regulation and 
signalling, for example using the PKCδ-specific reporter δCKAR. 
8.5 Potential Apoptin-induced signalling pathways 
linked to PKC activation 
Several cellular processes seem to contribute to the tumour cell-specific induction of 
apoptosis in Apoptin-expressing cells as discussed in section 1.3.2.5. The precise 
mechanism of cell killing probably depends on the tumour type, cell-specific genetic 
alterations in oncogenes or tumour suppressor genes and the mode of Apoptin delivery 
to the cell.  
The increased activity of PKC following Apoptin expression suggests a link between 
Apoptin and activation of downstream targets of PKC. Several conventional and novel 
PKC isoforms have been implicated in the activation of NF-κB signalling at different 
levels both through phosphorylation of IκB kinases (IKK) and IKK-independent 
pathways (Su et al. 2002; Shinohara et al. 2005; Holden et al. 2008; Li et al. 2009; 
Garg et al. 2012). Investigation of NF-κB signalling in response to Apoptin in HCT116 
cells revealed partially conflicting results. While Apoptin expression was associated with 
reduced levels of IκBα and partial translocation of p65 to the nucleus, the effect on 
NF-κB activity was only marginal but significant and occurred concurrent with Apoptin-
induced PKC activation. This is in contrast to a previous study showing marked NF-κB 
activation in H1299 non-small cell lung carcinoma cells expressing Apoptin but might 
reflect differences in the experimental setup (Tavassoli et al. 2005). Overall, further 
studies are required to establish the involvement for NF-κB in Apoptin signalling and to 
investigate the link between Apoptin-induced PKC activation and subsequent effects on 
NF-κB signalling. 
The transcription factor p73, a member of the p53 family, might provide another link 
between PKC activation and Apoptin signalling. Two recent studies have implicated 
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selective stabilisation of pro-apoptotic TAp73 isoforms in Apoptin-induced cell death 
(Klanrit et al. 2008; Taebunpakul et al. 2012). This potentially involves not only 
selective ubiquitination and degradation of anti-apoptotic isoforms but also other post-
translational modifications including acetylation and phosphorylation by cellular kinases 
such as JNK or c-Abl (Yuan et al. 1999; Jones et al. 2007). Cleaved PKCδ is known to 
promote p73α stabilisation in response to DNA damage (Ren et al. 2002) while PKCβ-
mediated phosphorylation of p73 was found to promote selective induction of cell cycle 
arrest following genotoxic stress (Nyman et al. 2009). Potentially, PKCβ and/or PKCδ 
might be responsible for the initial stabilisation of TAp73 in cells expressing Apoptin, 
resulting in the p73-dependent induction of the PIR2 ubiquitin ligase to target ΔNp73 
isoforms for degradation (Taebunpakul et al. 2012). Further investigation of the 
interplay between p73, PKC and subsequent induction of cell death or cell cycle arrest 
might help to connect several signalling pathways linked to Apoptin expression and 
therefore improve our understanding of Apoptin-induced signalling events. 
8.6 Conclusions 
In conclusion, the data presented in this study propose an important functional link 
between PKCβI and Apoptin in colon cancer cells based on three major observations: 
! PKCβI co-localises with CAV-Apoptin and HGyV-Apoptin in the nucleus of 
HCT116 cells, mediated by a domain within the N-terminal region of Apoptin. 
! The function of Apoptin, in particular its phosphorylation, correlates with 
expression levels of PKCβI in colon cancer versus normal cells. 
! Apoptin expression induces activation of PKC, potentially involving the PKCβI 
isozyme, in cancer cells but not in normal cells. 
In addition to establishing a function of PKCβI for Apoptin regulation through transient 
binding or co-localisation in a different cancer model than multiple myeloma this study 
for the first time showed that Apoptin expression is accompanied by an increase in PKC 
activity. Activated PKC can mediate phosphorylation and activation of Apoptin and 
might potentially also affect other cellular signalling pathways such as NF-κB which 
should be investigated in more detail in future studies. Whereas PKCβ has so far been 
associated with survival and proliferation, its involvement in Apoptin signalling might 
indicate a rather pro-apoptotic role that would require further investigations. 
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Overall, the obtained results also highlight the complexity of Apoptin regulation and 
signalling. Whereas PKCβI certainly represents one of the kinases directly affecting 
Apoptin phosphorylation in some cancer cells, other kinases can compensate for its 
lack in other types of cells. The specific regulators of Apoptin function as well as 
cellular pathways in cell death induction might also depend on the tumour type or 
specific genetic alterations in malignant cells. Rather than being dependent on a 
specific change, such as overexpression of a particular kinase, Apoptin potentially 
senses an altered environment in tumour cells such as enhanced proliferation or DNA 
damage and utilises the underlying molecular changes for its activation. 
Due to its relatively low toxicity, the need for high expression levels with potentially 
toxic side effects and partially contradicting studies on Apoptin signalling, it remains 
questionable whether Apoptin actually has potential for clinical application, although it 
has been tested successfully in a number of murine tumour models in vivo. It, 
however, represents a protein with an intriguing tumour-specific function that might 
provide a useful tool for unravelling cancer-associated signalling processes to identify 
potential novel and specific targets for cancer therapy. 
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Human Gyrovirus Apoptin shows a similar subcellular
distribution pattern and apoptosis induction as the
chicken anaemia virus derived VP3/Apoptin
J Bullenkamp1,3, D Cole1,3, F Malik2, H Alkhatabi2, A Kulasekararaj2, EW Odell1, F Farzaneh2, J Ga¨ken2,3 and M Tavassoli*,1,3
The chicken anaemia virus-derived protein Apoptin/VP3 (CAV-Apoptin) has the important ability to induce tumour-selective
apoptosis in a variety of human cancer cells. Recently the first human Gyrovirus (HGyV) was isolated from a human skin swab. It
shows significant structural and organisational resemblance to CAV and encodes a homologue of CAV-Apoptin/VP3. Using
overlapping primers we constructed a synthetic human Gyrovirus Apoptin (HGyV-Apoptin) fused to green fluorescent protein in
order to compare its apoptotic function in various human cancer cell lines to CAV-Apoptin. HGyV-Apoptin displayed a similar
subcellular expression pattern as observed for CAV-Apoptin, marked by translocation to the nucleus of cancer cells, although it
is predominantly located in the cytosol of normal human cells. Furthermore, expression of either HGyV-Apoptin or CAV-Apoptin
in several cancer cell lines triggered apoptosis at comparable levels. These findings indicate a potential anti-cancer role for
HGyV-Apoptin.
Cell Death and Disease (2012) 3, e296; doi:10.1038/cddis.2012.34; published online 12 April 2012
Subject Category: Cancer
Apoptin was originally identified as the death-inducing protein
VP3 from chicken anaemia virus (CAV), the first member of
the Gyrovirus genus. Infection with the virus, which is mainly
transmitted through contaminated feathers, has been shown
to trigger apoptosis in thymocytes and myeloid progenitor
cells of young chicken.1 CAV is a single-stranded DNA virus
which encodes three proteins, VP1 (capsid protein), VP2
(protein phosphatase and scaffold protein) and VP3.2 In vitro,
expression of VP3 alone induces apoptosis of chicken lympho-
blastoid T-cells and myeloid cells in a similar way as observed
after CAV infection.3,4 Hence, VP3 was renamed Apoptin.
CAV-Apoptin is a 121 amino-acid protein rich in proline,
serine, threonine and basic amino acids.5,6 It contains a
bipartite-type nuclear localisation signal (NLS1 and NLS2) at
position 82-88 and 111-121 and a nuclear export signal (NES)
suggesting potential shuttling of the protein between nucleus
and cytoplasm.7,8 Both predicted NLSs of Apoptin are
required for its efficient nuclear localisation.7 Furthermore,
Apoptin contains several potential phosphorylation sites,
including threonine 108.9
Importantly, Apoptin has the ability to induce apoptosis in
various human cancer cells but not in normal cells.10–12 It
triggers apoptosis through the intrinsic mitochondrial pathway
requiring caspase-3 and caspase-9, but not caspase-8. Cell
death is induced independently of p53 but possibly involves
the p53 family member p73 that can transactivate pro-
apoptotic targets such as Bax and Puma.13,14 Furthermore,
the sphingomyelin-ceramide pathway has been shown to
have a role in Apoptin-induced cytotoxicity.15 However, the
precise cellular mechanisms of Apoptin-induced cell death
and the mode of tumour selectivity remain unclear. There are
distinct differences regarding Apoptin expression between
normal and tumour cells, which may provide clues about the
mechanisms of tumour cell sensitivity to Apoptin. Firstly, in
tumour cells Apoptin localises to the nucleus, which is
important for its ability to induce apoptosis, whereas in normal
cells it is predominantly expressed in the cytoplasm.10,16 In
addition, Apoptin is phosphorylated on threonine 108 in
tumour but not in normal cells, which drives nuclear
accumulation in tumour cells.9 The specific kinase/s respon-
sible for Apoptin phosphorylation remain unidentified. How-
ever, several kinases, including PKCb and CDK2 have been
shown to phosphorylate Apoptin.17,18
Recently, a virus showing significant homology to CAV was
isolated from skin swabs of healthy volunteers and designated
human Gyrovirus or HGyV.19 Similar to CAV the HGyV
genome consists of a single-stranded negative-sense circular
DNA of 2.315 nucleotides (compared with 2.290–2.320 for
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CAV), containing three partially overlapping open reading
frames. Alignment with CAV revealed relatively low overall
sequence identity with a maximal identity of 70% in the region
of nucleotides 100–700 but a similar organisation of the
promoter region and the encoded proteins. In addition to VP1
and VP2 HGyV encodes a slightly larger, 125 amino-acid
homologue of CAV-Apoptin/VP3 (121 amino acids for
comparison). Despite a low overall identity important regions
such as the nuclear localisation and export signals and
phosphorylation sites are conserved between HGyV- and
CAV-Apoptin. The effects or involvement of this novel virus in
human disease and the functional properties of human
Gyrovirus Apoptin (HGyV-Apoptin) are currently unknown.
To investigate whether HGyV-Apoptin has apoptotic and
tumour selective activity similar to its homologue CAV-
Apoptin we developed a synthetic HGyV-Apoptin fused to
green fluorescent protein (GFP). Expression of this construct
in human cancer cell lines revealed a subcellular localisation
and pro-apoptotic function comparable to CAV-Apoptin.
Results
Expression of HGyV-Apoptin in human cancer cells. To
test the expression of the newly generated HGyV-Apoptin
constructs, HCT116 colon carcinoma and Saos-2 osteosar-
coma cells were transfected with the corresponding plasmids
pHGyV-GFP-AP and pHGyV-FLAG-AP. Western blot analy-
sis of transfected cells after 2 days revealed expression of
both HGyV-GFP-AP and HGyV-FLAG-AP that could be
detected at the estimated molecular weights (Figures 1a
and b). Compared with its CAV homologue HGyV-GFP-AP
is slightly larger as expected from the difference in length.
Re-probing with a CAV-Apoptin phospho-specific antibody
directed against phosphorylated threonine 108 did not reveal
any cross-reaction with HGyV-Apoptin (data not shown).
HGyV-Apoptin translocates to the nucleus and induces
changes in nuclear morphology in cancer cells. CAV-
Apoptin is known to translocate to the nucleus in transformed
cells which is at least partially important for the induction of
apoptosis in these cells. To investigate the subcellular
distribution of HGyV-Apoptin, which also contains putative
nuclear localisation and export signals (Figure 1a), as well as
morphological changes caused by its expression, cells were
transfected with different Apoptin constructs and analysed by
fluorescence microscopy. Imaging of HCT116 colon carci-
noma cells transfected with pCAV-GFP-AP or pHGyV-GFP-
AP at 24 and 48 h post transfection revealed a similar
Figure 1 Expression of CAV- and HGyV-Apoptin in cancer cells. (a) Alignment of the protein sequence of CAV-Apoptin (NP_056774.1) and HGyV-Apoptin (CBZ41794.1)
using computer software Align (http://xylian.igh.cnrs.fr/bin/align-guess.cgi). Important functional domains, including LRS (leucine-rich domain), NLS1/2 and NES are indicated
by boxes and the predicted phosphorylation sites threonine 108 or threonine 111 are indicated by black arrows. Whole cell lysates of HCT116 colon carcinoma (b) and Saos-2
osteosarcoma (c) cells transfected with the indicated plasmids were prepared and western blot analysis for detection of GFP- or FLAG-Apoptin, respectively, as well as b-Actin
as a loading control was performed. Molecular weights of the bands are indicated with arrows and blots were cut and combined at the black line
Human Gyrovirus Apoptin kills cancer cells
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expression pattern of CAV- and HGyV-Apoptin (Figure 2a).
CAV-Apoptin has been shown to initially exhibit a fine
granular distribution within the nucleus, later clustering to
form aggregates, at which point the cell becomes apoptotic.
This characteristic morphology was also observed with
HGyV-Apoptin in transfected Saos-2 osteosarcoma cells
after 2 and 5 days, respectively (Figure 2b). To exclude a
potential promoting effect of the GFP-tag on nuclear trans-
location Saos-2 cells were transfected with FLAG-CAV-AP or
FLAG-HGyV-AP. Subsequent indirect immunofluorescence
to detect FLAG-Apoptin revealed the same expression
pattern as observed for GFP-Apoptin (Figure 2c). Similar
cellular distribution was observed in the HT1080 breast
cancer cell line (data not shown).
HGyV-GFP-Apoptin induces cell death in Saos-2 osteo-
sarcoma cells. To examine the cytotoxic function of HGyV-
GFP-AP Saos-2 human osteosarcoma cells were transfected
by nucleofection with pHGyV-GFP-AP, pCAV-GFP-AP or the
corresponding pEGFP-C1 control vector. Apoptosis was
quantified by flow cytometric analysis as percentage of
Annexin-V-positive cells among the transfected cells after
Annexin-V-APC/ propidium iodide (PI) staining. After 5 days
between 40 and 50% of cells expressing GFP-Apoptin were
apoptotic compared with only 5% apoptotic cells in those
transfected with pEGFP-C1 (Figure 3a). The level of cell
death induced by HGyV-Apoptin was similar to the level
achieved by CAV-Apoptin.
Furthermore, a colony-forming assay of HT1080 cells
comparably transfected with pEGFP-C1 or pHGyV-GFP-AP
showed very few HGyV-GFP-AP expressing cells, whereas
the control pEGFP-C1 transfected cells were able to form
countless colonies in the presence of G418 (data not shown)
indicating a cytotoxic effect of HGyV-GFP-AP.
To compare the pro-apoptotic effect of GFP- and FLAG-
tagged Apoptin, Saos-2 cells were transfected with different
Apoptin and control plasmids. After 5 days cells were fixed,
stained with anti-FLAG antibody (for pCAV-FLAG-AP and
pHGyV-FLAG-AP) and counterstained with DAPI for the
detection of nuclear morphology. Apoptosis was quantified by
scoring cells expressing either GFP- or FLAG-Apoptin and
displaying clear apoptotic nuclear morphology. Results
suggested that both CAV- and HGyV-Apoptin efficiently
induce apoptosis as compared with the pEGFP-C1 control.
Furthermore, no significant differences between the GFP- or
FLAG-tagged Apoptin could be observed (Figure 3c).
HGyV-GFP-Apoptin is expressed in the cytoplasm of
normal human fibroblasts and translocates to the
nucleus of transformed counterparts. One of the
Figure 2 Nuclear translocation of GFP- and FLAG-Apoptin in cancer cells. HCT116 (a) and Saos-2 (b) cancer cells were transfected with pCAV-GFP-AP or pHGyV-GFP-
AP and the corresponding pEGFP-C1 control plasmid. Cells were directly imaged in culture dishes after 1 or 2 days (a) or fixed and counterstained with DAPI at 2 and 5 days
post-transfection (b) as indicated. Saos-2 cells (c) transfected with pCAV-FLAG-AP or pHGyV-FLAG-AP were fixed after 5 days and stained with a primary mouse anti-FLAG
and secondary FITC anti-mouse antibody for detection of FLAG-Apoptin. Nuclei were detected by counterstaining with DAPI. Arrows indicate apoptotic nuclei
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important characteristics of CAV-Apoptin is its distinct tumour
specific nuclear localisation, which is necessary for its ability
to selectively induce apoptosis in transformed but not in
normal cells. To investigate whether HGyV-Apoptin shows
the same tumour selectivity pEGFP-C1, pHGyV-GFP-AP,
pCAV-GFP-AP, pHGyV-FLAG-AP and pCAV-FLAG-AP
were transfected into 1BR3 normal human fibroblasts
and their SV40-LT transformed counterparts, (1BR3LT).
After 3 days cells were counterstained with DAPI and
analysed by fluorescent microscopy to quantify apoptosis
by scoring the GFP-positive cells containing condensed
or fragmented nuclei. The normal 1BR3 fibroblasts exhib-
ited a marked difference in cellular localisation of both
CAV-GFP-AP and HGyV-GFP-AP as compared with trans-
formed 1BR3LT (Figure 4a). In normal cells, HGyV- and
CAV-GFP-Apoptin were mainly expressed in the cytoplasm,
while in the transformed cells both CAV- and HGyV-GFP-
Apoptin had a predominantly nuclear localisation. Similarly,
FLAG-tagged CAV- or HGyV-Apoptin was localised to the
nucleus of transformed 1BR3LT cells, whereas it was
predominantly cytoplasmic in normal 1BR3 fibroblasts
(data not shown). This difference in subcellular localisation
was associated with increased apoptosis in the trans-
formed cells transduced with either FLAG- or GFP-Apoptin
(Figure 4b).
Discussion
Tumour specificity remains one of the main hurdles for
successful treatment of cancer.20 A number of viral and
Figure 3 Induction of cell death in Saos-2 cells at 5 days after transfection. Saos-2 cells were transfected by nucleofection with pCAV-GFP-AP, pHGyV-GFP-AP or the
corresponding pEGFP-C1 control plasmid, as well as pCAV-FLAG-AP and pHGyV-FLAG-AP. Cell death was measured by flow cytometric analysis after Annexin-V-APC/ PI
staining. (a) Quantification of cell death as % of APC-labelled cells in the GFP-positive population after 5 days (*Po0.01). Error bars indicate standard deviation of three
experiments. (b) Corresponding FACS dot plots of Annexin-V-APC (x-axis) versus PI (y-axis) obtained after 2 and 5 days. (c) After 5 days transfected Saos-2 cells were fixed,
stained with a primary mouse anti-FLAG and secondary FITC anti-mouse antibody (for pCAV-FLAG-AP and pHGyV-FLAG-AP) and counterstained with DAPI for the detection
of nuclear morphology. Cell death was quantified as the percentage of GFP- or FLAG-positive cells showing condensed or fragmented nuclei. Error bars indicate standard
deviation of two independent experiments
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cellular proteins have been described that show tumour-
specific toxicity, including Apoptin, Trail, mda-7 (etc).21 The
therapeutic potential of such proteins and their cellular targets
is of immense interest. Recently, a HGyV has been identified
encoding a viral protein resembling the CAV-derived Apoptin.
Here we provide clear evidence that this HGyV-Apoptin
shows a tumour-specific nuclear expression pattern as has
been described previously for CAV-Apoptin to be important for
its cytotoxicity.7 Furthermore, expression of HGyV-Apoptin
resulted in the induction of apoptosis in transformed cells but
not in the normal human cell line 1BR3. However, further
studies, including the use of different types of normal cells,
are necessary to confirm that HGyV-Apoptin has tumour-
selective cytotoxicity and could thus provide a novel tool for
cancer treatment.
Many studies in the past decade have provided insight into
the mechanism of Apoptin-induced apoptosis. However, the
basis for its increased sensitivity for cancer cells remains
largely unclear. In addition to translocation to the nucleus,
CAV-Apoptin is phosphorylated on threonine 108 in cancer
cells but not in normal cells, which seems to be important for
enabling Apoptin to induce apoptosis.9 Several cellular kinases
have been proposed to be responsible for CAV-Apoptin
phosphorylation.14,18 We have recently identified PKCb to
be important for phosphorylation and activation of CAV-
Apoptin.17 It would be important to investigate whether HGyV-
Apoptin is phosphorylated in a similar manner by the kinases
which have been shown to interact with CAV-Apoptin. These
studies are currently on-going.
Although so far no link between this novel HGyV and any
human disease has been identified, the clear apoptotic activity
of its encoded protein HGyV-Apoptin offers an intriguing
opportunity to investigate its potential pathological role.
Furthermore a better understanding of the function of the
viral protein HGyV-Apoptin may reveal involvement in human
disease and lead to the development of novel therapeutics for
cancer.
Materials and Methods
Cell lines and cell culture. HCT116 human colorectal carcinoma cells were
obtained from ATCC (Manassas, VA, USA) and maintained in McCoy’s 5A medium
supplemented with 10% foetal bovine serum 40 U/ml Penicillin and 40 mg/ml
Streptomycin (all PAA Laboratories, Yeovil, UK). Saos-2 human osteosarcoma
cells were purchased from ATCC and grown in DMEM (PAA Laboratories) supple-
mented with 10% foetal bovine serum 40U/ml Penicillin and 40mg/ml Streptomycin.
1BR3 normal and 1BR3 SV40 1BR3LT were a gift from Prof. Alan Lehmann (Sussex
Centre for Genome Damage and Stability, University of Sussex, UK) and maintained
Figure 4 Cytosolic expression of GFP-Apoptin and quantification of apoptosis in 1BR3 normal human fibroblasts. Normal (1BR3) and transformed (1BR3LT) human
fibroblast cell lines were transfected by nucleofection with pCAV-GFP-AP, pHGyV-GFP-AP or the corresponding pEGFP-C1 control plasmid as well as pCAV-FLAG-AP and
pHGyV-FLAG-AP. After 3 days cells were fixed and counterstained with DAPI to analyse the subcellular localisation of GFP-Apoptin. Expression of FLAG-AP was detected
using primary mouse anti-FLAG and secondary FITC anti-mouse antibody (a). Apoptosis was quantified by scoring GFP- or FLAG-positive cells containing condensed or
fragmented nuclei (b). Over one hundred transfected cells were analysed and experiments were repeated twice (error bars indicate standard deviation)
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in DMEM containing 15% foetal bovine serum 40 U/ml Penicillin and 40 mg/ml
Streptomycin. All cell lines were incubated at 37 1C and 5% CO2.
Generation of HGyV-Apoptin. A codon optimised HGyV-Apoptin gene
was constructed using primers overlapping by 15 bases (Table 1). FOR1
introduces a Kozak sequence upstream of the ATG start codon and a BamHI site
for subsequent cloning. REV5 introduces an EcoRI site for subsequent cloning.
Primers FOR1-5 and REV1-4 were mixed in equimolar amounts and heated to
95 0C for 2min and cooled slowly to room temperature. Gaps were filled in with T4
DNA Polymerase for 15min at 12 1C and finally the gaps were closed by treatment
with T4 DNA Ligase for 15min at RT. The resulting product was PCR amplified
with primers FOR1 and REV5 and the PCR product was TOPO TA cloned
(Invitrogen Life Technologies, Paisley, UK).
Inserts were sequence verified and a correct HGyV-AP was removed from
the TOPO vector by BamHI/EcoRI digestion and cloned in-frame with GFP into
the BglII/EcoRI digested mammalian expression vector pEGFP-C1 (Clontech,
Saint-Germain-en-Laye, France) and named pHGyV-GFP-AP.
pHGyV-FLAG-AP was cloned by removing HGyV-AP from the TOPO vector by
EcoRI digestion and filling in with Klenow. p3X-FLAG (Sigma-Aldrich, Poole, UK)
was digested with BamHI and EcoRI, blunt ended with Mungbean nuclease and
phosphates were removed by calf intestinal phosphatase treatment. Vector and
insert were blunt end ligated and the correct orientation was determined by BstXI
and BamHI digestion. Plasmids containing an insert in the correct orientation were
sequence verified.
Plasmids and transient transfection. Expression vectors for HGyV-
Apoptin (pHGyV-GFP-AP, pHGyV-FLAG-AP) were constructed as part of this
study. pCAV-GFP-AP was generated as described previously10 and pCAV-FLAG-
AP was received from Dr. Jose Teodoro (Goodman Cancer Research Centre,
Montreal, QC, Canada). Other control vectors used were pcDNA3.1 (Invitrogen)
and pEGFP-C1.
HCT116 cells were transiently transfected using X-tremeGENE HP transfection
reagent according to the manufacturer’s protocol (Roche Diagnostics, Burgess
Hill, UK). Transfection of Saos-2 and 1BR3/1BR3LT cells was achieved using
Nucleofector technology as recommended by the manufacturer (Lonza, Basel,
Switzerland).
Flow cytometric analysis. Cells were seeded on 12-well plates and
collected at 2 or 5 days after nucleofection. Apoptosis was quantified by staining
with Annexin-V-APC (Invitrogen) and PI (Sigma) and subsequent analysis on a BD
FACSCanto II (Becton Dickinson, Oxford, UK). Data was analysed using FlowJo
software (Tree Star, Inc., Ashland, OR, USA).
Western blot analysis. Protein extracts were prepared by washing cells and
directly lysing them in Laemmli sample buffer (62.5mM Tris-HCl pH 6.7, 100 mm
b-mercaptoethanol, 2% SDS, 1mg/ml aprotinin, 1mg/ml leupeptin, 100mg/ml
phenylmethylsulphoxide). SDS-PAGE was performed and proteins were
transferred to nitrocellulose membranes (Sigma). Membranes were incubated
with specific primary and secondary antibodies as indicated and developed using
a home-made enhanced chemiluminescent system. The antibodies used were:
rabbit anti-GFP (Cell Signaling, Beverly, MA, USA), mouse anti-FLAG (Sigma),
mouse anti-b-Actin (Sigma) and secondary anti-mouse (Sigma) or anti-rabbit
(GE Healthcare, Chalfont St. Giles, UK) linked to horseradish peroxidase.
Fluorescence microscopy. HCT116 cells were imaged directly on culture
plates at 1 or 2 days post-transfection using an Olympus CKX41 inverted
microscope (Southend-on-Sea, UK).
Saos-2 and 1BR3/1BR3LT cells were transfected by nucleofection and grown on
8-well culture slides (Becton Dickinson). After 3 or 5 days cells were washed once
with PBS, fixed in 2% paraformaldehyde for 30min at 37 1C and permeabilized with
0.2% Triton X-100 for 20min. For the detection of FLAG tag cells were washed in
PBS, blocked using 3% BSA in PBS-T for 30min at 37 1C and incubated with the
primary anti-FLAG antibody and the secondary antibody anti-mouse-FITC (both
Sigma) for 2 h or 1 h, respectively, at 37 1C with washing steps in PBS between the
incubations. All cells were mounted in Vectashield mounting medium containing
DAPI (Vector Laboratories, Peterborough, UK) for nuclear staining and images were
acquired using an Olympus BX61 automated fluorescence microscope.
Apoptosis was quantified by scoring the GFP-positive cells containing condensed
or fragmented nuclei. Over one hundred transfected cells were analysed and
experiments were repeated twice.
Statistical analysis. A paired two-tailed Student’s t-test was used to
calculate significance.
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